A	O
novel	O
missense	O
mutation	O
Asp506Gly	B-ProteinMutation
in	O
Exon	O
13	O
of	O
the	O
F11	O
gene	O
in	O
an	O
asymptomatic	O
Korean	O
woman	O
with	O
mild	O
factor	O
XI	O
deficiency	O
.	O

Factor	O
XI	O
(FXI)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
coagulation	O
disorder	O
most	O
commonly	O
found	O
in	O
Ashkenazi	O
and	O
Iraqi	O
Jews	O
,	O
but	O
it	O
is	O
also	O
found	O
in	O
other	O
ethnic	O
groups	O
.	O

It	O
is	O
a	O
trauma	O
or	O
surgery-related	O
bleeding	O
disorder	O
,	O
but	O
spontaneous	O
bleeding	O
is	O
rarely	O
seen	O
.	O

The	O
clinical	O
manifestation	O
of	O
bleeding	O
in	O
FXI	O
deficiency	O
cases	O
is	O
variable	O
and	O
seems	O
to	O
poorly	O
correlate	O
with	O
plasma	O
FXI	O
levels	O
.	O

The	O
molecular	O
pathology	O
of	O
FXI	O
deficiency	O
is	O
mutation	O
in	O
the	O
F11	O
gene	O
on	O
the	O
chromosome	O
band	O
4q35	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
F11	O
gene	O
in	O
an	O
18-year-old	O
asymptomatic	O
Korean	O
woman	O
with	O
mild	O
FXI	O
deficiency	O
.	O

Pre-operative	O
laboratory	O
screen	O
tests	O
for	O
lipoma	O
on	O
her	O
back	O
revealed	O
slightly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
45.2	O
sec	O
;	O
reference	O
range	O
,	O
23.2-39.4	O
sec	O
)	O
.	O

Her	O
FXI	O
activity	O
(35%)	O
was	O
slightly	O
lower	O
than	O
the	O
normal	O
FXI	O
activity	O
(	O
reference	O
range	O
,	O
50-150%	O
)	O
.	O

Direct	O
sequence	O
analysis	O
of	O
the	O
F11	O
gene	O
revealed	O
a	O
heterozygous	O
A	O
to	O
G	O
substitution	O
in	O
nucleotide	O
1517	O
c.1517A>G	B-DNAMutation
of	O
exon	O
13	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
aspartic	O
acid	O
with	O
glycine	O
in	O
codon	O
506	O
p.Asp506Gly	B-ProteinMutation
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
Asp506Gly	B-ProteinMutation
is	O
a	O
novel	O
missense	O
mutation	O
,	O
and	O
this	O
is	O
the	O
first	O
genetically	O
confirmed	O
case	O
of	O
mild	O
FXI	O
deficiency	O
in	O
Korea	O
.	O

Mutations	O
in	O
mitochondrially	O
encoded	O
complex	O
I	O
enzyme	O
as	O
the	O
second	O
common	O
cause	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
with	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
stroke-like	O
episodes	O
.	O

The	O
mutation	O
pattern	O
of	O
mitochondrial	O
DNA	O
(mtDNA)	O
in	O
mainland	O
Chinese	O
patients	O
with	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
stroke-like	O
episodes	O
(MELAS)	O
has	O
been	O
rarely	O
reported	O
,	O
though	O
previous	O
data	O
suggested	O
that	O
the	O
mutation	O
pattern	O
of	O
MELAS	O
could	O
be	O
different	O
among	O
geographically	O
localized	O
populations	O
.	O

We	O
presented	O
the	O
results	O
of	O
comprehensive	O
mtDNA	O
mutation	O
analysis	O
in	O
92	O
unrelated	O
Chinese	O
patients	O
with	O
MELAS	O
(	O
85	O
with	O
classic	O
MELAS	O
and	O
7	O
with	O
MELAS/Leigh	O
syndrome	O
(LS)	O
overlap	O
syndrome	O
)	O
.	O

The	O
mtDNA	O
A3243G	B-DNAMutation
mutation	O
was	O
the	O
most	O
common	O
causal	O
genotype	O
in	O
this	O
patient	O
group	O
(	O
79/92	O
and	O
85.9%	O
)	O
.	O

The	O
second	O
common	O
gene	O
mutation	O
was	O
G13513A	B-DNAMutation
(	O
7/92	O
and	O
7.6%	O
)	O
.	O

Additionally	O
,	O
we	O
identified	O
T10191C	B-DNAMutation
p.S45P	B-ProteinMutation
in	O
ND3	O
,	O
A11470C	B-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
K237N	I-ProteinMutation
)	O
in	O
ND4	O
,	O
T13046C	B-DNAMutation
p.M237T	B-ProteinMutation
in	O
ND5	O
and	O
a	O
large-scale	O
deletion	O
(13025-13033:14417-14425)	O
involving	O
partial	O
ND5	O
and	O
ND6	O
subunits	O
of	O
complex	O
I	O
in	O
one	O
patient	O
each	O
.	O

Among	O
them	O
,	O
A11470C	B-DNAMutation
,	O
T13046C	B-DNAMutation
and	O
the	O
single	O
deletion	O
were	O
novel	O
mutations	O
.	O

In	O
summary	O
,	O
patients	O
with	O
mutations	O
affecting	O
mitochondrially	O
encoded	O
complex	O
I	O
(MTND)	O
reached	O
12.0%	O
(11/92)	O
in	O
this	O
group	O
.	O

It	O
is	O
noteworthy	O
that	O
all	O
seven	O
patients	O
with	O
MELAS/LS	O
overlap	O
syndrome	O
were	O
associated	O
with	O
MTND	O
mutations	O
.	O

Our	O
data	O
emphasize	O
the	O
important	O
role	O
of	O
MTND	O
mutations	O
in	O
the	O
pathogenicity	O
of	O
MELAS	O
,	O
especially	O
MELAS/LS	O
overlap	O
syndrome	O
.	O

Novel	O
compound	O
heterozygous	O
mutation	O
of	O
MLYCD	O
in	O
a	O
Chinese	O
patient	O
with	O
malonic	O
aciduria	O
.	O

A	O
3-year-old	O
Chinese	O
boy	O
presented	O
with	O
prominent	O
clinical	O
features	O
of	O
malonic	O
aciduria	O
,	O
including	O
developmental	O
delay	O
,	O
short	O
stature	O
,	O
brain	O
abnormalities	O
and	O
massive	O
excretion	O
of	O
malonic	O
acid	O
and	O
methylmalonic	O
acid	O
.	O

Molecular	O
characterization	O
by	O
DNA	O
sequencing	O
analysis	O
and	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
of	O
the	O
MLYCD	O
gene	O
revealed	O
a	O
heterozygous	O
mutation	O
(	O
c.920T>G	B-DNAMutation
,	O
p.Leu307Arg	B-ProteinMutation
)	O
in	O
the	O
patient	O
and	O
his	O
father	O
and	O
a	O
heterozygous	O
deletion	O
comprising	O
exon	O
1	O
in	O
the	O
patient	O
and	O
his	O
mother	O
.	O

The	O
missense	O
mutation	O
c.920T>G	B-DNAMutation
was	O
not	O
found	O
in	O
100	O
healthy	O
controls	O
and	O
has	O
not	O
been	O
reported	O
previously	O
.	O

Our	O
findings	O
expand	O
the	O
number	O
of	O
reported	O
cases	O
and	O
add	O
a	O
novel	O
entry	O
to	O
the	O
repertoire	O
of	O
MLYCD	O
mutations	O
.	O

Genetic	O
and	O
epigenetic	O
alterations	O
of	O
the	O
NF2	O
gene	O
in	O
sporadic	O
vestibular	O
schwannomas	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
neurofibromatosis	O
type	O
2	O
(NF2)	O
tumor-suppressor	O
gene	O
have	O
been	O
identified	O
in	O
not	O
only	O
NF2-related	O
tumors	O
but	O
also	O
sporadic	O
vestibular	O
schwannomas	O
(VS)	O
.	O

This	O
study	O
investigated	O
the	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
tumors	O
and	O
blood	O
from	O
30	O
Korean	O
patients	O
with	O
sporadic	O
VS	O
and	O
correlated	O
these	O
alterations	O
with	O
tumor	O
behavior	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
NF2	O
gene	O
mutations	O
were	O
detected	O
using	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
and	O
three	O
highly	O
polymorphic	O
microsatellite	O
DNA	O
markers	O
were	O
used	O
to	O
assess	O
the	O
loss	O
of	O
heterozygosity	O
(LOH)	O
from	O
chromosome	O
22	O
.	O

Aberrant	O
hypermethylation	O
of	O
the	O
CpG	O
island	O
of	O
the	O
NF2	O
gene	O
was	O
also	O
analyzed	O
.	O

The	O
tumor	O
size	O
,	O
the	O
clinical	O
growth	O
index	O
,	O
and	O
the	O
proliferative	O
activity	O
assessed	O
using	O
the	O
Ki-67	O
labeling	O
index	O
were	O
evaluated	O
.	O

We	O
found	O
18	O
mutations	O
in	O
16	O
cases	O
of	O
30	O
schwannomas	O
(53%)	O
.	O

The	O
mutations	O
included	O
eight	O
frameshift	O
mutations	O
,	O
seven	O
nonsense	O
mutations	O
,	O
one	O
in-frame	O
deletion	O
,	O
one	O
splicing	O
donor	O
site	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

Nine	O
patients	O
(30%)	O
showed	O
allelic	O
loss	O
.	O

No	O
patient	O
had	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
and	O
correlation	O
between	O
NF2	O
genetic	O
alterations	O
and	O
tumor	O
behavior	O
was	O
not	O
observed	O
in	O
this	O
study	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
The	O
molecular	O
genetic	O
changes	O
in	O
sporadic	O
VS	O
identified	O
here	O
included	O
mutations	O
and	O
allelic	O
loss	O
,	O
but	O
no	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
was	O
detected	O
.	O

In	O
addition	O
,	O
no	O
clear	O
genotype/phenotype	O
correlation	O
was	O
identified	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
other	O
factors	O
contribute	O
to	O
tumor	O
formation	O
and	O
growth	O
.	O

RET	O
mutational	O
spectrum	O
in	O
Hirschsprung	O
disease	O
:	O
evaluation	O
of	O
601	O
Chinese	O
patients	O
.	O

Rare	O
(RVs)	O
and	O
common	O
variants	O
of	O
the	O
RET	O
gene	O
contribute	O
to	O
Hirschsprung	O
disease	O
(	O
HSCR	O
;	O
congenital	O
aganglionosis	O
)	O
.	O

While	O
RET	O
common	O
variants	O
are	O
strongly	O
associated	O
with	O
the	O
commonest	O
manifestation	O
of	O
the	O
disease	O
(	O
males	O
;	O
short-segment	O
aganglionosis	O
;	O
sporadic	O
)	O
,	O
rare	O
coding	O
sequence	O
(CDS)	O
variants	O
are	O
more	O
frequently	O
found	O
in	O
the	O
lesser	O
common	O
and	O
more	O
severe	O
forms	O
of	O
the	O
disease	O
(	O
females	O
;	O
long/total	O
colonic	O
aganglionosis	O
;	O
familial).Here	O
we	O
present	O
the	O
screening	O
for	O
RVs	O
in	O
the	O
RET	O
CDS	O
and	O
intron/exon	O
boundaries	O
of	O
601	O
Chinese	O
HSCR	O
patients	O
,	O
the	O
largest	O
number	O
of	O
patients	O
ever	O
reported	O
.	O

We	O
identified	O
61	O
different	O
heterozygous	O
RVs	O
(	O
50	O
novel	O
)	O
distributed	O
among	O
100	O
patients	O
(16.64%)	O
.	O

Those	O
include	O
14	O
silent	O
,	O
29	O
missense	O
,	O
5	O
nonsense	O
,	O
4	O
frame-shifts	O
,	O
and	O
one	O
in-frame	O
amino-acid	O
deletion	O
in	O
the	O
CDS	O
,	O
two	O
splice-site	O
deletions	O
,	O
4	O
nucleotide	O
substitutions	O
and	O
a	O
22-bp	O
deletion	O
in	O
the	O
intron/exon	O
boundaries	O
and	O
1	O
single-nucleotide	O
substitution	O
in	O
the	O
5'	O
untranslated	O
region	O
.	O

Exonic	O
variants	O
were	O
mainly	O
clustered	O
in	O
RET	O
the	O
extracellular	O
domain	O
.	O

RET	O
RVs	O
were	O
more	O
frequent	O
among	O
patients	O
with	O
the	O
most	O
severe	O
phenotype	O
(	O
24%	O
vs	O
.	O

15%	O
in	O
short-HSCR	O
)	O
.	O

Phasing	O
RVs	O
with	O
the	O
RET	O
HSCR-associated	O
haplotype	O
suggests	O
that	O
RVs	O
do	O
not	O
underlie	O
the	O
undisputable	O
association	O
of	O
RET	O
common	O
variants	O
with	O
HSCR	O
.	O

None	O
of	O
the	O
variants	O
were	O
found	O
in	O
250	O
Chinese	O
controls	O
.	O

A	O
deletion	O
of	O
FGFR2	O
creating	O
a	O
chimeric	O
IIIb/IIIc	O
exon	O
in	O
a	O
child	O
with	O
Apert	O
syndrome	O
.	O

BACKGROUND	O
:	O
Signalling	O
by	O
fibroblast	O
growth	O
factor	O
receptor	O
type	O
2	O
(FGFR2)	O
normally	O
involves	O
a	O
tissue-specific	O
alternative	O
splice	O
choice	O
between	O
two	O
exons	O
(	O
IIIb	O
and	O
IIIc	O
)	O
,	O
which	O
generates	O
two	O
receptor	O
isoforms	O
(	O
FGFR2b	O
and	O
FGFR2c	O
respectively	O
)	O
with	O
differing	O
repertoires	O
of	O
FGF-binding	O
specificity	O
.	O

Here	O
we	O
describe	O
a	O
unique	O
chimeric	O
IIIb/c	O
exon	O
in	O
a	O
patient	O
with	O
Apert	O
syndrome	O
,	O
generated	O
by	O
a	O
non-allelic	O
homologous	O
recombination	O
event	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
present	O
a	O
child	O
with	O
Apert	O
syndrome	O
in	O
whom	O
routine	O
genetic	O
testing	O
had	O
excluded	O
the	O
FGFR2	O
missense	O
mutations	O
commonly	O
associated	O
with	O
this	O
disorder	O
.	O

The	O
patient	O
was	O
found	O
to	O
harbour	O
a	O
heterozygous	O
1372	O
bp	O
deletion	O
between	O
FGFR2	O
exons	O
IIIb	O
and	O
IIIc	O
,	O
apparently	O
originating	O
from	O
recombination	O
between	O
13	O
bp	O
of	O
identical	O
DNA	O
sequence	O
present	O
in	O
both	O
exons	O
.	O

The	O
rearrangement	O
was	O
not	O
present	O
in	O
the	O
unaffected	O
parents	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
known	O
pathogenesis	O
of	O
Apert	O
syndrome	O
,	O
the	O
chimeric	O
FGFR2	O
protein	O
is	O
predicted	O
to	O
act	O
in	O
a	O
dominant	O
gain-of-function	O
manner	O
.	O

This	O
is	O
likely	O
to	O
result	O
from	O
its	O
expression	O
in	O
mesenchymal	O
tissues	O
,	O
where	O
retention	O
of	O
most	O
of	O
the	O
residues	O
essential	O
for	O
FGFR2b	O
binding	O
activity	O
would	O
result	O
in	O
autocrine	O
activation	O
.	O

This	O
report	O
adds	O
to	O
the	O
repertoire	O
of	O
rare	O
cases	O
of	O
Apert	O
syndrome	O
for	O
which	O
a	O
pathogenesis	O
based	O
on	O
atypical	O
FGFR2	O
rearrangements	O
can	O
be	O
demonstrated	O
.	O

Detection	O
of	O
a-thalassemia-1	O
Southeast	O
Asian	O
and	O
Thai	O
type	O
deletions	O
and	O
b-thalassemia	O
3.5-kb	O
deletion	O
by	O
single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
high-resolution	O
melting	O
analysis	O
.	O

BACKGROUND	O
:	O
Prevention	O
and	O
control	O
of	O
thalassemia	O
requires	O
simple	O
,	O
rapid	O
,	O
and	O
accurate	O
screening	O
tests	O
for	O
carrier	O
couples	O
who	O
are	O
at	O
risk	O
of	O
conceiving	O
fetuses	O
with	O
severe	O
thalassemia	O
.	O

METHODS	O
:	O
Single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
high-resolution	O
melting	O
(HRM)	O
analysis	O
were	O
used	O
for	O
the	O
identification	O
of	O
a-thalassemia-1	O
Southeast	O
Asian	O
(SEA)	O
and	O
Thai	O
type	O
deletions	O
and	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
using	O
conventional	O
gap-PCR	O
.	O

DNA	O
samples	O
were	O
derived	O
from	O
28	O
normal	O
individuals	O
,	O
11	O
individuals	O
with	O
a-thalassemia-1	O
SEA	O
type	O
deletion	O
,	O
2	O
with	O
a-thalassemia-1	O
Thai	O
type	O
deletion	O
,	O
and	O
2	O
with	O
heterozygous	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
.	O

RESULTS	O
:	O
HRM	O
analysis	O
indicated	O
that	O
the	O
amplified	O
fragments	O
from	O
a-thalassemia-1	O
SEA	O
type	O
deletion	O
,	O
a-thalassemia-1	O
Thai	O
type	O
deletion	O
,	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
,	O
and	O
the	O
wild-type	O
b-globin	O
gene	O
had	O
specific	O
peak	O
heights	O
at	O
mean	O
melting	O
temperature	O
(T(m))	O
values	O
of	O
86.89	O
	O
	O
,	O
85.66	O
	O
	O
,	O
77.24	O
	O
	O
,	O
and	O
74.92	O
	O
	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
using	O
single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
HRM	O
analysis	O
showed	O
100%	O
consistency	O
with	O
those	O
obtained	O
using	O
conventional	O
gap-PCR	O
.	O

CONCLUSIONS	O
:	O
Single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
HRM	O
analysis	O
is	O
a	O
potential	O
alternative	O
for	O
routine	O
clinical	O
screening	O
of	O
the	O
common	O
types	O
of	O
a-	O
and	O
b-thalassemia	O
large	O
gene	O
deletions	O
,	O
since	O
it	O
is	O
simple	O
,	O
cost-effective	O
,	O
and	O
highly	O
accurate	O
.	O

Xeroderma	O
pigmentosum	O
variant	O
:	O
complementary	O
molecular	O
approaches	O
to	O
detect	O
a	O
13	O
base	O
pair	O
deletion	O
in	O
the	O
DNA	O
polymerase	O
eta	O
gene	O
.	O

Deficiencies	O
of	O
DNA	O
polymerase	O
eta-an	O
enzyme	O
mediating	O
replication	O
past	O
UV-induced	O
DNA	O
damage-predispose	O
individuals	O
to	O
xeroderma	O
pigmentosum	O
variant	O
(XPV)	O
and	O
result	O
in	O
a	O
high	O
incidence	O
of	O
skin	O
cancers	O
.	O

We	O
designed	O
,	O
developed	O
and	O
assessed	O
several	O
complementary	O
molecular	O
approaches	O
to	O
detect	O
a	O
genetically	O
inherited	O
deletion	O
within	O
DNA	O
polymerase	O
eta	O
.	O

RNA	O
was	O
reverse	O
transcribed	O
from	O
XPV	O
fibroblasts	O
and	O
from	O
normal	O
human	O
cells	O
,	O
and	O
standard	O
polymerase	O
chain	O
reaction	O
(PCR)	O
was	O
conducted	O
on	O
the	O
cDNA	O
targeting	O
a	O
region	O
with	O
a	O
13	O
base	O
pair	O
deletion	O
within	O
the	O
polymerase	O
eta	O
gene	O
.	O

PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
and	O
cycle	O
DNA	O
sequencing	O
.	O

The	O
deletion	O
was	O
found	O
to	O
eliminate	O
a	O
BsrGI	O
restriction	O
site	O
and	O
affected	O
the	O
number	O
of	O
resultant	O
fragments	O
visualized	O
after	O
gel	O
electrophoresis	O
.	O

Cycle	O
sequencing	O
of	O
polymerase	O
eta-specific	O
amplicons	O
from	O
XPV	O
and	O
normal	O
cells	O
provided	O
a	O
second	O
approach	O
for	O
detecting	O
the	O
mutation	O
.	O

Additionally	O
,	O
the	O
use	O
of	O
a	O
fluorescent	O
nucleic	O
acid	O
dye-EvaGreen-in	O
real-time	O
PCR	O
and	O
melt	O
curve	O
analysis	O
distinguished	O
normal	O
and	O
XPV	O
patient-derived	O
amplicons	O
as	O
well	O
as	O
heteroduplexes	O
that	O
represent	O
heterozygotic	O
carriers	O
without	O
the	O
need	O
for	O
high	O
resolution	O
melt	O
analysis-compatible	O
software	O
.	O

Our	O
approaches	O
are	O
easily	O
adaptable	O
by	O
diagnostic	O
laboratories	O
that	O
screen	O
for	O
or	O
verify	O
genetically	O
inherited	O
disorders	O
and	O
identify	O
carriers	O
of	O
a	O
defective	O
gene	O
.	O

C10ORF97	O
is	O
a	O
novel	O
tumor-suppressor	O
gene	O
of	O
non-small-cell	O
lung	O
cancer	O
and	O
a	O
functional	O
variant	O
of	O
this	O
gene	O
increases	O
the	O
risk	O
of	O
non-small-cell	O
lung	O
cancer	O
.	O

In	O
an	O
earlier	O
study	O
we	O
showed	O
that	O
C10ORF97	O
(	O
chromosome-10	O
,	O
open	O
reading	O
frame-97	O
)	O
was	O
expressed	O
in	O
almost	O
all	O
of	O
the	O
tissues	O
and	O
cell	O
lines	O
tested	O
,	O
and	O
that	O
it	O
inhibited	O
the	O
growth	O
of	O
seven	O
tumor	O
cell	O
lines	O
,	O
including	O
two	O
lung	O
carcinoma	O
cell	O
lines	O
(	O
A549	O
and	O
PG	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
C10ORF97	O
is	O
downregulated	O
in	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
tissue	O
compared	O
with	O
normal	O
lung	O
tissue	O
.	O

Overexpression	O
of	O
C10ORF97	O
significantly	O
suppressed	O
human	O
lung	O
carcinoma	O
A549	O
cell	O
growth	O
(	O
proliferation	O
and	O
anchorage-independent	O
growth	O
in	O
soft	O
agar	O
)	O
and	O
motility	O
(	O
migration	O
and	O
adhesion	O
)	O
.	O

This	O
tumor-suppressive	O
function	O
of	O
C10ORF97	O
was	O
also	O
verified	O
in	O
vivo	O
.	O

We	O
further	O
found	O
that	O
C10ORF97	O
caused	O
G(1)	O
arrest	O
of	O
A549	O
cells	O
and	O
modulated	O
the	O
expression	O
level	O
of	O
several	O
cell-cycle	O
regulators	O
(	O
such	O
as	O
CDK2	O
,	O
cyclin-E	O
and	O
p27	O
)	O
.	O

These	O
effects	O
of	O
C10ORF97	O
were	O
mediated	O
by	O
physical	O
association	O
between	O
C10ORF97	O
and	O
Jun-activating	O
domain-binding	O
protein-1	O
(JAB1)	O
,	O
and	O
blocking	O
of	O
JAB1-mediated	O
translocation	O
of	O
p27	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Together	O
,	O
these	O
results	O
indicated	O
that	O
C10ORF97	O
functions	O
as	O
a	O
novel	O
tumor	O
suppressor	O
by	O
modulating	O
several	O
key	O
G(1)/S-regulatory	O
proteins	O
by	O
interacting	O
with	O
JAB1	O
.	O

These	O
findings	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
single-nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
C10ORF97	O
gene	O
that	O
affects	O
its	O
expression	O
might	O
be	O
associated	O
with	O
susceptibility	O
to	O
NSCLC	O
.	O

SNP216	O
C>T	B-DNAMutation
rs2297882	B-SNP
in	O
the	O
C10ORF97	O
Kozak	O
sequence	O
was	O
identified	O
,	O
and	O
allele	O
T	O
of	O
SNP216	O
suppressed	O
C10ORF97	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
TT	O
genotype	O
of	O
SNP216	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
NSCLC	O
(	O
adjusted	O
odds	O
ratio=1.73	O
(	O
95%	O
confidence	O
interval	O
:	O
1.33-2.25	O
)	O
,	O
P=4.6	O
	O
	O
10(-5)	O
)	O
.	O

These	O
data	O
indicated	O
that	O
C10ORF97	O
is	O
a	O
tumor	O
suppressor	O
of	O
NSCLC	O
progression	O
and	O
C10ORF97-SNP216	O
may	O
serve	O
as	O
a	O
predictor	O
of	O
NSCLC	O
.	O

MHC	O
region	O
and	O
risk	O
of	O
systemic	O
lupus	O
erythematosus	O
in	O
African	O
American	O
women	O
.	O

The	O
major	O
histocompatibility	O
complex	O
(MHC)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
.	O

Although	O
SLE	O
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
,	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	O
region	O
in	O
relationship	O
to	O
SLE	O
in	O
African	O
Americans	O
.	O

We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	O
region	O
for	O
1,536	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	O
gene	O
in	O
a	O
SLE	O
case-control	O
study	O
(	O
380	O
cases	O
,	O
765	O
age-matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women's	O
Health	O
Study	O
.	O

We	O
also	O
genotyped	O
1,509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O

The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	O
was	O
the	O
rs9271366	B-SNP
(	O
odds	O
ratio	O
,	O
OR	O
=	O
1.70	O
,	O
p	O
=	O
5.6	O
	O
	O
10(-5)	O
)	O
near	O
the	O
HLA-DRB1	O
gene	O
.	O

Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
,	O
rs204890	B-SNP
(	O
OR	O
=	O
1.86	O
,	O
p	O
=	O
1.2	O
	O
	O
10(-4)	O
)	O
,	O
rs2071349	B-SNP
(	O
OR	O
=	O
1.53	O
,	O
p	O
=	O
1.0	O
	O
	O
10(-3)	O
)	O
,	O
and	O
rs2844580	B-SNP
(	O
OR	O
=	O
1.43	O
,	O
p	O
=	O
1.3	O
	O
	O
10(-3)	O
)	O
,	O
to	O
be	O
associated	O
with	O
SLE	O
independent	O
of	O
the	O
rs9271366	B-SNP
SNP	O
.	O

In	O
univariate	O
analysis	O
,	O
the	O
OR	O
for	O
the	O
C4A	O
deletion	O
was	O
1.38	O
,	O
p	O
=	O
0.075	O
,	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1.01	O
,	O
p	O
=	O
0.98	O
.	O

A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high-risk	O
alleles	O
(	O
OR	O
=	O
1.67	O
per	O
high-risk	O
allele	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Our	O
strongest	O
signal	O
,	O
the	O
rs9271366	B-SNP
SNP	O
,	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	O
in	O
a	O
previous	O
Chinese	O
genome-wide	O
association	O
study	O
(GWAS)	O
.	O

In	O
addition	O
,	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	O
were	O
confirmed	O
in	O
our	O
study	O
,	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	O
with	O
European	O
and	O
Chinese	O
subjects	O
.	O

In	O
summary	O
,	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	O
region	O
associated	O
with	O
risk	O
of	O
SLE	O
in	O
African	O
American	O
women	O
.	O

Molecular	O
and	O
clinical	O
analysis	O
of	O
glioblastoma	O
with	O
an	O
oligodendroglial	O
component	O
(GBMO)	O
.	O

The	O
genetic	O
and	O
clinical	O
features	O
of	O
glioblastoma	O
with	O
an	O
oligodendroglial	O
component	O
(GBMO)	O
,	O
pathologically	O
defined	O
as	O
anaplastic	O
oligo-astrocytoma	O
with	O
necrosis	O
,	O
remain	O
unclear	O
.	O

We	O
investigated	O
the	O
correlation	O
between	O
genetic	O
alterations	O
and	O
clinical	O
outcomes	O
in	O
19	O
GBMO	O
patients	O
we	O
have	O
encountered	O
since	O
1997	O
.	O

Using	O
single	O
nucleotide	O
polymorphism	O
oligonucleotide	O
genomic	O
(SNP)	O
microarrays	O
,	O
we	O
analyzed	O
gene	O
amplification	O
,	O
loss	O
of	O
heterozygosity	O
(LOH)	O
,	O
and	O
homozygous	O
deletions	O
in	O
their	O
whole	O
genome	O
.	O

We	O
also	O
analyzed	O
their	O
overall	O
survival	O
(OS)	O
.	O

Pathological	O
studies	O
revealed	O
the	O
presence	O
of	O
calcification	O
in	O
11	O
and	O
of	O
a	O
cyst	O
in	O
9	O
of	O
the	O
19	O
patients	O
.	O

Whole-genome	O
analysis	O
using	O
SNP	O
microarrays	O
revealed	O
LOH	O
of	O
chromosome	O
10	O
in	O
11	O
,	O
EGFR	O
amplification	O
in	O
8	O
,	O
9p21	O
(	O
INK4	O
locus	O
)	O
deletion	O
in	O
12	O
,	O
PDGFR	O
amplification	O
in	O
2	O
,	O
and	O
LOH	O
of	O
1p19q	O
in	O
2	O
patients	O
.	O

Median	O
OS	O
was	O
14	O
	O
months	O
(	O
average	O
22.8	O
	O
months	O
)	O
.	O

The	O
pattern	O
of	O
genetic	O
alterations	O
was	O
similar	O
in	O
GBMO	O
and	O
glioblastoma	O
multiforme	O
(GBM)	O
patients	O
,	O
and	O
the	O
clinical	O
outcomes	O
were	O
similar	O
in	O
GBMO	O
and	O
GBM	O
patients	O
.	O

Exploratory	O
investigation	O
on	O
functional	O
significance	O
of	O
ETS2	O
and	O
SIM2	O
genes	O
in	O
Down	O
syndrome	O
.	O

Trisomy	O
of	O
the	O
21{st}	O
chromosome	O
leads	O
to	O
an	O
over	O
dosage	O
of	O
several	O
regulatory	O
genes	O
in	O
Down	O
syndrome	O
(DS)	O
.	O

Though	O
allelic	O
and	O
genotypic	O
combinations	O
formed	O
between	O
genes	O
are	O
interesting	O
,	O
till	O
date	O
,	O
this	O
particular	O
area	O
has	O
never	O
been	O
explored	O
in	O
DS	O
.	O

In	O
the	O
present	O
investigation	O
four	O
SNPs	O
in	O
two	O
transcription	O
factors	O
,	O
Single	O
minded	O
2	O
(SIM2)	O
and	O
V-ets	O
erythroblastosis	O
virus	O
E26	O
oncogene	O
homolog2	O
(ETS2)	O
,	O
located	O
in	O
the	O
21{st}	O
chromosome	O
were	O
genotyped	O
to	O
understand	O
their	O
role	O
in	O
DS	O
.	O

Genomic	O
DNA	O
of	O
eastern	O
Indian	O
probands	O
with	O
DS	O
(N=132)	O
,	O
their	O
parents	O
(N=209)	O
and	O
ethnically	O
matched	O
controls	O
(N=149)	O
was	O
subjected	O
to	O
PCR-based	O
analyses	O
of	O
functionally	O
important	O
SNPs	O
followed	O
by	O
statistical	O
analyses	O
.	O

ETS2	O
rs461155	B-SNP
showed	O
high	O
heterozygosity	O
in	O
DS	O
.	O

Significantly	O
lower	O
frequency	O
of	O
SIM2	O
C-G	O
haplotype	O
rs2073601	B-SNP
-	O
rs2073416	B-SNP
was	O
noticed	O
in	O
individuals	O
with	O
DS	O
(	O
P	O
value	O
=0.01669	O
)	O
and	O
their	O
fathers	O
(	O
P	O
value=0.01185	O
)	O
.	O

Significantly	O
lower	O
frequency	O
of	O
the	O
A-C-C-G	O
with	O
higher	O
frequency	O
of	O
A-C-A-G	O
haplotypes	O
was	O
also	O
noticed	O
in	O
subjects	O
with	O
DS	O
(	O
P	O
value	O
=0.02089	O
and	O
0.00588	O
respectively	O
)	O
.	O

Data	O
obtained	O
indicate	O
that	O
the	O
rs2073601	B-SNP
'A'	O
allele	O
,	O
responsible	O
for	O
nonsynonymous	O
substitution	O
of	O
leucine	O
to	O
methionine	O
,	O
may	O
have	O
some	O
role	O
in	O
DS	O
in	O
this	O
population	O
.	O

APOE	O
genotype-function	O
relationship	O
:	O
evidence	O
of	O
-491	B-DNAMutation
A/T	I-DNAMutation
promoter	O
polymorphism	O
modifying	O
transcription	O
control	O
but	O
not	O
type	O
2	O
diabetes	O
risk	O
.	O

BACKGROUND	O
:	O
The	O
apolipoprotein	O
E	O
gene	O
(APOE)	O
coding	O
polymorphism	O
modifies	O
the	O
risks	O
of	O
Alzheimer's	O
disease	O
,	O
type	O
2	O
diabetes	O
,	O
and	O
coronary	O
heart	O
disease	O
.	O

Aside	O
from	O
the	O
coding	O
variants	O
,	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
of	O
the	O
APOE	O
promoter	O
has	O
also	O
been	O
shown	O
to	O
modify	O
the	O
risk	O
of	O
Alzheimer's	O
disease	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
In	O
this	O
study	O
we	O
investigate	O
the	O
genotype-function	O
relationship	O
of	O
APOE	O
promoter	O
polymorphism	O
at	O
molecular	O
level	O
and	O
at	O
physiological	O
level	O
:	O
i.e.	O
,	O
in	O
transcription	O
control	O
of	O
the	O
gene	O
and	O
in	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

In	O
molecular	O
studies	O
,	O
the	O
effect	O
of	O
the	O
APOE	O
-491A/T	B-DNAMutation
rs449647	B-SNP
polymorphism	O
on	O
gene	O
transcription	O
was	O
accessed	O
by	O
dual-luciferase	O
reporter	O
gene	O
assays	O
.	O

The	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
substitution	O
decreased	O
the	O
activity	O
(p<0.05)	O
of	O
the	O
cloned	O
APOE	O
promoter	O
(	O
-1017	O
to	O
+406	O
)	O
.	O

Using	O
the	O
-501	O
to	O
-481	O
nucleotide	O
sequence	O
of	O
the	O
APOE	O
promoter	O
as	O
a	O
'bait'	O
to	O
screen	O
the	O
human	O
brain	O
cDNA	O
library	O
by	O
yeast	O
one-hybrid	O
system	O
yielded	O
ATF4	O
,	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
gene	O
,	O
as	O
one	O
of	O
the	O
interacting	O
factors	O
.	O

Electrophoretic-mobility-shift	O
assays	O
(EMSA)	O
and	O
chromatin	O
immuno-precipitation	O
(ChIP)	O
analyses	O
further	O
substantiated	O
the	O
physical	O
interaction	O
between	O
ATF4	O
and	O
the	O
APOE	O
promoter	O
.	O

Over-expression	O
of	O
ATF4	O
stimulated	O
APOE	O
expression	O
whereas	O
siRNA	O
against	O
ATF4	O
suppressed	O
the	O
expression	O
of	O
the	O
gene	O
.	O

However	O
,	O
interaction	O
between	O
APOE	O
promoter	O
and	O
ATF4	O
was	O
not	O
-491A/T-specific	B-DNAMutation
.	O

At	O
physiological	O
level	O
,	O
the	O
genotype-function	O
relationship	O
of	O
APOE	O
promoter	O
polymorphism	O
was	O
studied	O
in	O
type	O
2	O
diabetes	O
.	O

In	O
630	O
cases	O
and	O
595	O
controls	O
,	O
three	O
APOE	O
promoter	O
SNPs	O
-491A/T	B-DNAMutation
,	O
-219G/T	B-DNAMutation
rs405509	B-SNP
,	O
and	O
+113G/C	B-DNAMutation
rs440446	B-SNP
were	O
genotyped	O
and	O
tested	O
for	O
association	O
with	O
type	O
2	O
diabetes	O
in	O
Hong	O
Kong	O
Chinese	O
.	O

No	O
SNP	O
or	O
haplotype	O
association	O
with	O
type	O
2	O
diabetes	O
was	O
detected	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
At	O
molecular	O
level	O
,	O
polymorphism	O
-491A/T	B-DNAMutation
and	O
ATF4	O
elicit	O
independent	O
control	O
of	O
APOE	O
gene	O
expression	O
.	O

At	O
physiological	O
level	O
,	O
no	O
genotype-risk	O
association	O
was	O
detected	O
between	O
the	O
studied	O
APOE	O
promoter	O
SNPs	O
and	O
type	O
2	O
diabetes	O
in	O
Hong	O
Kong	O
Chinese	O
.	O

Resequencing	O
of	O
IRS2	O
reveals	O
rare	O
variants	O
for	O
obesity	O
but	O
not	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Our	O
objective	O
was	O
to	O
resequence	O
insulin	O
receptor	O
substrate	O
2	O
(IRS2)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity-	O
and	O
diabetes-related	O
traits	O
in	O
Hispanic	O
children	O
.	O

Exonic	O
and	O
intronic	O
segments	O
,	O
5'	O
and	O
3'	O
flanking	O
regions	O
of	O
IRS2	O
(	O
	O
	O
14.5	O
kb	O
)	O
,	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O

Additionally	O
,	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1-Quad	O
BeadChips	O
were	O
analyzed	O
.	O

Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	O
and	O
diabetes-related	O
traits	O
.	O

Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O

A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(MAF)	O
ranging	O
from	O
0.001	O
to	O
0.47	O
.	O

Forty-two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
;	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
,	O
12	O
in	O
introns	O
,	O
28	O
in	O
the	O
3'-UTR	O
,	O
and	O
2	O
in	O
the	O
5'-UTR	O
.	O

Two	O
insertion/deletions	O
(indels)	O
were	O
detected	O
.	O

Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0.001-0.009	O
)	O
were	O
associated	O
with	O
obesity-related	O
traits	O
(	O
P	O
=	O
0.01-0.00002	O
)	O
.	O

SNP	O
10510452_139	O
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0.77-0.86	O
)	O
of	O
influencing	O
BMI	O
,	O
fat	O
mass	O
,	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O

SNP	O
10510452_139	O
contributed	O
between	O
2	O
and	O
4%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O

None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes-related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	O
.	O

Rare	O
but	O
not	O
common	O
IRS2	O
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

A	O
large	O
heterozygous	O
deletion	O
including	O
the	O
entire	O
C1	O
inhibitor	O
gene	O
in	O
a	O
sporadic	O
case	O
of	O
hereditary	O
angio-oedema	O
.	O

C1	O
inhibitor	O
(C1-INH)	O
deficiency	O
[	O
hereditary	O
or	O
acquired	O
angio-oedema	O
(	O
HAE	O
or	O
AAE)	O
]	O
is	O
characterized	O
by	O
recurring	O
episodes	O
of	O
subcutaneous	O
or	O
submucosal	O
oedema	O
.	O

Many	O
different	O
mutations	O
in	O
the	O
C1-INH	O
gene	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
HAE	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
in	O
a	O
Japanese	O
woman	O
with	O
sporadic	O
HAE	O
.	O

Direct	O
sequencing	O
of	O
genomic	O
DNA	O
revealed	O
no	O
point	O
mutation	O
in	O
the	O
C1-INH	O
gene	O
.	O

Quantitative	O
real-time	O
PCR	O
showed	O
that	O
the	O
copy	O
number	O
of	O
the	O
C1-INH	O
gene	O
in	O
the	O
patient	O
was	O
half	O
that	O
of	O
a	O
healthy	O
control	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
650-kbp	O
deletion	O
on	O
the	O
chromosome	O
,	O
which	O
included	O
the	O
C1-INH	O
gene	O
.	O

We	O
evaluated	O
the	O
correlation	O
between	O
the	O
patient's	O
attacks	O
and	O
her	O
coagulation	O
activity	O
.	O

The	O
levels	O
of	O
D-dimer	O
were	O
high	O
during	O
the	O
angio-oedema	O
attacks	O
,	O
and	O
often	O
exceeded	O
the	O
normal	O
range	O
even	O
during	O
remission	O
,	O
thus	O
the	O
level	O
of	O
D-dimer	O
reflected	O
the	O
activity	O
of	O
HAE	O
in	O
this	O
patient	O
.	O

Phenotype	O
of	O
the	O
202	O
adenine	O
deletion	O
in	O
the	O
parkin	O
gene	O
:	O
40	O
years	O
of	O
follow-up	O
.	O

BACKGROUND	O
:	O
We	O
describe	O
the	O
four	O
decades	O
follow-up	O
of	O
14	O
parkin	O
patients	O
belonging	O
to	O
two	O
large	O
eight-generation-long	O
in-bred	O
Muslim-Arab	O
kindreds	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
a	O
single	O
base-pair	O
of	O
adenine	O
deletion	O
at	O
nucleotide	O
202	O
of	O
exon	O
2	O
(202A)	O
of	O
the	O
parkin	O
gene	O
(	O
all	O
homozygous	O
,	O
one	O
heterozygous	O
)	O
.	O

Parkinson's	O
disease	O
onset	O
age	O
was	O
17-68	O
years	O
.	O

Special	O
features	O
were	O
intractable	O
axial	O
symptoms	O
(	O
low	O
back	O
pain	O
,	O
scoliosis	O
,	O
camptocormia	O
,	O
antecollis	O
)	O
,	O
postural	O
tremor	O
,	O
and	O
preserved	O
cognition	O
.	O

CONCLUSIONS	O
:	O
The	O
202A	O
deletion	O
of	O
the	O
parkin	O
gene	O
causes	O
early-onset	O
Parkinson's	O
disease	O
with	O
marked	O
levodopa/STN-DBS-resistant	O
axial	O
features	O
.	O

Postural	O
tremor	O
and	O
preserved	O
cognition	O
,	O
even	O
after	O
40	O
years	O
of	O
disease	O
,	O
were	O
also	O
evident	O
.	O

Two	O
novel	O
mutations	O
of	O
the	O
PAX6	O
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
.	O

PURPOSE	O
:	O
Aniridia	O
(AN)	O
is	O
a	O
rare	O
congenital	O
panocular	O
disorder	O
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	O
box	O
homeotic	O
gene	O
6(PAX6)	O
gene	O
.	O

The	O
PAX6gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	O
segment	O
malformations	O
including	O
Peters	O
anomaly	O
.	O

We	O
studied	O
the	O
PAX6gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroid	O
,	O
or	O
anterior	O
segment	O
malformations	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	O
were	O
examined	O
clinically	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O

Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR-amplified	O
DNA	O
fragments	O
.	O

Multiplex	O
ligation-dependent	O
probe	O
amplification	O
(MLPA)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O

RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	O
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroids	O
,	O
and	O
the	O
anterior	O
segment	O
malformations	O
including	O
peters	O
anomaly	O
.	O

Sequencing	O
of	O
the	O
PAX6gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing-site	O
mutations	O
c.357-3C>G	B-DNAMutation
p.Ser119fsX	B-ProteinMutation
were	O
identified	O
in	O
the	O
patients	O
of	O
the	O
AN	O
group	O
.	O

A	O
novel	O
missense	O
mutation	O
c.643T>C	B-DNAMutation
p.S216P	B-ProteinMutation
was	O
detected	O
in	O
the	O
anterior	O
segment	O
malformation	O
group	O
.	O

The	O
mutation	O
p.S216P	B-ProteinMutation
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	O
caused	O
the	O
phenotype	O
of	O
Peters	O
anomaly	O
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O

Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6gene	O
and	O
DKFZ	O
p686k1684gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	O
from	O
the	O
AN	O
group	O
.	O

Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	O
of	O
iris	O
and	O
choroid	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6gene	O
.	O

Screening	O
and	O
cell-based	O
assessment	O
of	O
mutations	O
in	O
the	O
Aristaless-related	O
homeobox	O
(ARX)	O
gene	O
.	O

ARX	O
mutations	O
cause	O
a	O
diverse	O
spectrum	O
of	O
human	O
disorders	O
,	O
ranging	O
from	O
severe	O
brain	O
and	O
genital	O
malformations	O
to	O
non-syndromic	O
intellectual	O
disability	O
(ID)	O
.	O

ARX	O
is	O
a	O
transcription	O
factor	O
with	O
multiple	O
domains	O
that	O
include	O
four	O
polyalanine	O
(pA)	O
tracts	O
,	O
the	O
first	O
two	O
of	O
which	O
are	O
frequently	O
expanded	O
by	O
mutations	O
.	O

We	O
progressively	O
screened	O
DNA	O
samples	O
from	O
613	O
individuals	O
with	O
ID	O
initially	O
for	O
the	O
most	O
frequent	O
ARX	O
mutations	O
(	O
c.304ins(GCG)(7)'expansion'	B-DNAMutation
of	O
pA1	O
and	O
c.429_452dup	B-DNAMutation
'dup24bp'	B-DNAMutation
of	O
pA2	O
)	O
.	O

Five	O
hundred	O
samples	O
without	O
pA1	O
or	O
pA2	O
mutations	O
had	O
the	O
entire	O
ARX	O
ORF	O
screened	O
by	O
single	O
stranded	O
polymorphism	O
conformation	O
(SSCP)	O
and/or	O
denaturing	O
high	O
pressure	O
liquid	O
chromatography	O
(dHPLC)	O
analysis	O
.	O

Overall	O
,	O
eight	O
families	O
with	O
six	O
mutations	O
in	O
ARX	O
were	O
identified	O
(1.31%)	O
:	O
five	O
duplication	O
mutations	O
in	O
pA2	O
(0.82%)	O
with	O
three	O
new	O
clinical	O
reports	O
of	O
families	O
with	O
the	O
dup24bp	B-DNAMutation
and	O
two	O
duplications	O
larger	O
than	O
the	O
dup24bp	B-DNAMutation
mutation	O
discovered	O
(	O
dup27bp	B-DNAMutation
,	O
dup33bp	B-DNAMutation
)	O
;	O
and	O
three	O
point	O
mutations	O
(0.6%)	O
,	O
including	O
one	O
novel	O
mutation	O
in	O
the	O
homeodomain	O
c.1074G>T	B-DNAMutation
.	O

Four	O
ultraconserved	O
regions	O
distal	O
to	O
ARX	O
(uc466-469)	O
were	O
also	O
screened	O
in	O
a	O
subset	O
of	O
94	O
patients	O
,	O
with	O
three	O
unique	O
nucleotide	O
changes	O
identified	O
in	O
two	O
(	O
uc466	O
,	O
uc467	O
)	O
.	O

The	O
subcellular	O
localization	O
of	O
full	O
length	O
ARX	O
proteins	O
was	O
assessed	O
for	O
11	O
variants	O
.	O

Protein	O
mislocalization	O
increased	O
as	O
a	O
function	O
of	O
pA2	O
tract	O
length	O
and	O
phenotypic	O
severity	O
,	O
as	O
has	O
been	O
previously	O
suggested	O
for	O
pA1	O
.	O

Similarly	O
,	O
protein	O
mislocalization	O
of	O
the	O
homeodomain	O
mutations	O
also	O
correlated	O
with	O
clinical	O
severity	O
,	O
suggesting	O
an	O
emerging	O
genotype	O
vs	O
cellular	O
phenotype	O
correlation	O
.	O

Variation	O
in	O
genotype	O
and	O
higher	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
causing	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

Sporotrichosis	O
is	O
usually	O
a	O
localized	O
,	O
lymphocutaneous	O
disease	O
,	O
but	O
its	O
disseminated	O
type	O
was	O
rarely	O
reported	O
.	O

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
specific	O
DNA	O
sequence	O
variation	O
and	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
isolated	O
from	O
the	O
lesion	O
of	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

We	O
confirmed	O
this	O
strain	O
to	O
be	O
S	O
.	O

schenckii	O
by(	O
	O
)	O
tubulin	O
and	O
chitin	O
synthase	O
gene	O
sequence	O
analysis	O
in	O
addition	O
to	O
the	O
routine	O
mycological	O
and	O
partial	O
ITS	O
and	O
NTS	O
sequencing	O
.	O

We	O
found	O
a	O
10-bp	O
deletion	O
in	O
the	O
ribosomal	O
NTS	O
region	O
of	O
this	O
strain	O
,	O
in	O
reference	O
to	O
the	O
sequence	O
of	O
control	O
strains	O
isolated	O
from	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

After	O
inoculated	O
into	O
immunosuppressed	O
mice	O
,	O
this	O
strain	O
caused	O
more	O
extensive	O
system	O
involvement	O
and	O
showed	O
stronger	O
virulence	O
than	O
the	O
control	O
strain	O
isolated	O
from	O
a	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

Our	O
study	O
thus	O
suggests	O
that	O
different	O
clinical	O
manifestation	O
of	O
sporotrichosis	O
may	O
be	O
associated	O
with	O
variation	O
in	O
genotype	O
and	O
virulence	O
of	O
the	O
strain	O
,	O
independent	O
of	O
effects	O
due	O
to	O
the	O
immune	O
status	O
of	O
the	O
host	O
.	O

Identification	O
of	O
a	O
novel	O
FBN1	O
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin-1	O
gene	O
(FBN1)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
(MFS)	O
.	O

METHODS	O
:	O
Patients	O
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	O
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4.0.1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
c.3703T>C	B-DNAMutation
change	O
in	O
exon	O
29	O
of	O
FBN1	O
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
by	O
proline	O
at	O
codon	O
1235	O
p.S1235P	B-ProteinMutation
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	O
binding	O
epidermal	O
growth	O
factor-like#15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
p.S1235P	B-ProteinMutation
mutation	O
in	O
FBN1	O
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	O
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	O
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	O
syndrome	O
.	O

The	O
57	O
kb	O
deletion	O
in	O
cystinosis	O
patients	O
extends	O
into	O
TRPV1	O
causing	O
dysregulation	O
of	O
transcription	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

BACKGROUND	O
:	O
Cystinosis	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterised	O
by	O
the	O
abnormal	O
accumulation	O
of	O
lysosomal	O
cystine	O
.	O

Mutations	O
in	O
the	O
cystinosin	O
gene	O
(CTNS)	O
represent	O
known	O
causes	O
for	O
the	O
disease	O
.	O

The	O
major	O
cystinosis	O
mutation	O
is	O
a	O
57	O
kb	O
deletion	O
on	O
human	O
chromosome	O
17p13	O
that	O
removes	O
the	O
majority	O
of	O
CTNS	O
and	O
the	O
entire	O
adjacent	O
gene	O
,	O
CARKL/SHPK	O
.	O

OBJECTIVES	O
:	O
In	O
order	O
to	O
identify	O
other	O
genes	O
that	O
may	O
influence	O
the	O
cystinosis	O
pathobiological	O
pathway	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMC)	O
were	O
collected	O
from	O
cystinosis	O
family	O
members	O
,	O
and	O
DNA	O
and	O
RNA	O
extracted	O
.	O

RESULTS	O
:	O
Using	O
whole	O
genome	O
transcriptional	O
profiling	O
,	O
transient	O
receptor	O
potential	O
vanilloid	O
1	O
(TRPV1)	O
was	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
association	O
with	O
cystinosis	O
.	O

This	O
was	O
verified	O
using	O
TaqMan	O
qRT-PCR	O
.	O

There	O
was	O
a	O
72%	O
reduction	O
in	O
PBMC	O
TRPV1	O
mRNA	O
levels	O
in	O
cystinosis	O
individuals	O
homozygous	O
for	O
the	O
57	O
kb	O
deletion	O
(n=6)	O
compared	O
to	O
unaffected	O
individuals	O
without	O
the	O
deletion	O
(n=6)	O
(p=0.002)	O
.	O

TRPV1	O
is	O
a	O
sensory	O
receptor	O
located	O
on	O
chromosome	O
17p13	O
,	O
adjacent	O
to	O
CARKL/SHPK	O
.	O

It	O
was	O
ascertained	O
that	O
the	O
57	O
kb	O
deletion	O
extends	O
from	O
exon	O
10	O
of	O
CTNS	O
,	O
upstream	O
through	O
CARKL/SHPK	O
,	O
to	O
intron	O
2	O
of	O
TRPV1	O
,	O
thus	O
deleting	O
the	O
first	O
two	O
non-coding	O
exons	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
57	O
kb	O
deletion	O
extends	O
into	O
the	O
TRPV1	O
gene	O
causing	O
dysregulation	O
of	O
transcription	O
in	O
PBMC	O
isolated	O
from	O
cystinosis	O
patients	O
.	O

Strong	O
association	O
of	O
677	B-DNAMutation
C>T	I-DNAMutation
substitution	O
in	O
the	O
MTHFR	O
gene	O
with	O
male	O
infertility--a	O
study	O
on	O
an	O
indian	O
population	O
and	O
a	O
meta-analysis	O
.	O

BACKGROUND	O
:	O
Methylenetetrahydrofolate	O
reductase	O
(MTHFR)	O
is	O
an	O
important	O
enzyme	O
of	O
folate	O
and	O
methionine	O
metabolism	O
,	O
making	O
it	O
crucial	O
for	O
DNA	O
synthesis	O
and	O
methylation	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
MTHFR	O
gene	O
677C>T	B-DNAMutation
polymorphism	O
in	O
infertile	O
male	O
individuals	O
from	O
North	O
India	O
,	O
followed	O
by	O
a	O
meta-analysis	O
on	O
our	O
data	O
and	O
published	O
studies	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
We	O
undertook	O
genotyping	O
on	O
a	O
total	O
of	O
837	O
individuals	O
including	O
well	O
characterized	O
infertile	O
(N=522)	O
and	O
confirmed	O
fertile	O
(N=315)	O
individuals	O
.	O

The	O
SNP	O
was	O
typed	O
by	O
direct	O
DNA	O
sequencing	O
.	O

Chi	O
square	O
test	O
was	O
done	O
for	O
statistical	O
analysis	O
.	O

Published	O
studies	O
were	O
searched	O
using	O
appropriate	O
keywords	O
.	O

Source	O
of	O
data	O
collection	O
for	O
meta-analysis	O
included	O
'Pubmed'	O
,	O
'Ovid'	O
and	O
'Google	O
Scholar'	O
.	O

Those	O
studies	O
analyzing	O
677C>T	B-DNAMutation
polymorphism	O
in	O
male	O
infertility	O
and	O
presenting	O
all	O
relevant	O
data	O
were	O
included	O
in	O
meta-analysis	O
.	O

The	O
genotype	O
data	O
for	O
infertile	O
subjects	O
and	O
fertile	O
controls	O
was	O
extracted	O
from	O
each	O
study	O
.	O

Chi	O
square	O
test	O
was	O
done	O
to	O
obtain	O
odds	O
ratio	O
(OR)	O
and	O
p-value	O
.	O

Meta-analysis	O
was	O
performed	O
using	O
Comprehensive	O
Meta-analysis	O
software	O
(	O
Version	O
2	O
)	O
.	O

The	O
frequency	O
of	O
mutant	O
(T)	O
allele	O
(p=0.0025)	O
and	O
genotypes	O
(CT+TT)	O
(p=0.0187)	O
was	O
significantly	O
higher	O
in	O
infertile	O
individuals	O
in	O
comparison	O
to	O
fertile	O
controls	O
in	O
our	O
case-control	O
study	O
.	O

The	O
overall	O
summary	O
estimate	O
(OR)	O
for	O
allele	O
and	O
genotype	O
meta-analysis	O
were	O
1.304	O
(p=0.000)	O
,	O
1.310	O
(p=0.000)	O
,	O
respectively	O
,	O
establishing	O
significant	O
association	O
of	O
677C>T	B-DNAMutation
polymorphism	O
with	O
male	O
infertility	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
677C>T	B-DNAMutation
substitution	O
associated	O
strongly	O
with	O
male	O
infertility	O
in	O
Indian	O
population	O
.	O

Allele	O
and	O
genotype	O
meta-analysis	O
also	O
supported	O
its	O
strong	O
correlation	O
with	O
male	O
infertility	O
,	O
thus	O
establishing	O
it	O
as	O
a	O
risk	O
factor	O
.	O

Angiotensin-converting	O
enzyme	O
(ACE)	O
serum	O
levels	O
and	O
gene	O
polymorphism	O
in	O
Egyptian	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
polymorphism	O
and	O
serum	O
ACE	O
level	O
among	O
Egyptian	O
SLE	O
patients	O
and	O
its	O
relation	O
to	O
disease	O
activity	O
parameters	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
We	O
enrolled	O
50	O
Egyptian	O
female	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
patients	O
and	O
29	O
healthy	O
controls	O
.	O

Measurement	O
of	O
serum	O
ACE	O
level	O
was	O
done	O
using	O
ELISA	O
,	O
and	O
the	O
ACE	O
genotype	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
using	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
.	O

RESULTS	O
:	O
A	O
significant	O
difference	O
was	O
found	O
in	O
ACE	O
genotypes	O
between	O
SLE	O
patients	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
7.84	O
,	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

The	O
frequency	O
of	O
ACE	O
DD	O
versus	O
(	O
DI	O
and	O
II	O
)	O
genotypes	O
was	O
significantly	O
higher	O
in	O
SLE	O
patients	O
compared	O
with	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
5.57	O
,	O
p	O
=	O
0.018	O
and	O
OR	O
for	O
risk	O
of	O
SLE	O
was	O
3.1	O
with	O
95%	O
confidence	O
interval	O
:	O
1.198.06	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
SLE	O
group	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.006	O
)	O
.	O

Subjects	O
with	O
DD	O
genotype	O
had	O
a	O
significantly	O
higher	O
mean	O
level	O
than	O
those	O
with	O
DI	O
(	O
p	O
	O
	O
=	O
	O
	O
0.015	O
)	O
and	O
II	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Lupus	O
nephritis	O
patients	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI	O
and	O
II	O
genotypes	O
compared	O
with	O
lupus	O
patients	O
without	O
nephritis	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.025	O
)	O
and	O
controls	O
(	O
	O
	O
(2)	O
=8.74	O
,	O
p	O
	O
	O
=	O
	O
	O
0.003	O
)	O
.	O

SLE	O
patients	O
with	O
vasculopathy	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI/II	O
genotypes	O
compared	O
with	O
SLE	O
patients	O
without	O
vasculopathy	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
9.84	O
and	O
p	O
	O
	O
=	O
	O
	O
0.002	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
lupus	O
nephritis	O
and	O
SLE	O
patients	O
with	O
vasculopathy	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.008	O
,	O
p	O
	O
	O
=	O
	O
	O
0.001	O
,	O
respectively	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
found	O
between	O
serum	O
ACE	O
level	O
and	O
serum	O
creatinine	O
and	O
24	O
	O
	O
h	O
proteinuria	O
(	O
p	O
	O
	O
=	O
	O
	O
0.03	O
,	O
0.009	O
,	O
respectively	O
)	O
.	O

SLE	O
patients	O
with	O
DD	O
genotype	O
had	O
a	O
statistically	O
significant	O
higher	O
mean	O
SLEDAI	O
score	O
than	O
those	O
with	O
(DI/II)	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Significant	O
positive	O
correlation	O
was	O
found	O
between	O
serum	O
ACE	O
levels	O
and	O
SLEDAI	O
scores	O
(	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
.	O

CONCLUSION	O
:	O
ACE	O
genotype	O
and	O
subsequently	O
serum	O
ACE	O
level	O
could	O
be	O
associated	O
with	O
the	O
disease	O
activity	O
of	O
Egyptian	O
SLE	O
patients	O
;	O
in	O
addition	O
,	O
ACE	O
deletion	O
polymorphism	O
might	O
be	O
used	O
as	O
one	O
of	O
the	O
predictive	O
factors	O
for	O
the	O
activity	O
of	O
SLE	O
.	O

Further	O
studies	O
on	O
a	O
larger	O
number	O
of	O
patients	O
should	O
be	O
done	O
to	O
determine	O
the	O
exact	O
prevalence	O
of	O
ACE	O
gene	O
polymorphism	O
among	O
Egyptian	O
SLE	O
patients	O
.	O

Genotype	O
rs8099917	B-SNP
near	O
the	O
IL28B	O
gene	O
and	O
amino	O
acid	O
substitution	O
at	O
position	O
70	O
in	O
the	O
core	O
region	O
of	O
the	O
hepatitis	O
C	O
virus	O
are	O
determinants	O
of	O
serum	O
apolipoprotein	O
B-100	O
concentration	O
in	O
chronic	O
hepatitis	O
C	O
.	O

The	O
life	O
cycle	O
of	O
the	O
hepatitis	O
C	O
virus	O
(HCV)	O
is	O
closely	O
related	O
to	O
host	O
lipoprotein	O
metabolism	O
.	O

Serum	O
levels	O
of	O
lipid	O
are	O
associated	O
with	O
the	O
response	O
to	O
pegylated	O
interferon	O
plus	O
ribavirin	O
(PEG-IFN/RBV)	O
therapy	O
,	O
while	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
around	O
the	O
human	O
interleukin	O
28B	O
(IL28B)	O
gene	O
locus	O
and	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
have	O
been	O
reported	O
to	O
affect	O
the	O
efficacy	O
of	O
PEG-IFN/RBV	O
therapy	O
in	O
chronic	O
hepatitis	O
with	O
HCV	O
genotype	O
1b	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
relationship	O
between	O
serum	O
lipid	O
and	O
factors	O
that	O
are	O
able	O
to	O
predict	O
the	O
efficacy	O
of	O
PEG-IFN/RB	O
therapy	O
,	O
with	O
specific	O
focus	O
on	O
apolipoprotein	O
B-100	O
(apoB-100)	O
in	O
148	O
subjects	O
with	O
chronic	O
HCV	O
G1b	O
infection	O
.	O

Our	O
results	O
demonstrated	O
that	O
both	O
the	O
aa	O
70	O
substitution	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
and	O
the	O
rs8099917	B-SNP
SNP	O
located	O
proximal	O
to	O
the	O
IL28B	O
were	O
independent	O
factors	O
in	O
determining	O
serum	O
apoB-100	O
and	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	O
levels	O
.	O

A	O
significant	O
association	O
was	O
noted	O
between	O
higher	O
levels	O
of	O
apoB-100	O
(	O
P	O
=	O
1.1	O
	O
	O
10(-3)	O
)	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
0.02	O
)	O
and	O
the	O
subjects	O
having	O
Arg70	O
.	O

A	O
significant	O
association	O
was	O
also	O
observed	O
between	O
subjects	O
carrying	O
the	O
rs8099917	B-SNP
TT	O
responder	O
genotype	O
and	O
higher	O
levels	O
of	O
apoB-100	O
(	O
P	O
=	O
6.4	O
	O
	O
10(-3)	O
)	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
4.2	O
	O
	O
10(-3)	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
apoB-100	O
and	O
LDL	O
cholesterol	O
are	O
markers	O
of	O
impaired	O
cellular	O
lipoprotein	O
pathways	O
and/or	O
host	O
endogenous	O
interferon	O
response	O
to	O
HCV	O
in	O
chronic	O
HCV	O
infection	O
.	O

In	O
particular	O
,	O
serum	O
apoB-100	O
concentration	O
might	O
be	O
an	O
informative	O
marker	O
for	O
judging	O
changes	O
in	O
HCV-associated	O
intracellular	O
lipoprotein	O
metabolism	O
in	O
patients	O
carrying	O
the	O
rs8099917	B-SNP
responder	O
genotype	O
.	O

SLURP1	O
mutation-impaired	O
T-cell	O
activation	O
in	O
a	O
family	O
with	O
mal	O
de	O
Meleda	O
.	O

BACKGROUND	O
:	O
Mal	O
de	O
Meleda	O
(MDM)	O
is	O
palmoplantar	O
erythrokeratoderma	O
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP-1	O
(	O
lymphocyte	O
antigen	O
6/urokinase-type	O
plasminogen	O
activator	O
receptor	O
related	O
protein-1	O
)	O
.	O

SLURP-1	O
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
(nAchR)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O

In	O
addition	O
,	O
murine	O
studies	O
have	O
shown	O
that	O
nAchR	O
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T-cell	O
function	O
.	O

Among	O
the	O
family	O
members	O
,	O
patients	O
with	O
the	O
homozygous	O
SLURP1	O
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	O
and	O
viral	O
infection	O
,	O
which	O
might	O
link	O
to	O
defective	O
T-cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	O
gene	O
mutation	O
with	O
T-cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	O
.	O

To	O
test	O
that	O
SLURP-1	O
is	O
essential	O
for	O
T-cell	O
activation	O
.	O

METHODS	O
:	O
Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	O
family	O
bearing	O
the	O
G	O
to	O
A	O
substitution	O
in	O
nucleotide	O
256	O
in	O
the	O
SLURP1	O
gene	O
,	O
corresponding	O
to	O
a	O
glycine	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
86	O
G86R	B-ProteinMutation
in	O
the	O
SLURP-1	O
protein	O
.	O

PBMCs	O
from	O
homozygotes	O
and	O
wild-type	O
controls	O
were	O
stimulated	O
with	O
anti-CD3/anti-CD28	O
antibodies	O
and	O
the	O
level	O
of	O
T-cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O

RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP-1	O
G86R	B-ProteinMutation
mutation	O
had	O
defective	O
T-cell	O
activation	O
.	O

This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
	O
5	O
ug	O
mL(-1)	O
recombinant	O
human	O
SLURP-1	O
protein	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
MDM	O
with	O
the	O
homozygous	O
SLURP-1	O
G86R	B-ProteinMutation
mutation	O
may	O
have	O
an	O
impaired	O
T-cell	O
activation	O
.	O

The	O
presence	O
of	O
wild-type	O
SLURP-1	O
is	O
essential	O
for	O
normal	O
T-cell	O
activation	O
.	O

Interstitial	O
deletion	O
of	O
13q14.13-q32.3	O
presenting	O
with	O
Arima	O
syndrome	O
and	O
bilateral	O
retinoblastoma	O
.	O

A	O
patient	O
with	O
a	O
large	O
deletion	O
of	O
the	O
distal	O
part	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
13	O
showed	O
severe	O
psychomotor	O
retardation	O
,	O
a	O
characteristic	O
face	O
,	O
nystagmus	O
,	O
retinopathy	O
,	O
cystic	O
kidney	O
disease	O
,	O
and	O
brain	O
malformation	O
with	O
molar	O
tooth	O
sign	O
and	O
cerebellar	O
vermis	O
hypoplasia	O
,	O
a	O
phenotype	O
typical	O
of	O
Arima	O
syndrome	O
.	O

This	O
patient	O
also	O
had	O
bilateral	O
retinoblastoma	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
and	O
single-nucleotide-polymorphism	O
genotyping	O
microarray	O
demonstrated	O
an	O
interstitial	O
deletion	O
of	O
54	O
Mbp	O
,	O
ranging	O
from	O
13q14.13	O
to	O
13q32.3	O
and	O
involving	O
the	O
RB1	O
gene	O
.	O

This	O
patient	O
is	O
the	O
first	O
case	O
of	O
Arima	O
syndrome	O
,	O
or	O
a	O
Joubert	O
syndrome-related	O
disorder	O
,	O
that	O
showed	O
linkage	O
to	O
chromosome	O
13q	O
.	O

Impact	O
of	O
5,10-methylenetetrahydrofolate	O
reductase	O
gene	O
polymorphism	O
on	O
neural	O
tube	O
defects	O
.	O

OBJECT	O
:	O
Neural	O
tube	O
defects	O
(NTDs)	O
are	O
among	O
the	O
most	O
common	O
congenital	O
malformations	O
worldwide	O
.	O

Their	O
etiology	O
and	O
exact	O
mechanisms	O
of	O
development	O
are	O
incompletely	O
understood	O
.	O

Many	O
enzymes	O
involved	O
in	O
folate	O
metabolism	O
and	O
the	O
genes	O
encoding	O
these	O
enzymes	O
have	O
been	O
studied	O
as	O
candidates	O
in	O
their	O
etiology	O
.	O

A	O
mutation	O
in	O
the	O
methylenetetrahydrofolate	O
reductase	O
(MTHFR)	O
gene--a	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677--is	I-DNAMutation
one	O
among	O
them	O
.	O

The	O
mutation	O
results	O
in	O
substitution	O
of	O
alanine	O
by	O
valine	O
at	O
a	O
functionally	O
important	O
site	O
in	O
the	O
enzyme	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
a	O
risk	O
factor	O
for	O
development	O
of	O
NTDs	O
in	O
certain	O
populations	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
MTHFR	O
677	B-DNAMutation
C-->T	I-DNAMutation
mutation	O
as	O
a	O
risk	O
factor	O
for	O
NTD	O
in	O
the	O
South	O
Indian	O
population	O
and	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
the	O
genotypes	O
in	O
the	O
affected	O
child	O
and	O
its	O
mother	O
.	O

METHODS	O
:	O
Blood	O
samples	O
were	O
collected	O
from	O
the	O
test	O
and	O
the	O
control	O
groups	O
.	O

The	O
test	O
group	O
consisted	O
of	O
children	O
with	O
NTDs	O
and	O
their	O
mothers	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
apparently	O
healthy	O
controls	O
.	O

MTHFR	O
C677T	B-DNAMutation
polymorphism	O
in	O
the	O
3	O
groups	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
studies	O
.	O

Comparison	O
of	O
polymorphism	O
in	O
the	O
3	O
groups	O
was	O
using	O
the	O
chi-square	O
test	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
MTHFR	O
677	B-DNAMutation
C-->T	I-DNAMutation
mutation	O
among	O
the	O
3	O
groups	O
(	O
p	O
=	O
0.002	O
)	O
.	O

The	O
risk	O
conferred	O
by	O
the	O
TT	O
genotype	O
in	O
the	O
child	O
was	O
statistically	O
significant	O
(	O
OR	O
12.625	O
,	O
95%	O
CI	O
1.430-111.465	O
)	O
.	O

In	O
the	O
mothers	O
,	O
however	O
,	O
although	O
there	O
was	O
an	O
increased	O
prevalence	O
of	O
the	O
mutation	O
compared	O
with	O
the	O
control	O
individuals	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.152	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
MTHFR	O
677TT	O
genotype	O
is	O
considered	O
to	O
be	O
a	O
definite	O
risk	O
factor	O
for	O
development	O
of	O
NTDs	O
.	O

It	O
is	O
the	O
TT	O
genotype	O
status	O
of	O
the	O
developing	O
embryo	O
,	O
rather	O
than	O
the	O
TT	O
genotype	O
status	O
of	O
its	O
mother	O
,	O
that	O
is	O
the	O
critical	O
genetic	O
determinant	O
of	O
MTHFR-related	O
NTD	O
risk	O
.	O

Bikunin	O
and	O
a1-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
mutational	O
screening	O
in	O
patients	O
with	O
kidney	O
stones	O
:	O
a	O
case-control	O
study	O
.	O

OBJECTIVE	O
:	O
Bikunin	O
is	O
an	O
inhibitor	O
of	O
kidney	O
stone	O
formation	O
synthesized	O
in	O
the	O
liver	O
together	O
with	O
a(1)-microglobulin	O
from	O
the	O
a(1)-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
bikunin/AMBP	O
gene	O
polymorphisms	O
and	O
urinary	O
stone	O
formation	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
To	O
analyse	O
the	O
DNA	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
75	O
kidney	O
stone	O
formers	O
who	O
had	O
a	O
familial	O
stone	O
history	O
,	O
35	O
sporadic	O
stone	O
formers	O
and	O
101	O
healthy	O
individuals	O
.	O

Four	O
exons	O
of	O
bikunin	O
gene	O
and	O
five	O
parts	O
of	O
the	O
promoter	O
region	O
of	O
the	O
AMBP	O
gene	O
were	O
screened	O
using	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
The	O
Init-2	O
region	O
of	O
the	O
promoter	O
of	O
AMBP	O
gene	O
had	O
polymorphisms	O
at	O
positions	O
-218	O
and	O
-189	O
nt	O
giving	O
three	O
different	O
genotypes	O
having	O
1,3	O
,	O
2,4	O
and	O
1,2,3,4	O
alleles	O
with	O
frequencies	O
of	O
17.06%	O
,	O
60.19%	O
and	O
22.75%	O
,	O
respectively	O
,	O
in	O
all	O
groups	O
.	O

Therefore	O
,	O
the	O
Init-2	O
region	O
appears	O
to	O
be	O
polymorphic	O
.	O

As	O
a	O
result	O
,	O
the	O
1,3	O
allele	O
has	O
-218G	O
and	O
-189T	O
complying	O
with	O
the	O
reference	O
database	O
sequence	O
,	O
the	O
2,4	O
allele	O
has	O
-218G	O
and	O
T-189C	B-DNAMutation
substitution	O
and	O
the	O
allele	O
1,2,3,4	O
genotype	O
has	O
substitutions	O
at	O
positions	O
G-218C	B-DNAMutation
and	O
T-189C	B-DNAMutation
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
allele	O
distribution	O
between	O
patients	O
and	O
controls	O
.	O

These	O
common	O
alleles	O
exist	O
in	O
the	O
Turkish	O
population	O
independent	O
of	O
stone	O
formation	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
existence	O
of	O
bikunin	O
and	O
AMBP	O
promoter	O
polymorphism	O
.	O

Although	O
the	O
Init-2	O
region	O
of	O
the	O
AMBP	O
gene	O
is	O
the	O
binding	O
site	O
for	O
various	O
transcription	O
factors	O
,	O
the	O
results	O
showed	O
no	O
association	O
between	O
these	O
observed	O
genotypes	O
and	O
stone-forming	O
phenotypes	O
.	O

Novel	O
CRELD1	O
gene	O
mutations	O
in	O
patients	O
with	O
atrioventricular	O
septal	O
defect	O
.	O

BACKGROUND	O
:	O
Atrioventricular	O
septal	O
defects	O
(AVSDs)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
,	O
as	O
autosomal	O
dominant	O
defects	O
,	O
and	O
as	O
sporadically	O
occurring	O
malformations	O
.	O

Consequently	O
,	O
there	O
is	O
genetic	O
heterogeneity	O
,	O
but	O
until	O
recently	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	O
.	O

CRELD1	O
gene	O
,	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	O
.	O

METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	O
with	O
AVSD	O
and	O
200	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O

CRELD1	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
with	O
specific	O
primers	O
.	O

The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	O
and	O
controls	O
.	O

RESULTS	O
:	O
In	O
a	O
patient	O
,	O
a	O
C-to-G	O
transition	O
was	O
identified	O
at	O
nucleotide	O
857	O
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	O
for	O
proline	O
at	O
amino	O
acid	O
286	O
in	O
the	O
first	O
calcium-binding	O
EGF	O
domain	O
.	O

This	O
patient	O
had	O
an	O
isolated	O
partial	O
AVSD	O
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O

Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	O
with	O
a	O
partial	O
AVSD	O
and	O
evidence	O
of	O
Down	O
syndrome	O
.	O

The	O
heterozygous	O
c.973G>A	B-DNAMutation
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	O
for	O
glutamic	O
acid	O
at	O
amino	O
acid	O
325	O
E325K	B-ProteinMutation
in	O
the	O
second	O
calcium-binding	O
EGF	O
domain	O
.	O

CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	O
mutations	O
were	O
identified	O
in	O
the	O
calcium-binding	O
EGF	O
domain	O
in	O
patients	O
with	O
AVSD	O
.	O

CRELD1	O
is	O
likely	O
to	O
be	O
an	O
AVSD-susceptibility	O
gene	O
and	O
CRELD1	O
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	O
defect	O
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O

Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2/CYP11B1	O
locus	O
and	O
postoperative	O
hypertension	O
risk	O
in	O
the	O
patients	O
with	O
aldosterone-producing	O
adenomas	O
.	O

OBJECTIVES	O
:	O
Hypertension	O
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O

Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	O
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	O
synthesis	O
genes	O
(	O
CYP11B2	O
,	O
CYP11B1	O
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
for	O
aldosterone-producing	O
adenomas	O
(APA)	O
.	O

METHODS	O
:	O
Ninety-three	O
patients	O
with	O
APA	O
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	O
.	O

All	O
patients	O
were	O
genotyped	O
for	O
rs1799998	B-SNP
(	O
C-344	B-DNAMutation
T	I-DNAMutation
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	B-SNP
A2718G	B-DNAMutation
within	O
CYP11B2	O
and	O
rs6410	B-SNP
(	O
G22	B-DNAMutation
5A	I-DNAMutation
)	O
,	O
rs6387	B-SNP
A2803G	B-DNAMutation
within	O
CYP11B1	O
.	O

The	O
associations	O
between	O
CYPB11B2/CYP11B1	O
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	O
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O
CYP11B2-CYP11B1	O
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
with	O
APA	O
(	O
P	O
=	O
.006	O
)	O
.	O

Specifically	O
,	O
the	O
rs4539	B-SNP
(AA)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.002	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(AGACT)	O
,	O
H2	O
(AGAWT)	O
,	O
and	O
H3	O
(AGAWC)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.01	O
,	O
0.03	O
,	O
0.005	O
after	O
Bonferroni	O
correction	O
)	O
.	O

Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	O
included	O
duration	O
of	O
hypertension	O
(	O
P	O
<.0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	O
(	O
P	O
=	O
.001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.015	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rs4539	B-SNP
(AA)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	O
for	O
Chinese	O
patients	O
treated	O
by	O
adrenalectomy	O
with	O
APA	O
.	O

DNA	O
polymorphisms	O
at	O
CYP11B2/B1	O
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	O
of	O
patients	O
with	O
APA	O
.	O

The	O
GALT	O
rush	O
:	O
high	O
carrier	O
frequency	O
of	O
an	O
unusual	O
deletion	O
mutation	O
of	O
the	O
GALT	O
gene	O
in	O
the	O
Ashkenazi	O
population	O
.	O

Classic	O
galactosemia	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
galactose	O
metabolism	O
manifesting	O
in	O
the	O
first	O
weeks	O
of	O
life	O
following	O
exposure	O
to	O
a	O
milk-based	O
diet	O
.	O

Despite	O
the	O
benefit	O
of	O
avoidance	O
of	O
lactose	O
,	O
many	O
patients	O
suffer	O
from	O
long-term	O
complications	O
including	O
neurological	O
deficits	O
and	O
ovarian	O
failure	O
.	O

To	O
date	O
,	O
over	O
230	O
mutations	O
have	O
been	O
described	O
in	O
the	O
GALT	O
gene	O
resulting	O
in	O
galactosemia	O
.	O

Recently	O
,	O
an	O
unusual	O
mutation	O
was	O
characterized	O
causing	O
a	O
5.5	O
kb	O
deletion	O
,	O
with	O
a	O
relatively	O
high	O
carrier	O
rate	O
in	O
subjects	O
of	O
Ashkenazi	O
Jewish	O
(AJ)	O
descent	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
carrier	O
frequency	O
of	O
this	O
mutation	O
in	O
the	O
AJ	O
population	O
in	O
Israel	O
.	O

For	O
this	O
purpose	O
we	O
developed	O
a	O
high-throughput	O
methodology	O
to	O
genotype	O
both	O
normal	O
and	O
deleted	O
alleles	O
using	O
a	O
chip-based	O
matrix-assisted	O
laser	O
desorption-time-of-flight	O
(MALDI-TOF)	O
mass	O
spectrometer	O
and	O
Multiplex	O
PCR	O
.	O

DNA	O
samples	O
of	O
760	O
anonymous	O
AJ	O
subjects	O
were	O
submitted	O
for	O
analysis	O
,	O
subsequently	O
detecting	O
six	O
individuals	O
heterozygous	O
for	O
the	O
GALT	O
deletion	O
mutation	O
,	O
giving	O
a	O
carrier	O
frequency	O
of	O
1	O
in	O
127	O
(0.79%)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
provides	O
a	O
basis	O
for	O
genetic	O
screening	O
and	O
prenatal	O
counseling	O
and	O
can	O
potentially	O
reduce	O
the	O
morbidity	O
and	O
mortality	O
associated	O
with	O
delayed	O
diagnosis	O
of	O
galactosemia	O
in	O
this	O
patient	O
population	O
.	O

Characterisation	O
of	O
two	O
novel	O
large	O
F8	O
deletions	O
in	O
patients	O
with	O
severe	O
haemophilia	O
A	O
and	O
factor	O
VIII	O
inhibitors	O
.	O

Large	O
deletions	O
are	O
found	O
in	O
approximately	O
5%	O
of	O
patients	O
with	O
severe	O
haemophilia	O
A	O
,	O
but	O
only	O
a	O
few	O
deletion	O
breakpoints	O
have	O
been	O
characterised	O
precisely	O
so	O
far	O
.	O

In	O
this	O
study	O
we	O
characterised	O
the	O
deletion	O
breakpoints	O
of	O
two	O
patients	O
with	O
severe	O
haemophilia	O
A	O
,	O
large	O
deletions	O
and	O
factor	O
VIII	O
(FVIII)	O
inhibitors	O
,	O
and	O
subsequently	O
established	O
deletion-specific	O
assays	O
for	O
the	O
identification	O
of	O
carriers	O
.	O

Patient	O
1	O
had	O
a	O
deletion	O
of	O
37,410	O
bp	O
comprising	O
exon	O
1	O
and	O
the	O
F8	O
promoter	O
region	O
,	O
and	O
a	O
5	O
bp	O
homology	O
(GGGCC)	O
is	O
present	O
at	O
the	O
chromosomal	O
fusion	O
site	O
.	O

In	O
patient	O
2	O
,	O
a	O
deletion	O
of	O
22,230	O
bp	O
including	O
parts	O
of	O
intron	O
25	O
,	O
exon	O
26	O
and	O
3'-UTR	O
was	O
identified	O
.	O

No	O
homologous	O
repetitive	O
elements	O
were	O
found	O
at	O
the	O
breakpoints	O
.	O

However	O
,	O
both	O
breakpoints	O
were	O
located	O
within	O
long	O
terminal	O
repeats	O
of	O
endogenous	O
retroviruses	O
and	O
the	O
DNA	O
motif	O
TTTAAA	O
-	O
known	O
to	O
be	O
able	O
to	O
bend	O
DNA	O
molecules	O
-	O
was	O
identified	O
at	O
the	O
centromeric	O
breakpoint	O
.	O

By	O
deletion-specific	O
PCR	O
experiments	O
we	O
were	O
able	O
to	O
identify	O
a	O
heterozygous	O
state	O
in	O
mother	O
2	O
(carrier)	O
while	O
mother	O
1	O
presented	O
only	O
with	O
wild-type	O
alleles	O
(non-carrier)	O
.	O

Both	O
deletions	O
are	O
most	O
likely	O
created	O
by	O
DNA	O
double	O
strand	O
breaks	O
and	O
subsequent	O
DNA	O
repair	O
by	O
the	O
non-homologous	O
end	O
joining	O
DNA	O
repair	O
pathway	O
(NHEJ)	O
.	O

The	O
exact	O
identification	O
of	O
the	O
deletion	O
breakpoints	O
provides	O
a	O
reliable	O
diagnostic	O
tool	O
for	O
carrier	O
identification	O
in	O
affected	O
families	O
by	O
means	O
of	O
a	O
deletion-specific	O
PCR	O
.	O

Lack	O
of	O
association	O
of	O
C-C	O
chemokine	O
receptor	O
5	O
/\32	O
deletion	O
status	O
with	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
lupus	O
nephritis	O
,	O
and	O
disease	O
severity	O
.	O

OBJECTIVE	O
:	O
C-C	O
chemokine	O
receptor	O
5	O
(CCR5)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
.	O

A	O
32	O
base-pair	O
(/\32)	O
deletion	O
in	O
the	O
CCR5	O
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O

This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	O
diseases	O
.	O

We	O
investigated	O
whether	O
the	O
/\32	O
deletion	O
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(RA)	O
,	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
,	O
and	O
lupus	O
nephritis	O
(LN)	O
;	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	O
patients	O
,	O
97	O
SLE	O
patients	O
,	O
113	O
LN	O
patients	O
,	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	O
/\32	O
deletion	O
.	O

Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	O
and	O
controls	O
.	O

Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy-Weinberg	O
equilibrium	O
.	O

The	O
genotype	O
frequencies	O
of	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5//\32	O
,	O
/\32//\32	O
:	O
RA	O
18.3%	O
and	O
1.2%	O
,	O
respectively	O
;	O
SLE	O
17.5%	O
and	O
2.1%	O
;	O
LN	O
13.3%	O
and	O
1.8%	O
;	O
controls	O
20.0%	O
and	O
2.8%	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
for	O
lower	O
/\32	O
deletion	O
allele	O
frequency	O
in	O
LN	O
patients	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0.08	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	O
status	O
and	O
disease	O
severity	O
in	O
RA	O
,	O
SLE	O
,	O
or	O
LN	O
.	O

CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	O
cannot	O
be	O
excluded	O
,	O
the	O
CCR5	O
/\32	O
deletion	O
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	O
,	O
SLE	O
,	O
or	O
LN	O
.	O

No	O
significant	O
effect	O
of	O
the	O
/\32	O
deletion	O
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O

A	O
novel	O
mutation	O
in	O
GJA8	O
causing	O
congenital	O
cataract-microcornea	O
syndrome	O
in	O
a	O
Chinese	O
pedigree	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
underlying	O
genetic	O
defect	O
in	O
a	O
four-generation	O
family	O
of	O
Chinese	O
origin	O
with	O
autosomal	O
dominant	O
congenital	O
cataract-microcornea	O
syndrome	O
(CCMC)	O
.	O

METHODS	O
:	O
All	O
individuals	O
in	O
the	O
study	O
underwent	O
a	O
full	O
clinical	O
examination	O
and	O
the	O
details	O
of	O
history	O
were	O
collected	O
.	O

Genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
and	O
the	O
exons	O
of	O
all	O
candidate	O
genes	O
were	O
sequenced	O
.	O

RESULTS	O
:	O
Direct	O
sequencing	O
of	O
the	O
encoding	O
regions	O
of	O
the	O
candidate	O
genes	O
revealed	O
a	O
heterozygous	O
mutation	O
c.592C-->T	B-DNAMutation
in	O
exon	O
2	O
of	O
the	O
gap	O
junction	O
protein	O
,	O
alpha	O
8	O
(GJA8)	O
gene	O
.	O

This	O
mutation	O
was	O
responsible	O
for	O
the	O
familial	O
disorder	O
through	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
arginine	O
to	O
tryptophan	O
at	O
codon	O
198	O
p.R198W	B-ProteinMutation
.	O

This	O
change	O
co-segregated	O
with	O
all	O
affected	O
members	O
of	O
the	O
family	O
,	O
but	O
was	O
not	O
detected	O
either	O
in	O
the	O
non-carrier	O
relatives	O
or	O
in	O
the	O
100	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
is	O
the	O
first	O
to	O
relate	O
p.R198W	B-ProteinMutation
mutation	O
in	O
GJA8	O
with	O
CCMC	O
.	O

The	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
GJA8	O
in	O
associated	O
with	O
congenital	O
cataract	O
and	O
microcornea	O
,	O
and	O
implies	O
that	O
this	O
gene	O
has	O
direct	O
involvement	O
with	O
the	O
development	O
of	O
the	O
lens	O
as	O
well	O
as	O
the	O
other	O
anterior	O
segment	O
of	O
the	O
eye	O
.	O

Alpha2B-adrenergic	O
receptor	O
insertion/deletion	O
polymorphism	O
in	O
women	O
with	O
spontaneous	O
recurrent	O
abortions	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
alpha2B-adrenoreceptor	O
insertion/deletion	O
(I/D)	O
polymorphism	O
and	O
recurrent	O
spontaneous	O
abortions	O
(RSA)	O
.	O

METHODS	O
:	O
Genotyping	O
was	O
performed	O
in	O
48	O
women	O
with	O
a	O
history	O
of	O
at	O
least	O
three	O
consecutive	O
spontaneous	O
abortions	O
and	O
96	O
women	O
with	O
at	O
least	O
two	O
live	O
births	O
and	O
no	O
history	O
of	O
pregnancy	O
loss	O
.	O

Peripheral	O
venous	O
puncture	O
,	O
DNA	O
extraction	O
and	O
PCR	O
were	O
used	O
for	O
the	O
research	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotype	O
characters	O
.	O

RESULTS	O
:	O
The	O
distribution	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotypes	O
of	O
the	O
alpha2B-adrenoreceptor	O
gene	O
was	O
2	O
(4.2%)	O
,	O
19	O
(39.6%)	O
and	O
27	O
(56.2%)	O
in	O
the	O
study	O
group	O
and	O
6	O
(6.5%)	O
,	O
28	O
(30.4%)	O
and	O
58	O
(63%)	O
in	O
the	O
control	O
group	O
,	O
respectively	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
.	O

The	O
presence	O
of	O
the	O
D	O
allele	O
was	O
not	O
associated	O
with	O
RSA	O
(	O
P	O
=	O
0.78	O
,	O
odds	O
ratio	O
=	O
0.88	O
,	O
95%	O
CI	O
=	O
0.47-1.65	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
fall	O
short	O
of	O
showing	O
any	O
association	O
between	O
the	O
presence	O
of	O
the	O
alpha2B	O
D	O
allele	O
and	O
the	O
occurrence	O
of	O
spontaneous	O
abortions	O
in	O
the	O
examined	O
population	O
.	O

Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O

Approximately	O
30%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(PTCs)	O
,	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O

However	O
,	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O

Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(indel)	O
of	O
three	O
nucleotides	O
.	O

We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	O
fibrosis	O
patients	O
homozygous	O
for	O
the	O
E831X	B-ProteinMutation
mutation	O
2623G>T	B-DNAMutation
in	O
the	O
CFTR	O
gene	O
.	O

Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
,	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O

Structure-function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
,	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease-causing	O
UAG	O
stop	O
codon	O
.	O

This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O

This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O

Lack	O
of	O
association	O
between	O
ADRA2B-4825	O
gene	O
insertion/deletion	O
polymorphism	O
and	O
migraine	O
in	O
Chinese	O
Han	O
population	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	O
and	O
the	O
12-nucleotide	O
insertion/deletion	O
(indel)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha(2B)-adrenergic	O
receptor	O
gene	O
(ADRA2B)	O
.	O

METHODS	O
:	O
A	O
case-control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	O
and	O
517	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O

Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	O
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	O
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	O
indel	O
polymorphism	O
at	O
position	O
-4825	O
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	O
subjects	O
.	O

Two	O
novel	O
mutations	O
of	O
the	O
TSH-beta	O
subunit	O
gene	O
underlying	O
congenital	O
central	O
hypothyroidism	O
undetectable	O
in	O
neonatal	O
TSH	O
screening	O
.	O

CONTEXT	O
:	O
Patients	O
with	O
TSH-beta	O
subunit	O
defects	O
and	O
congenital	O
hypothyroidism	O
are	O
missed	O
by	O
TSH-based	O
neonatal	O
screening	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
report	O
the	O
molecular	O
consequences	O
of	O
a	O
novel	O
splice-junction	O
mutation	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
TSH-beta	O
subunit	O
gene	O
found	O
in	O
two	O
patients	O
with	O
congenital	O
central	O
hypothyroidism	O
and	O
conventional	O
treatment-resistant	O
anemia	O
.	O

RESULTS	O
:	O
Patient	O
1	O
had	O
a	O
homozygous	O
G	O
to	O
A	O
nucleotide	O
change	O
at	O
the	O
5'	O
donor	O
splice	O
site	O
of	O
exon/intron	O
2	O
.	O

This	O
resulted	O
in	O
a	O
silent	O
change	O
at	O
codon	O
34	O
of	O
the	O
mature	O
protein	O
.	O

In	O
vitro	O
splicing	O
assays	O
showed	O
that	O
the	O
mutant	O
minigene	O
dramatically	O
affected	O
pre-mRNA	O
processing	O
,	O
causing	O
exon	O
2	O
to	O
be	O
completely	O
skipped	O
.	O

The	O
putative	O
product	O
from	O
a	O
new	O
out-of-frame	O
translational	O
start	O
point	O
in	O
exon	O
3	O
is	O
expected	O
to	O
yield	O
a	O
nonsense	O
25-amino-acid	O
peptide	O
.	O

In	O
patient	O
2	O
,	O
sequence	O
analysis	O
revealed	O
a	O
compound	O
heterozygosis	O
for	O
the	O
already	O
reported	O
313delT	B-DNAMutation
C105Vfs114X	B-ProteinMutation
mutation	O
and	O
for	O
a	O
second	O
novel	O
mutation	O
in	O
exon	O
3	O
,	O
substituting	O
G	O
for	O
A	O
at	O
cDNA	O
nucleotide	O
position	O
323	O
,	O
resulting	O
in	O
a	O
C88Y	B-ProteinMutation
change	O
.	O

This	O
cysteine	O
residue	O
is	O
conserved	O
among	O
all	O
dimeric	O
pituitary	O
and	O
placental	O
glycoprotein	O
hormone-beta	O
subunits	O
.	O

Data	O
from	O
in	O
silico	O
analysis	O
confirmed	O
that	O
the	O
C88Y	B-ProteinMutation
mutation	O
would	O
affect	O
subunit	O
conformation	O
.	O

Indeed	O
,	O
two	O
different	O
bioinformatics	O
approaches	O
,	O
PolyPhen	O
and	O
SIFT	O
analysis	O
,	O
predicted	O
C88Y	B-ProteinMutation
to	O
be	O
a	O
damaging	O
substitution	O
.	O

CONCLUSIONS	O
:	O
In	O
isolated	O
TSH	O
deficiency	O
,	O
the	O
exact	O
molecular	O
diagnosis	O
is	O
mandatory	O
for	O
diagnosis	O
of	O
isolated	O
pituitary	O
deficiency	O
,	O
delineation	O
of	O
prognosis	O
,	O
and	O
genetic	O
counseling	O
.	O

Moreover	O
,	O
diagnosis	O
of	O
central	O
hypothyroidism	O
should	O
be	O
considered	O
in	O
the	O
face	O
of	O
severe	O
infant	O
anemia	O
of	O
uncertain	O
etiology	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
CD18	O
causing	O
leukocyte	O
adhesion	O
deficiency	O
in	O
a	O
Chinese	O
patient	O
.	O

BACKGROUND	O
:	O
Leukocyte	O
adhesion	O
deficiency	O
type	O
1	O
(LAD-1)	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
inherited	O
immunodeficiency	O
disease	O
characterized	O
by	O
recurrent	O
severe	O
bacterial	O
infection	O
,	O
impaired	O
pus	O
formation	O
,	O
poor	O
wound	O
healing	O
,	O
associated	O
with	O
the	O
mutation	O
in	O
the	O
CD18	O
gene	O
responsible	O
for	O
the	O
ability	O
of	O
the	O
leucocytes	O
to	O
migrate	O
from	O
the	O
blood	O
stream	O
towards	O
the	O
site	O
of	O
inflammation	O
.	O

Correct	O
and	O
early	O
diagnosis	O
of	O
LAD-1	O
is	O
vital	O
to	O
the	O
success	O
of	O
treatment	O
and	O
prevention	O
of	O
aggressive	O
infections	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
collect	O
the	O
clinical	O
findings	O
of	O
the	O
disease	O
and	O
to	O
identify	O
the	O
genetic	O
entity	O
.	O

METHODS	O
:	O
CD18	O
expression	O
in	O
the	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
his	O
parents	O
and	O
normal	O
control	O
was	O
measured	O
with	O
flow	O
cytometry	O
.	O

The	O
entire	O
coding	O
regions	O
of	O
the	O
CD18	O
gene	O
were	O
screened	O
with	O
direct	O
sequencing	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
CD18	O
expression	O
level	O
on	O
this	O
patient's	O
leukocyte	O
surface	O
was	O
significantly	O
decreased	O
,	O
with	O
normal	O
level	O
in	O
control	O
group	O
,	O
his	O
father	O
and	O
mother	O
.	O

Gene	O
analysis	O
revealed	O
that	O
this	O
patient	O
had	O
a	O
homozygous	O
c.899A	B-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
missense	O
mutation	O
in	O
exon	O
8	O
of	O
CD18	O
gene	O
,	O
causing	O
the	O
substitution	O
of	O
Asp	O
to	O
Val	O
at	O
the	O
300	O
amino	O
acid	O
.	O

His	O
parents	O
were	O
both	O
heterozygous	O
carriers	O
while	O
no	O
such	O
mutation	O
was	O
found	O
in	O
50	O
normal	O
controls	O
.	O

CONCLUSION	O
:	O
This	O
study	O
disclosed	O
a	O
novel	O
point	O
mutation	O
Asp	B-ProteinMutation
300	I-ProteinMutation
Val	I-ProteinMutation
located	O
in	O
a	O
highly	O
conserved	O
region	O
(HCR)	O
of	O
CD18	O
and	O
confirmed	O
the	O
heterogeneity	O
of	O
the	O
mutations	O
causing	O
LAD-1	O
,	O
indicating	O
it	O
was	O
quite	O
beneficial	O
to	O
establish	O
correct	O
and	O
early	O
diagnosis	O
in	O
children	O
with	O
severe	O
LAD-1	O
.	O

Association	O
study	O
of	O
complement	O
factor	O
H	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
and	O
age-related	O
macular	O
degeneration	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	O
factor	O
H	O
(CFH)	O
,	O
C2/BF	O
,	O
and	O
C3	O
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age-related	O
macular	O
degeneration	O
(AMD)	O
.	O

Genetic	O
variants	O
,	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
in	O
these	O
genes	O
were	O
geno-typed	O
for	O
a	O
case-control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty-eight	O
patients	O
with	O
wet	O
AMD	O
,	O
80	O
patients	O
with	O
soft	O
drusen	O
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O

Seven	O
SNPs	O
in	O
CFH	O
and	O
two	O
SNPs	O
in	O
C2	O
,	O
CFB'	O
,	O
and	O
C3	O
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O

A	O
deletion	O
of	O
84,682	O
base	O
pairs	O
covering	O
the	O
CFHR1	O
and	O
CFHR3	O
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	B-SNP
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-SNP
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-SNP
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-SNP
(	O
P	O
=	O
0.0089	O
)	O
,	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(CATA)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	O
with	O
a	O
P	O
value	O
of	O
0.0005	O
and	O
an	O
odds	O
ratio	O
of	O
0.29	O
(	O
95%	O
confidence	O
interval	O
:	O
0.15-0.60	O
)	O
.	O

Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	B-SNP
and	O
rs1410996	B-SNP
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	O
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O

None	O
of	O
the	O
SNPs	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
drusen	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	O
or	O
drusen	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

The	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	O
or	O
drusen	O
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	B-SNP
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-SNP
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-SNP
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-SNP
(	O
P	O
=	O
0.0089	O
)	O
,	O
but	O
not	O
rs7535263	B-SNP
,	O
rs1410996	B-SNP
,	O
or	O
rs2274700	B-SNP
,	O
in	O
CFH	O
were	O
significantly	O
associated	O
with	O
wet	O
AMD	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

This	O
study	O
showed	O
that	O
CFH	O
was	O
more	O
likely	O
to	O
be	O
AMD	O
susceptibility	O
gene	O
at	O
Chr.1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	O
in	O
a	O
white	O
population	O
in	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	O
.	O

4G/5G	O
polymorphism	O
and	O
haplotypes	O
of	O
SERPINE1	O
in	O
atherosclerotic	O
diseases	O
of	O
coronary	O
arteries	O
.	O

We	O
assessed	O
the	O
association	O
between	O
common	O
variation	O
at	O
the	O
SERPINE1	O
(PAI1)	O
locus	O
and	O
myocardial	O
infarction	O
(MI)	O
.	O

Haplotype-tagging	O
polymorphisms	O
,	O
including	O
the	O
4G/5G	O
deletion/insertion	O
polymorphism	O
and	O
seven	O
single	O
nucleotide	O
polymorphisms	O
,	O
were	O
analysed	O
in	O
a	O
German	O
sample	O
containing	O
3,657	O
cases	O
with	O
MI	O
and	O
1,211	O
controls	O
.	O

The	O
association	O
between	O
the	O
4G/5G	O
polymorphism	O
and	O
MI	O
was	O
examined	O
in	O
a	O
meta-analysis	O
of	O
data	O
extracted	O
from	O
32	O
studies	O
(	O
13,267	O
cases/14,716	O
controls	O
)	O
.	O

In	O
addition	O
,	O
the	O
relation	O
between	O
the	O
4G/5G	O
polymorphism	O
and	O
coronary	O
diseases	O
,	O
comprising	O
MI	O
,	O
coronary	O
artery	O
disease	O
,	O
coronary	O
heart	O
disease	O
,	O
or	O
the	O
acute	O
coronary	O
syndrome	O
,	O
was	O
assessed	O
in	O
a	O
combined	O
analysis	O
enclosing	O
43	O
studies	O
(	O
17,278	O
cases/18,039	O
controls	O
)	O
.	O

None	O
of	O
the	O
tagging	O
polymorphisms	O
was	O
associated	O
with	O
MI	O
in	O
the	O
present	O
sample	O
(	O
p	O
<or=	O
0.34	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
(OR)	O
for	O
4G	O
allele	O
carriers	O
was	O
1.02	O
(	O
95%	O
confidence	O
interval	O
[CI]	O
0.87-1.19	O
)	O
compared	O
to	O
the	O
5G5G	O
genotype	O
.	O

None	O
of	O
13	O
common	O
(	O
frequency	O
>1.0%	O
)	O
8-marker	O
haplotypes	O
was	O
related	O
to	O
the	O
risk	O
of	O
MI	O
.	O

In	O
a	O
meta-analysis	O
specifically	O
addressing	O
the	O
association	O
with	O
MI	O
,	O
no	O
elevated	O
risk	O
was	O
found	O
in	O
the	O
carriers	O
of	O
the	O
4G	O
allele	O
(	O
OR	O
1.07	O
,	O
95%	O
CI	O
0.99-1.16	O
;	O
p	O
=	O
0.11	O
)	O
.	O

A	O
more	O
general	O
combined	O
analysis	O
of	O
coronary	O
diseases	O
showed	O
a	O
marginally	O
increased	O
risk	O
in	O
4G	O
allele	O
carriers	O
(	O
OR	O
1.08	O
,	O
95%	O
CI	O
1.00-1.16	O
;	O
p	O
=	O
0.044	O
)	O
.	O

In	O
essence	O
,	O
tagging	O
polymorphisms	O
,	O
including	O
the	O
4G/5G	O
polymorphism	O
,	O
and	O
common	O
haplotypes	O
of	O
the	O
SERPINE1	O
gene	O
region	O
were	O
not	O
associated	O
with	O
MI	O
in	O
a	O
German	O
sample	O
,	O
and	O
no	O
compelling	O
evidence	O
was	O
obtained	O
for	O
a	O
relationship	O
of	O
the	O
4G/5G	O
polymorphism	O
to	O
MI	O
and	O
coronary	O
atherosclerosis	O
in	O
a	O
meta-analysis	O
.	O

Recent	O
nosocomial	O
transmission	O
and	O
genotypes	O
of	O
multidrug-resistant	O
Mycobacterium	O
tuberculosis	O
.	O

SETTING	O
:	O
Multidrug-resistant	O
tuberculosis	O
(MDR-TB)	O
is	O
a	O
serious	O
health	O
problem	O
in	O
Eastern	O
European	O
countries	O
,	O
including	O
Latvia	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
proportion	O
of	O
tuberculosis	O
,	O
including	O
MDR-TB	O
cases	O
,	O
attributable	O
to	O
recent	O
transmission	O
and	O
risk	O
factors	O
associated	O
with	O
clustering	O
.	O

DESIGN	O
:	O
Retrospective	O
nested	O
case-control	O
study	O
.	O

The	O
data	O
set	O
incorporated	O
a	O
wide	O
spectrum	O
of	O
social	O
features	O
,	O
as	O
well	O
as	O
genotypes	O
of	O
Mycobacterium	O
tuberculosis	O
isolates	O
determined	O
by	O
insertion	O
sequence	O
6110	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
PvuII	O
cleaved	O
genomic	O
DNA	O
and	O
spoligotyping	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
non-clustered	O
M	O
.	O

tuberculosis	O
,	O
the	O
Beijing	O
genotype	O
(	O
OR	O
12.15	O
)	O
and	O
multidrug	O
resistance	O
(	O
OR	O
5.61	O
,	O
P	O
<	O
0.01	O
)	O
were	O
associated	O
with	O
clustering	O
.	O

In	O
comparison	O
with	O
clustered	O
drug-susceptible	O
M	O
.	O

tuberculosis	O
,	O
clustering	O
of	O
MDR	O
M	O
.	O

tuberculosis	O
was	O
associated	O
with	O
Beijing	O
genotype	O
(	O
OR	O
41.67	O
)	O
,	O
previous	O
hospitalisation	O
(	O
OR	O
18.33	O
)	O
and	O
previous	O
TB	O
treatment	O
(	O
OR	O
17.68	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Direct	O
epidemiological	O
links	O
in	O
hospitals	O
were	O
found	O
for	O
almost	O
one	O
third	O
(32%)	O
of	O
MDR	O
Beijing	O
cases	O
.	O

CONCLUSIONS	O
:	O
MDR	O
cases	O
were	O
more	O
likely	O
to	O
be	O
found	O
in	O
clusters	O
than	O
drug-susceptible	O
cases	O
(	O
74.0%	O
vs	O
.	O

33.6%	O
)	O
.	O

Recent	O
nosocomial	O
transmission	O
of	O
MDR-TB	O
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
spread	O
of	O
multiresistance	O
,	O
and	O
is	O
associated	O
with	O
the	O
Beijing	O
genotype	O
.	O

Special	O
attention	O
should	O
be	O
paid	O
to	O
infection	O
control	O
measures	O
in	O
hospitals	O
and	O
ambulatory	O
treatment	O
should	O
be	O
enforced	O
.	O

U87MG	O
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	O
cancer	O
cell	O
line	O
.	O

U87MG	O
is	O
a	O
commonly	O
studied	O
grade	O
IV	O
glioma	O
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1,700	O
publications	O
over	O
four	O
decades	O
.	O

In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	O
genome	O
sequencing	O
,	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50-base	O
mate	O
paired	O
strategy	O
with	O
a	O
1.4kb	O
mean	O
insert	O
library	O
.	O

A	O
total	O
of	O
1,014,984,286	O
mate-end	O
and	O
120,691,623	O
single-end	O
two-base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O

All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
,	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O

The	O
aligned	O
sequence	O
reads	O
and	O
mate-pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
,	O
1,315	O
structural	O
variations	O
(	O
>100	O
bp	O
)	O
,	O
191,743	O
small	O
(	O
<21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(indels)	O
,	O
and	O
2,384,470	O
single	O
nucleotide	O
variations	O
(SNVs)	O
.	O

Among	O
these	O
observations	O
,	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	O
was	O
robustly	O
identified	O
,	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O

Data	O
were	O
compared	O
to	O
219,187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93.83%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99.99%	O
sequence	O
accuracy	O
.	O

Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	O
cell	O
line	O
due	O
to	O
small	O
indels	O
,	O
large	O
deletions	O
,	O
and	O
translocations	O
.	O

In	O
total	O
,	O
512	O
genes	O
were	O
homozygously	O
mutated	O
,	O
including	O
154	O
by	O
SNVs	O
,	O
178	O
by	O
small	O
indels	O
,	O
145	O
by	O
large	O
microdeletions	O
,	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O

Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
,	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O

These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	O
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O

The	O
sequence	O
analysis	O
of	O
U87MG	O
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O

Development	O
and	O
validation	O
of	O
a	O
SYBR	O
Green	O
I-based	O
real-time	O
polymerase	O
chain	O
reaction	O
method	O
for	O
detection	O
of	O
haptoglobin	O
gene	O
deletion	O
in	O
clinical	O
materials	O
.	O

BACKGROUND	O
:	O
Anhaptoglobinemic	O
patients	O
run	O
the	O
risk	O
of	O
severe	O
anaphylactic	O
transfusion	O
reaction	O
because	O
they	O
produce	O
serum	O
haptoglobin	O
(Hp)	O
antibodies	O
.	O

Being	O
homozygous	O
for	O
the	O
Hp	O
gene	O
deletion	O
(HP(del))	O
is	O
the	O
only	O
known	O
cause	O
of	O
congenital	O
anhaptoglobinemia	O
,	O
and	O
clinical	O
diagnosis	O
of	O
HP(del)	O
before	O
transfusion	O
is	O
important	O
to	O
prevent	O
anaphylactic	O
shock	O
.	O

We	O
recently	O
developed	O
a	O
5'-nuclease	O
(TaqMan)	O
real-time	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
SYBR	O
Green	O
I-based	O
duplex	O
real-time	O
PCR	O
assay	O
using	O
two	O
forward	O
primers	O
and	O
a	O
common	O
reverse	O
primer	O
followed	O
by	O
melting	O
curve	O
analysis	O
was	O
developed	O
to	O
determine	O
HP(del)	O
zygosity	O
in	O
a	O
single	O
tube	O
.	O

In	O
addition	O
,	O
to	O
obviate	O
initial	O
DNA	O
extraction	O
,	O
we	O
examined	O
serially	O
diluted	O
blood	O
samples	O
as	O
PCR	O
templates	O
.	O

RESULTS	O
:	O
Allelic	O
discrimination	O
of	O
HP(del)	O
yielded	O
optimal	O
results	O
at	O
blood	O
sample	O
dilutions	O
of	O
1:64	O
to	O
1:1024	O
.	O

The	O
results	O
from	O
2231	O
blood	O
samples	O
were	O
fully	O
concordant	O
with	O
those	O
obtained	O
by	O
the	O
TaqMan-based	O
real-time	O
PCR	O
method	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
rate	O
of	O
the	O
HP(del)	O
allele	O
by	O
the	O
SYBR	O
Green	O
I-based	O
method	O
is	O
comparable	O
with	O
that	O
using	O
the	O
TaqMan-based	O
method	O
.	O

This	O
method	O
is	O
readily	O
applicable	O
due	O
to	O
its	O
low	O
initial	O
cost	O
and	O
analyzability	O
using	O
economical	O
real-time	O
PCR	O
machines	O
and	O
is	O
suitable	O
for	O
high-throughput	O
analysis	O
as	O
an	O
alternative	O
method	O
for	O
allelic	O
discrimination	O
of	O
HP(del)	O
.	O

Investigation	O
of	O
SERPINE1	O
genetic	O
polymorphism	O
in	O
Macedonian	O
patients	O
with	O
occlusive	O
artery	O
disease	O
and	O
deep	O
vein	O
thrombosis	O
.	O

BACKGROUND	O
:	O
Raised	O
SERPINE1	O
plasma	O
levels	O
are	O
related	O
to	O
a	O
1-bp	O
guanine	O
deletion/insertion	O
(4G5G)	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
SERPINE1	O
(	O
plasminogen	O
activator	O
inhibitor	O
1	O
-	O
PAI1	O
)	O
gene	O
.	O

Evidence	O
suggested	O
that	O
the	O
plasma	O
levels	O
of	O
SERPINE1	O
modulate	O
the	O
risk	O
of	O
coronary	O
artery	O
disease	O
;	O
furthermore	O
,	O
that	O
the	O
4G5G	O
polymorphism	O
affects	O
the	O
expression	O
of	O
the	O
SERPINE1	O
gene	O
.	O

AIM	O
:	O
To	O
analyse	O
association	O
of	O
SERPINE1	O
polymorphism	O
with	O
occlusive	O
artery	O
disease	O
(OAD)	O
and	O
deep	O
venous	O
thrombosis	O
(DVT)	O
in	O
Macedonians	O
in	O
order	O
to	O
investigate	O
its	O
role	O
as	O
a	O
part	O
of	O
candidate	O
genes	O
in	O
different	O
vascular	O
diseases	O
in	O
Macedonians	O
.	O

METHODS	O
:	O
Investigated	O
groups	O
consisted	O
of	O
82	O
healthy	O
patients	O
,	O
75	O
with	O
OAD	O
,	O
and	O
66	O
with	O
DVT	O
.	O

Blood	O
samples	O
were	O
collected	O
after	O
written	O
informed	O
consent	O
was	O
obtained	O
,	O
and	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
.	O

Identification	O
of	O
SERPINE1	O
polymorphism	O
was	O
done	O
with	O
CVD	O
StripAssay	O
(	O
ViennaLab	O
,	O
Labordiagnostica	O
GmbH	O
,	O
Austria	O
)	O
.	O

The	O
population	O
genetics	O
analysis	O
package	O
,	O
PyPop	O
,	O
was	O
used	O
for	O
analysis	O
of	O
the	O
SERPINE1	O
data	O
.	O

Pearson's	O
P-values	O
,	O
crude	O
odds	O
ratio	O
and	O
Wald's	O
95%	O
CI	O
were	O
calculated	O
with	O
Bonferroni	O
corrected	O
p	O
value	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
4G	O
allele	O
for	O
SERPINE1	O
was	O
0.538	O
for	O
DVT	O
,	O
0.555	O
for	O
healthy	O
participants	O
,	O
and	O
0.607	O
for	O
OAD	O
.	O

The	O
frequency	O
of	O
5G	O
allele	O
for	O
SERPINE1	O
was	O
the	O
smallest	O
in	O
patients	O
with	O
OAD	O
(0.393)	O
and	O
was	O
higher	O
in	O
healthy	O
participants	O
(0.445)	O
,	O
and	O
patients	O
with	O
DVT	O
(0.462)	O
.	O

Test	O
of	O
neutrality	O
(Fnd)	O
showed	O
negative	O
value	O
,	O
but	O
was	O
significantly	O
different	O
from	O
0	O
for	O
SERPINE1	O
in	O
healthy	O
participants	O
(	O
p	O
of	O
F	O
=	O
0.041	O
)	O
and	O
in	O
patients	O
with	O
DVT	O
(	O
p	O
of	O
F	O
=	O
0.030	O
)	O
.	O

SERPINE1	O
genotypes	O
in	O
healthy	O
participants	O
and	O
patients	O
with	O
OAD	O
were	O
not	O
in	O
Hardy	O
Weinberg	O
proportions	O
(	O
p	O
=	O
0.019	O
and	O
0.001	O
,	O
respectively	O
)	O
.	O

No	O
association	O
between	O
SERPINE1	O
polymorphisms	O
and	O
OAD	O
or	O
DVT	O
was	O
found	O
.	O

CONCLUSION	O
:	O
There	O
is	O
no	O
significant	O
relationship	O
between	O
SERPINE1	O
polymorphisms	O
and	O
occlusive	O
artery	O
disease	O
or	O
deep	O
venous	O
thrombosis	O
in	O
Macedonian	O
population	O
.	O

A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	O
gene	O
may	O
be	O
associated	O
with	O
essential	O
hypertension	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

BACKGROUND	O
:	O
Mice	O
with	O
defects	O
in	O
the	O
Klotho	O
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	O
.	O

We	O
hypothesised	O
that	O
the	O
G-395A	B-DNAMutation
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
Klotho	O
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	O
Hypertension	O
(EH)	O
.	O

METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G-395A	B-DNAMutation
polymorphism	O
of	O
Klotho	O
is	O
associated	O
with	O
EH	O
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	O
with	O
EH	O
and	O
220	O
non-hypertensive	O
subjects	O
.	O

We	O
also	O
tested	O
whether	O
a	O
G/A	B-DNAMutation
substitution	O
at	O
the	O
G-395A	B-DNAMutation
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual-luciferase	O
reporter	O
assay	O
.	O

RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G-395A	B-DNAMutation
polymorphism	O
between	O
the	O
EH	O
and	O
non-hypertension	O
groups	O
are	O
statistically	O
significant	O
(P=0.032)	O
.	O

There	O
are	O
differential	O
effects	O
of	O
age	O
,	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G-395A	B-DNAMutation
polymorphism	O
with	O
EH	O
;	O
the	O
G-395A	B-DNAMutation
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	O
in	O
subjects	O
over	O
60years	O
old	O
,	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	O
in	O
the	O
-395A	O
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0.593	O
(P=0.024)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O

The	O
dual-luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-395A	O
carrier	O
of	O
a	O
498-bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G-395A	B-DNAMutation
site	O
)	O
upstream	O
of	O
the	O
Klotho	O
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-395G	O
carrier	O
.	O

CONCLUSIONS	O
:	O
The	O
G-395A	B-DNAMutation
polymorphism	O
of	O
the	O
human	O
Klotho	O
gene	O
is	O
associated	O
with	O
EH	O
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O

An	O
intronic	O
polymorphism	O
of	O
IRF4	O
gene	O
influences	O
gene	O
transcription	O
in	O
vitro	O
and	O
shows	O
a	O
risk	O
association	O
with	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
in	O
males	O
.	O

The	O
interferon	O
regulatory	O
factor	O
(IRF)	O
family	O
of	O
DNA-binding	O
proteins	O
regulates	O
expression	O
of	O
interferon-inducible	O
genes	O
with	O
roles	O
in	O
the	O
immune	O
response	O
and	O
carcinogenesis	O
.	O

IRF4	O
is	O
involved	O
in	O
the	O
differentiation	O
of	O
B	O
and	O
T	O
cells	O
and	O
is	O
overexpressed	O
in	O
B-cell	O
malignancies	O
as	O
a	O
result	O
of	O
c-REL	O
(NF-kappaB)	O
hyperactivation	O
.	O

IRF4	O
polymorphisms	O
are	O
associated	O
with	O
susceptibility	O
to	O
chronic	O
lymphoid	O
leukemia	O
(CLL)	O
and	O
non-Hodgkin	O
lymphoma	O
(NHL)	O
.	O

We	O
examined	O
13	O
IRF4	O
SNPs	O
in	O
114	O
cases	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
and	O
388	O
newborn	O
controls	O
from	O
Wales	O
(U.K.)	O
using	O
TaqMan	O
assays	O
.	O

IRF4	O
intron	O
4	O
SNP	O
rs12203592	B-SNP
showed	O
a	O
male-specific	O
risk	O
association	O
(	O
OR=4.4	O
,	O
95%	O
CI=1.5	O
to	O
12.6	O
,	O
P=0.007	O
)	O
.	O

Functional	O
consequences	O
of	O
the	O
C>T	B-DNAMutation
substitution	O
at	O
this	O
SNP	O
were	O
assessed	O
by	O
cell-based	O
reporter	O
assays	O
using	O
three	O
different	O
cell	O
lines	O
.	O

We	O
found	O
a	O
repressive	O
effect	O
of	O
the	O
rs12203592	B-SNP
wildtype	O
allele	O
C	O
on	O
IRF4	O
promoter	O
activity	O
(P<0.001)	O
but	O
no	O
repression	O
by	O
the	O
variant	O
allele	O
in	O
any	O
cell	O
line	O
tested	O
.	O

Thus	O
,	O
homozygosity	O
for	O
the	O
rs12203592	B-SNP
variant	O
allele	O
would	O
result	O
in	O
increased	O
IRF4	O
expression	O
.	O

This	O
increase	O
would	O
be	O
compounded	O
by	O
high	O
levels	O
of	O
NF-kappaB	O
activity	O
in	O
males	O
due	O
to	O
the	O
absence	O
of	O
estrogen	O
.	O

IRF4	O
differs	O
from	O
other	O
IRFs	O
in	O
its	O
anti-interferon	O
activity	O
which	O
interferes	O
with	O
immune	O
surveillance	O
.	O

We	O
propose	O
that	O
a	O
detailed	O
study	O
of	O
IRF4	O
can	O
provide	O
information	O
on	O
the	O
mechanism	O
of	O
the	O
sex	O
effect	O
and	O
the	O
role	O
of	O
immune	O
surveillance	O
in	O
childhood	O
ALL	O
development	O
.	O

A	O
novel	O
insertion	O
mutation	O
in	O
the	O
SEDL	O
gene	O
results	O
in	O
X-linked	O
spondyloepiphyseal	O
dysplasia	O
tarda	O
in	O
a	O
large	O
Chinese	O
pedigree	O
.	O

BACKGROUND	O
:	O
Spondyloepiphyseal	O
dysplasia	O
tarda	O
(SEDT)	O
is	O
an	O
X-chromosome	O
linked	O
primary	O
skeletal	O
dysplasia	O
characterized	O
by	O
a	O
disproportionate	O
short-trunked	O
short	O
stature	O
,	O
dysplasia	O
of	O
the	O
large	O
joints	O
and	O
flattened	O
thoracic	O
and	O
lumber	O
vertebral	O
bodies	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
describe	O
a	O
large	O
Chinese	O
SEDT	O
family	O
with	O
a	O
milder	O
phenotype	O
and	O
describe	O
the	O
molecular	O
and	O
clinical	O
findings	O
.	O

METHODS	O
:	O
Eight	O
affected	O
males	O
of	O
the	O
family	O
were	O
diagnosed	O
with	O
SEDT	O
according	O
to	O
their	O
clinical	O
and	O
radiological	O
features	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
the	O
SEDL	O
gene	O
was	O
performed	O
.	O

RT-PCR	O
experiments	O
on	O
total	O
RNA	O
from	O
blood	O
lymphocytes	O
were	O
performed	O
to	O
confirm	O
the	O
defect	O
on	O
the	O
SEDL	O
gene	O
.	O

A	O
short	O
summary	O
of	O
all	O
currently	O
known	O
SEDL	O
gene	O
mutations	O
is	O
presented	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
revealed	O
that	O
all	O
the	O
affected	O
males	O
carried	O
an	O
insertion	O
mutation	O
c.370-371insA	B-DNAMutation
unreported	O
previously	O
,	O
predicted	O
to	O
result	O
in	O
frameshifts	O
and	O
generate	O
a	O
premature	O
stop	O
codon	O
p.S124fsX127	B-ProteinMutation
.	O

The	O
identical	O
mutation	O
was	O
also	O
observed	O
in	O
a	O
10-year	O
old	O
presymptomatic	O
boy	O
of	O
the	O
family	O
.	O

Eight	O
female	O
carriers	O
had	O
the	O
typical	O
sequencing	O
chromatograms	O
of	O
heterozygotes	O
.	O

CONCLUSIONS	O
:	O
Identification	O
of	O
the	O
novel	O
insertion	O
mutation	O
c.370-371insA	B-DNAMutation
in	O
this	O
SEDT	O
family	O
enables	O
carrier	O
detection	O
and	O
presymptomatic/prenatal	O
diagnosis	O
,	O
but	O
also	O
the	O
detailed	O
molecular	O
and	O
clinical	O
features	O
will	O
be	O
useful	O
for	O
extending	O
the	O
evidence	O
for	O
genetic	O
and	O
phenotypic	O
heterogeneity	O
in	O
SEDT	O
.	O

Congestive	O
heart	O
failure	O
with	O
rhabdomyolysis	O
and	O
acute	O
renal	O
failure	O
in	O
a	O
manifesting	O
female	O
carrier	O
of	O
Duchenne	O
muscular	O
dystrophy	O
with	O
duplication	O
of	O
dystrophin	O
gene	O
.	O

We	O
report	O
a	O
69-year-old	O
woman	O
who	O
presented	O
with	O
dyspnea	O
,	O
orthopnea	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

She	O
also	O
had	O
proximal	O
muscle	O
weakness	O
suggestive	O
of	O
muscle	O
disease	O
.	O

Her	O
symptoms	O
were	O
alleviated	O
by	O
induced	O
dieresis	O
,	O
although	O
there	O
was	O
high-serum	O
creatine	O
kinase	O
.	O

Investigations	O
for	O
any	O
possible	O
etiologies	O
of	O
rhabdomyolysis	O
were	O
all	O
negative	O
.	O

An	O
X-linked	O
recessive	O
muscle	O
disease	O
was	O
highly	O
suspicious	O
in	O
view	O
of	O
the	O
fact	O
that	O
both	O
of	O
her	O
sons	O
had	O
suffered	O
from	O
muscle	O
disease	O
and	O
died	O
of	O
respiratory	O
failure	O
at	O
the	O
ages	O
of	O
22	O
and	O
29	O
,	O
respectively	O
.	O

Her	O
muscle	O
biopsy	O
showed	O
mosaic	O
pattern	O
with	O
dystrophin	O
antibody	O
against	O
amino-terminal	O
,	O
carboxy-terminal	O
,	O
and	O
rod	O
domain	O
.	O

Her	O
DNA	O
study	O
revealed	O
heterozygous	O
duplication	O
at	O
exon	O
1	O
to	O
6	O
of	O
the	O
dystrophin	O
gene	O
as	O
well	O
.	O

Therefore	O
,	O
she	O
is	O
a	O
manifesting	O
carrier	O
of	O
dystrophinopathy	O
who	O
was	O
first	O
diagnosed	O
in	O
late	O
adulthood	O
with	O
congestive	O
heart	O
failure	O
,	O
acute	O
episode	O
of	O
spontaneous	O
rhabdomyolysis	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

Forty-two	O
novel	O
COL7A1	O
mutations	O
and	O
the	O
role	O
of	O
a	O
frequent	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
MMP1	O
promoter	O
in	O
modulation	O
of	O
disease	O
severity	O
in	O
a	O
large	O
European	O
dystrophic	O
epidermolysis	O
bullosa	O
cohort	O
.	O

BACKGROUND	O
:	O
Dystrophic	O
epidermolysis	O
bullosa	O
(DEB)	O
is	O
a	O
severe	O
genetic	O
skin	O
blistering	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
COL7A1	O
,	O
encoding	O
collagen	O
VII	O
.	O

Recently	O
,	O
the	O
MMP1	O
promoter	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
rs1799750	B-SNP
,	O
designated	O
as	O
1G	O
2G	O
,	O
was	O
shown	O
to	O
be	O
involved	O
in	O
modulation	O
of	O
disease	O
severity	O
in	O
patients	O
with	O
recessive	O
DEB	O
(RDEB)	O
,	O
and	O
was	O
proposed	O
as	O
a	O
genetic	O
modifier	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
molecular	O
basis	O
of	O
DEB	O
in	O
103	O
individuals	O
and	O
to	O
replicate	O
the	O
results	O
of	O
the	O
MMP1	O
promoter	O
SNP	O
analysis	O
in	O
an	O
independent	O
patient	O
group	O
,	O
as	O
verification	O
is	O
necessary	O
in	O
such	O
a	O
rare	O
and	O
heterogeneous	O
disorder	O
.	O

METHODS	O
:	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
,	O
we	O
performed	O
COL7A1	O
mutation	O
screening	O
,	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
real-time	O
quantitative	O
PCR	O
.	O

The	O
status	O
of	O
the	O
MMP1	O
SNP	O
was	O
analysed	O
by	O
PCR	O
and	O
restriction	O
enzyme	O
digestion	O
and	O
verified	O
by	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
disclosed	O
42	O
novel	O
COL7A1	O
mutations	O
,	O
including	O
the	O
first	O
large	O
genomic	O
deletion	O
of	O
4	O
kb	O
affecting	O
only	O
the	O
COL7A1	O
gene	O
,	O
and	O
three	O
apparently	O
silent	O
mutations	O
affecting	O
splicing	O
.	O

Even	O
though	O
the	O
frequency	O
of	O
the	O
high-risk	O
allele	O
was	O
increased	O
in	O
patients	O
with	O
RDEB	O
,	O
no	O
statistically	O
significant	O
correlation	O
between	O
disease	O
severity	O
and	O
genotype	O
could	O
be	O
made	O
.	O

Also	O
,	O
no	O
correlation	O
was	O
observed	O
with	O
development	O
of	O
squamous	O
cell	O
carcinoma	O
,	O
a	O
severe	O
complication	O
of	O
DEB	O
.	O

CONCLUSIONS	O
:	O
Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
the	O
MMP1	O
SNP	O
is	O
not	O
the	O
sole	O
disease	O
modifier	O
in	O
different	O
forms	O
of	O
DEB	O
,	O
and	O
other	O
genetic	O
and	O
environmental	O
factors	O
contribute	O
to	O
the	O
clinical	O
phenotype	O
.	O

A	O
combination	O
of	O
defective	O
DNA	O
and	O
protective	O
host	O
factors	O
are	O
found	O
in	O
a	O
set	O
of	O
HIV-1	O
ancestral	O
LTNPs	O
.	O

We	O
studied	O
viral	O
evolution	O
in	O
three	O
HIV-1	O
ancestral	O
patients	O
from	O
a	O
group	O
of	O
LTNPs	O
;	O
although	O
some	O
minor	O
sequences	O
showing	O
viral	O
evolution	O
were	O
detected	O
in	O
all	O
patients	O
,	O
the	O
extremely	O
low	O
viral	O
evolution	O
of	O
their	O
viruses	O
was	O
shown	O
by	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
env	O
sequences	O
.	O

Complete	O
nucleotide	O
sequencing	O
of	O
viral	O
DNA	O
showed	O
the	O
major	O
presence	O
of	O
deletions	O
.	O

In	O
two	O
patients	O
,	O
deletions	O
of	O
1088	O
and	O
228	O
nucleotides	O
mapped	O
to	O
5'	O
LTR-gag	O
region	O
;	O
in	O
the	O
other	O
,	O
a	O
247	O
nucleotide	O
deletion	O
was	O
positioned	O
in	O
pol	O
gene	O
up	O
to	O
the	O
vif	O
ORF	O
.	O

These	O
deleted	O
genomes	O
became	O
dominant	O
during	O
follow	O
up	O
.	O

Patient's	O
viruses	O
displayed	O
13	O
common	O
mutations	O
in	O
conserved	O
residues	O
,	O
from	O
the	O
5'	O
LTR	O
to	O
the	O
nef	O
gene	O
.	O

These	O
mutations	O
provided	O
evidence	O
of	O
a	O
common	O
origin	O
.	O

Regarding	O
host	O
characteristics	O
,	O
one	O
patient	O
had	O
HLA	O
B2705/B5801	O
;	O
another	O
B1402/B5701	O
;	O
whereas	O
a	O
third	O
showed	O
B3901/B4402	O
and	O
was	O
Delta32-CCR5	B-DNAMutation
heterozygous	O
.	O

These	O
HIV	O
controllers	O
presented	O
a	O
combination	O
of	O
deleted	O
viral	O
genomes	O
and	O
host	O
protective	O
factors	O
.	O

Mutation	O
of	O
SYNE-1	O
,	O
encoding	O
an	O
essential	O
component	O
of	O
the	O
nuclear	O
lamina	O
,	O
is	O
responsible	O
for	O
autosomal	O
recessive	O
arthrogryposis	O
.	O

Arthrogryposis	O
multiplex	O
congenita	O
(AMC)	O
is	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
congenital	O
joint	O
contractures	O
caused	O
by	O
reduced	O
fetal	O
movements	O
.	O

AMC	O
has	O
an	O
incidence	O
of	O
1	O
in	O
3000	O
newborns	O
and	O
is	O
genetically	O
heterogeneous	O
.	O

We	O
describe	O
an	O
autosomal	O
recessive	O
form	O
of	O
myogenic	O
AMC	O
in	O
a	O
large	O
consanguineous	O
family	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
bilateral	O
clubfoot	O
,	O
decreased	O
fetal	O
movements	O
,	O
delay	O
in	O
motor	O
milestones	O
,	O
then	O
progressive	O
motor	O
decline	O
after	O
the	O
first	O
decade	O
.	O

Genome-wide	O
linkage	O
analysis	O
revealed	O
a	O
single	O
locus	O
on	O
chromosome	O
6q25	O
with	O
Z(max)	O
=	O
3.55	O
at	O
theta	O
=	O
0.0	O
and	O
homozygosity	O
of	O
the	O
polymorphic	O
markers	O
at	O
this	O
locus	O
in	O
patients	O
.	O

Homozygous	O
A	O
to	O
G	O
nucleotide	O
substitution	O
of	O
the	O
conserved	O
AG	O
splice	O
acceptor	O
site	O
at	O
the	O
junction	O
of	O
intron	O
136	O
and	O
exon	O
137	O
of	O
the	O
SYNE-1	O
gene	O
was	O
found	O
in	O
patients	O
.	O

This	O
mutation	O
results	O
in	O
an	O
aberrant	O
retention	O
of	O
intron	O
136	O
of	O
SYNE-1	O
RNA	O
leading	O
to	O
premature	O
stop	O
codons	O
and	O
the	O
lack	O
of	O
the	O
C-terminal	O
transmembrane	O
domain	O
KASH	O
of	O
nesprin-1	O
,	O
the	O
SYNE-1	O
gene	O
product	O
.	O

Mice	O
lacking	O
the	O
KASH	O
domain	O
of	O
nesprin-1	O
display	O
a	O
myopathic	O
phenotype	O
similar	O
to	O
that	O
observed	O
in	O
patients	O
.	O

Altogether	O
,	O
these	O
data	O
strongly	O
suggest	O
that	O
the	O
splice	O
site	O
mutation	O
of	O
SYNE-1	O
gene	O
found	O
in	O
the	O
family	O
is	O
responsible	O
for	O
AMC	O
.	O

Recent	O
reports	O
have	O
shown	O
that	O
mutations	O
of	O
the	O
SYNE-1	O
gene	O
might	O
be	O
responsible	O
for	O
autosomal	O
recessive	O
adult	O
onset	O
cerebellar	O
ataxia	O
.	O

These	O
data	O
indicate	O
that	O
mutations	O
of	O
nesprin-1	O
which	O
interacts	O
with	O
lamin	O
A/C	O
may	O
lead	O
to	O
at	O
least	O
two	O
distinct	O
human	O
disease	O
phenotypes	O
,	O
myopathic	O
or	O
neurological	O
,	O
a	O
feature	O
similar	O
to	O
that	O
found	O
in	O
laminopathies	O
.	O

Identified	O
hidden	O
genomic	O
changes	O
in	O
mantle	O
cell	O
lymphoma	O
using	O
high-resolution	O
single	O
nucleotide	O
polymorphism	O
genomic	O
array	O
.	O

OBJECTIVE	O
:	O
Mantle	O
cell	O
lymphoma	O
(MCL)	O
is	O
a	O
lymphoma	O
characterized	O
by	O
aberrant	O
activation	O
of	O
CCND1/cyclin	O
D1	O
followed	O
by	O
sequential	O
genetic	O
abnormalities	O
.	O

Genomic	O
abnormalities	O
in	O
MCL	O
have	O
been	O
extensively	O
examined	O
by	O
classical	O
cytogenetics	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
techniques	O
,	O
pointing	O
out	O
a	O
number	O
of	O
alterations	O
in	O
genomic	O
regions	O
that	O
correlate	O
with	O
the	O
neoplastic	O
phenotype	O
and	O
survival	O
.	O

Recently	O
,	O
single	O
nucleotide	O
polymorphism	O
genomic	O
microarrays	O
(SNP-chip)	O
have	O
been	O
developed	O
and	O
used	O
for	O
analysis	O
of	O
cancer	O
genomics	O
.	O

This	O
technique	O
allows	O
detection	O
of	O
genomic	O
changes	O
with	O
higher	O
resolution	O
,	O
including	O
loss	O
of	O
heterozygosity	O
without	O
changes	O
of	O
gene	O
dosage	O
,	O
so-called	O
acquired	O
uniparental	O
disomy	O
(aUPD)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
have	O
examined	O
33	O
samples	O
of	O
MCL	O
(	O
28	O
primary	O
MCL	O
and	O
5	O
cell	O
lines	O
)	O
using	O
the	O
250,000	O
SNP-chip	O
from	O
Affymetrix	O
.	O

RESULTS	O
:	O
Known	O
alterations	O
were	O
confirmed	O
by	O
SNP	O
arrays	O
,	O
including	O
deletion	O
of	O
INK4A/ARF	O
,	O
duplication/amplification	O
of	O
MYC	O
,	O
deletion	O
of	O
ATM	O
,	O
and	O
deletion	O
of	O
TP53	O
.	O

We	O
also	O
identified	O
a	O
duplication/amplification	O
that	O
occurred	O
at	O
13q	O
involving	O
oncogenic	O
microRNA	O
,	O
miR17-92	O
.	O

We	O
found	O
other	O
genomic	O
abnormalities	O
,	O
including	O
duplication/amplification	O
of	O
cyclin	O
D1	O
,	O
del(1p)	O
,	O
del(6q)	O
,	O
dup(3q)	O
and	O
dup(18q)	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
these	O
abnormalities	O
at	O
high	O
resolution	O
,	O
allowing	O
us	O
to	O
narrow	O
the	O
size	O
of	O
the	O
commonly	O
deleted	O
regions	O
,	O
including	O
1p	O
and	O
6q	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
a	O
number	O
of	O
aUPD	O
sites	O
,	O
including	O
whole	O
chromosome	O
9	O
aUPD	O
and	O
9p	O
aUPD	O
.	O

We	O
also	O
found	O
an	O
MCL	O
case	O
with	O
19p	O
,	O
leading	O
to	O
homozygous	O
deletion	O
of	O
TNFSF	O
genes	O
.	O

CONCLUSION	O
:	O
SNP-chip	O
analysis	O
detected	O
in	O
MCL	O
very	O
small	O
genomic	O
gains/losses	O
,	O
as	O
well	O
as	O
aUPDs	O
,	O
which	O
could	O
not	O
be	O
detected	O
by	O
more	O
conventional	O
methods	O
.	O

COL3A1	O
2209G>A	B-DNAMutation
is	O
a	O
predictor	O
of	O
pelvic	O
organ	O
prolapse	O
.	O

INTRODUCTION	O
AND	O
HYPOTHESIS	O
:	O
A	O
familial	O
tendency	O
has	O
been	O
demonstrated	O
in	O
the	O
etiology	O
of	O
pelvic	O
organ	O
prolapse	O
(POP)	O
,	O
but	O
the	O
specific	O
genetic	O
defects	O
have	O
not	O
been	O
identified	O
.	O

Type	O
III	O
collagen	O
is	O
an	O
important	O
factor	O
in	O
the	O
repair	O
of	O
connective	O
tissue	O
,	O
and	O
gene	O
polymorphisms	O
may	O
impair	O
the	O
tensile	O
strength	O
.	O

We	O
hypothesized	O
that	O
polymorphisms	O
in	O
the	O
alpha	O
I	O
chain	O
of	O
the	O
type	O
III	O
collagen	O
protein-encoding	O
gene	O
(COL3A1)	O
pose	O
women	O
at	O
risk	O
for	O
POP	O
.	O

METHODS	O
:	O
In	O
this	O
case-control	O
study	O
,	O
the	O
prevalence	O
of	O
type	O
III	O
collagen	O
polymorphisms	O
was	O
compared	O
in	O
women	O
with	O
and	O
without	O
signs	O
and	O
symptoms	O
of	O
POP	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
and	O
two	O
POP	O
patients	O
and	O
102	O
normal	O
parous	O
controls	O
were	O
included	O
.	O

A	O
homozygous	O
single-nucleotide	O
substitution	O
in	O
the	O
coding	O
region	O
of	O
type	O
III	O
collagen	O
(	O
COL3A1	O
2209G>A	B-DNAMutation
,	O
rs1800255	B-SNP
)	O
was	O
identified	O
in	O
27	O
(13%)	O
POP	O
patients	O
and	O
three	O
(3%)	O
controls	O
(	O
odds	O
ratio	O
,	O
5.0	O
;	O
95%	O
confidence	O
interval	O
,	O
1.4-17.1	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
probability	O
of	O
POP	O
was	O
higher	O
in	O
women	O
with	O
COL3A1	O
2209G>A	B-DNAMutation
.	O

This	O
polymorphism	O
showed	O
to	O
be	O
a	O
relevant	O
risk	O
factor	O
for	O
POP	O
.	O

A	O
novel	O
ATP7A	O
gross	O
deletion	O
mutation	O
in	O
a	O
Korean	O
patient	O
with	O
Menkes	O
disease	O
.	O

Menkes	O
disease	O
(	O
MD	O
,	O
MIM	O
309400	O
)	O
is	O
a	O
fatal	O
X-linked	O
recessive	O
disorder	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
ATP7A	O
,	O
a	O
copper-transporting	O
,	O
P-type	O
ATPase	O
.	O

Patients	O
with	O
MD	O
are	O
characterized	O
by	O
progressive	O
hypotonia	O
,	O
seizures	O
,	O
failure	O
to	O
thrive	O
,	O
and	O
death	O
in	O
early	O
childhood	O
.	O

Two	O
Korean	O
patients	O
were	O
diagnosed	O
with	O
Menkes	O
disease	O
by	O
clinical	O
and	O
biochemical	O
findings	O
.	O

We	O
found	O
one	O
missense	O
mutation	O
and	O
one	O
gross	O
deletion	O
in	O
the	O
ATP7A	O
gene	O
in	O
the	O
patients	O
.	O

The	O
missense	O
mutation	O
in	O
Patient	O
1	O
,	O
c.3943G>A	B-DNAMutation
p.G1315R	B-ProteinMutation
in	O
exon	O
20	O
,	O
was	O
identified	O
in	O
a	O
previous	O
report	O
.	O

Patient	O
2	O
had	O
a	O
gross	O
deletion	O
of	O
c.1544-?_2916+?	B-DNAMutation
,	O
which	O
was	O
a	O
novel	O
mutation	O
.	O

The	O
patients'	O
mothers	O
were	O
shown	O
to	O
be	O
carriers	O
of	O
the	O
respective	O
mutations	O
.	O

Prenatal	O
DNA	O
diagnosis	O
in	O
the	O
family	O
of	O
Patient	O
2	O
was	O
successfully	O
performed	O
,	O
showing	O
a	O
male	O
fetus	O
with	O
the	O
wild-type	O
genotype	O
.	O

The	O
gross	O
deletion	O
is	O
the	O
first	O
mutation	O
to	O
be	O
identified	O
in	O
the	O
ATP7A	O
gene	O
in	O
Korean	O
MD	O
patients	O
.	O

We	O
expect	O
that	O
our	O
findings	O
will	O
be	O
helpful	O
in	O
understanding	O
the	O
wide	O
range	O
of	O
genetic	O
variation	O
in	O
ATP7A	O
in	O
Korean	O
MD	O
patients	O
.	O

The	O
first	O
founder	O
DGUOK	O
mutation	O
associated	O
with	O
hepatocerebral	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
.	O

Deoxyguanosine	O
kinase	O
(dGK)	O
deficiency	O
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	O
DNA	O
depletion	O
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	O
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	O
patients	O
.	O

This	O
new	O
DGUOK	O
homozygous	O
mutation	O
c.444-62C>A	B-DNAMutation
was	O
identified	O
in	O
three	O
patients	O
from	O
two	O
North-African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	O
chain	O
deficiencies	O
and	O
mitochondrial	O
DNA	O
depletion	O
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	O
patients	O
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	O
abnormal	O
myelination	O
and	O
moderate	O
hyperintensity	O
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	O
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in-frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	O
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	O
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
)	O
,	O
which	O
span	O
4.6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	O
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	O
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	O
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North-African	O
population	O
.	O

Macular	O
corneal	O
dystrophy	O
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	O
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	O
sulfotransferase	O
gene	O
(CHST6)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	O
corneal	O
dystrophy	O
(MCD)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O

METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O

The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(LM)	O
and	O
an	O
electron	O
microscope	O
(EM)	O
separately	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
,	O
and	O
the	O
coding	O
region	O
of	O
CHST6	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O

RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	O
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O

Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O

The	O
compound	O
heterozygous	O
mutations	O
,	O
c.892C>T	B-DNAMutation
and	O
c.1072T>C	B-DNAMutation
,	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	O
in	O
three	O
patients	O
.	O

The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	O
codon	O
for	O
glutamine	O
at	O
codon	O
298	O
p.Q298X	B-ProteinMutation
and	O
a	O
missense	O
mutation	O
at	O
codon	O
358	O
,	O
tyrosine	O
to	O
histidine	O
p.Y358H	B-ProteinMutation
.	O

The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O

These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O

CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	O
function	O
,	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	O
sulfate	O
(KS)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O

It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	O
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O

Genetic	O
polymorphism	O
in	O
chemokine	O
CCL22	O
and	O
susceptibility	O
to	O
Helicobacter	O
pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Gastric	O
carcinoma	O
is	O
widely	O
considered	O
to	O
be	O
related	O
to	O
Helicobacter	O
pylori	O
infection	O
,	O
and	O
the	O
chemokine	O
(	O
C-C	O
motif	O
)	O
ligand	O
22	O
(CCL22)	O
plays	O
an	O
important	O
role	O
in	O
suppressing	O
immune	O
responses	O
against	O
H	O
.	O

pylori	O
and	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
examined	O
the	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
CCL22	O
gene	O
and	O
the	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

METHODS	O
:	O
Information	O
on	O
SNPs	O
in	O
the	O
CCL22	O
coding	O
region	O
was	O
obtained	O
from	O
the	O
HapMap	O
Project	O
database	O
.	O

Genotypes	O
were	O
determined	O
in	O
a	O
case-control	O
cohort	O
that	O
consisted	O
of	O
1001	O
patients	O
with	O
gastric	O
carcinoma	O
and	O
1066	O
controls	O
,	O
and	O
odds	O
ratios	O
(ORs)	O
and	O
95%	O
confidence	O
intervals	O
(	O
95%	O
CIs	O
)	O
were	O
computed	O
by	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

Serum	O
H	O
.	O

pylori	O
antibody	O
levels	O
were	O
measured	O
by	O
using	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
The	O
16C-->A	B-DNAMutation
SNP	O
(	O
reference	B-SNP
SNP	I-SNP
no	I-SNP
.	I-SNP
4359426	I-SNP
)	O
in	O
exon	O
1	O
of	O
the	O
CCL22	O
gene	O
,	O
which	O
causes	O
a	O
2	O
aspartate	O
(2Asp)	O
to	O
2	O
alanine	O
(2Ala)	O
substitution	O
in	O
the	O
CCL22	O
protein	O
,	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

Individuals	O
who	O
were	O
homozygous	O
for	O
the	O
Ala/Ala	O
genotype	O
had	O
an	O
OR	O
of	O
2.27	O
(	O
95%	O
CI	O
,	O
1.28-4.02	O
)	O
compared	O
with	O
individuals	O
who	O
had	O
the	O
Asp/Asp	O
genotype	O
.	O

Stratification	O
analysis	O
indicated	O
that	O
the	O
association	O
was	O
more	O
pronounced	O
among	O
men	O
(	O
OR	O
,	O
2.64	O
;	O
95%	O
CI	O
,	O
1.29-5.41	O
)	O
and	O
among	O
younger	O
individuals	O
(	O
OR	O
,	O
2.85	O
;	O
95%	O
CI	O
,	O
1.36-5.96	O
)	O
compared	O
with	O
women	O
and	O
older	O
individuals	O
.	O

Moreover	O
,	O
a	O
multiplicative	O
joint	O
effect	O
between	O
the	O
CCL22	O
SNP	O
and	O
H	O
.	O

pylori	O
infection	O
that	O
intensified	O
the	O
risk	O
was	O
observed	O
(	O
OR	O
for	O
the	O
presence	O
of	O
both	O
Ala/Ala	O
genotype	O
and	O
H	O
.	O

pylori	O
infection	O
,	O
18.37	O
;	O
95%	O
CI	O
,	O
2.30-146.67	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
from	O
this	O
study	O
suggested	O
that	O
the	O
CCL22	O
polymorphism	O
is	O
associated	O
with	O
an	O
increase	O
risk	O
of	O
developing	O
H	O
.	O

pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

Impact	O
of	O
pepsinogen	O
C	O
polymorphism	O
on	O
individual	O
susceptibility	O
to	O
gastric	O
cancer	O
and	O
its	O
precancerous	O
conditions	O
in	O
a	O
Northeast	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Human	O
pepsinogen	O
C	O
(PGC)	O
is	O
an	O
aspartic	O
protease	O
produced	O
specifically	O
by	O
the	O
gastric	O
mucosa	O
,	O
and	O
is	O
considered	O
as	O
a	O
mature	O
marker	O
of	O
gastric	O
epithelium	O
.	O

This	O
study	O
examined	O
the	O
contributions	O
of	O
PGC	O
polymorphisms	O
and	O
the	O
Helicobacter	O
pylori	O
(	O
H	O
.	O

pylori	O
)	O
infection	O
to	O
the	O
risk	O
of	O
gastric	O
cancer	O
(GC)	O
,	O
and	O
its	O
precancerous	O
conditions	O
in	O
a	O
Northeast	O
Chinese	O
population	O
.	O

METHODS	O
:	O
The	O
PGC	O
insertion/deletion	O
polymorphism	O
was	O
evaluated	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
in	O
564	O
cases	O
of	O
GC	O
,	O
atrophic	O
gastritis	O
(AG)	O
,	O
gastric	O
ulcer	O
(GU)	O
and	O
superficial	O
gastritis	O
(	O
as	O
control	O
)	O
.	O

All	O
cases	O
were	O
frequency-matched	O
1:1	O
by	O
gender	O
and	O
age	O
(+/-5)	O
.	O

H	O
.	O

pylori	O
infection	O
was	O
identified	O
by	O
serum	O
anti-H	O
.	O

pylori	O
IgG	O
measurement	O
through	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
Patients	O
with	O
a	O
homozygous	O
PGC	O
allele	O
1	O
genotype	O
had	O
a	O
significant	O
risk	O
of	O
AG	O
[	O
adjusted	O
odds	O
ratio	O
(OR)	O
3.11	O
;	O
95%	O
confidence	O
interval	O
(CI)	O
1.44-6.71	O
]	O
or	O
of	O
GC	O
(	O
OR	O
3.00	O
;	O
95%	O
CI	O
1.38-6.51	O
)	O
,	O
and	O
a	O
significantly	O
elevated	O
risk	O
of	O
intestinal	O
metaplasia	O
(	O
OR	O
1.90	O
,	O
95%	O
CI	O
1.11-3.27	O
)	O
.	O

PGC	O
polymorphism	O
with	O
H	O
.	O

pylori	O
infection	O
increased	O
risk	O
of	O
GU	O
(	O
OR	O
8.69	O
;	O
95%	O
CI	O
1.01-74.69	O
)	O
,	O
and	O
AG	O
(	O
OR	O
11.12	O
;	O
95%	O
CI	O
1.37-90.84	O
)	O
or	O
GC	O
(	O
OR	O
10.61	O
;	O
95%	O
CI	O
1.28-87.79	O
)	O
in	O
a	O
super-multiplicative	O
manner	O
.	O

The	O
S	O
value	O
was	O
5.40	O
,	O
6.48	O
and	O
4.34	O
;	O
and	O
the	O
AP	O
value	O
was	O
72.09	O
,	O
7.00	O
and	O
69.69%	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
PGC	O
gene	O
polymorphism	O
increases	O
an	O
individual's	O
susceptibility	O
to	O
GC	O
and	O
its	O
precancerous	O
conditions	O
.	O

Moreover	O
,	O
the	O
PGC	O
gene	O
polymorphism	O
shows	O
a	O
positive	O
link	O
to	O
H	O
.	O

pylori	O
infection	O
in	O
the	O
development	O
of	O
GC	O
.	O

Three	O
novel	O
IGFALS	O
gene	O
mutations	O
resulting	O
in	O
total	O
ALS	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiency	O
in	O
children	O
of	O
different	O
ethnic	O
origins	O
.	O

BACKGROUND/AIMS	O
:	O
To	O
date	O
,	O
four	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
have	O
been	O
reported	O
.	O

We	O
now	O
describe	O
two	O
children	O
of	O
different	O
ethnic	O
background	O
with	O
total	O
acid-labile	O
subunit	O
(ALS)	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiencies	O
resulting	O
from	O
three	O
novel	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
.	O

PATIENTS/METHODS	O
:	O
Serum	O
and	O
DNA	O
of	O
patients	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Case	O
1	O
is	O
a	O
12-year-old	O
boy	O
of	O
Mayan	O
origin	O
.	O

Case	O
2	O
is	O
a	O
5-year-old	O
girl	O
of	O
Jewish/Eastern	O
European	O
(	O
Polish	O
,	O
Russian	O
,	O
Austrian-Hungarian)/Icelandic/European	O
(	O
French	O
,	O
English	O
)	O
ancestry	O
.	O

The	O
reported	O
cases	O
had	O
moderate	O
short	O
stature	O
(	O
-2.91	O
and	O
-2.14	O
SDS	O
,	O
respectively	O
)	O
,	O
nondetectable	O
serum	O
ALS	O
and	O
extremely	O
low	O
serum	O
concentrations	O
of	O
IGF-I	O
and	O
IGFBP-3	O
.	O

Case	O
1	O
harbored	O
a	O
novel	O
homozygous	O
1308_1316	B-DNAMutation
dup9	I-DNAMutation
mutation	O
in	O
a	O
highly	O
conserved	O
leucine-rich	O
repeat	O
(LRR)	O
17	O
motif	O
of	O
exon	O
2	O
,	O
representing	O
an	O
in-frame	O
insertion	O
of	O
3	O
amino	O
acids	O
,	O
LEL	O
.	O

Case	O
2	O
harbored	O
a	O
novel	O
heterozygous	O
C60S	B-ProteinMutation
/	O
L244F	B-ProteinMutation
mutation	O
in	O
exon	O
2	O
,	O
located	O
within	O
a	O
highly	O
conserved	O
LRR	O
1	O
and	O
LRR	O
9	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
identification	O
of	O
additional	O
novel	O
IGFALS	O
mutations	O
,	O
resulting	O
in	O
severe	O
IGF-I/IGFBP-3	O
and	O
ALS	O
deficiencies	O
,	O
supports	O
IGFALS	O
as	O
a	O
candidate	O
gene	O
of	O
the	O
GH/IGF	O
system	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
primary	O
IGF	O
deficiency	O
,	O
and	O
represents	O
an	O
important	O
part	O
of	O
its	O
differential	O
diagnosis	O
.	O

A	O
recessive	O
skeletal	O
dysplasia	O
,	O
SEMD	O
aggrecan	O
type	O
,	O
results	O
from	O
a	O
missense	O
mutation	O
affecting	O
the	O
C-type	O
lectin	O
domain	O
of	O
aggrecan	O
.	O

Analysis	O
of	O
a	O
nuclear	O
family	O
with	O
three	O
affected	O
offspring	O
identified	O
an	O
autosomal-recessive	O
form	O
of	O
spondyloepimetaphyseal	O
dysplasia	O
characterized	O
by	O
severe	O
short	O
stature	O
and	O
a	O
unique	O
constellation	O
of	O
radiographic	O
findings	O
.	O

Homozygosity	O
for	O
a	O
haplotype	O
that	O
was	O
identical	O
by	O
descent	O
between	O
two	O
of	O
the	O
affected	O
individuals	O
identified	O
a	O
locus	O
for	O
the	O
disease	O
gene	O
within	O
a	O
17.4	O
Mb	O
interval	O
on	O
chromosome	O
15	O
,	O
a	O
region	O
containing	O
296	O
genes	O
.	O

These	O
genes	O
were	O
assessed	O
and	O
ranked	O
by	O
cartilage	O
selectivity	O
with	O
whole-genome	O
microarray	O
data	O
,	O
revealing	O
only	O
two	O
genes	O
,	O
encoding	O
aggrecan	O
and	O
chondroitin	O
sulfate	O
proteoglycan	O
4	O
,	O
that	O
were	O
selectively	O
expressed	O
in	O
cartilage	O
.	O

Sequence	O
analysis	O
of	O
aggrecan	O
complementary	O
DNA	O
from	O
an	O
affected	O
individual	O
revealed	O
homozygosity	O
for	O
a	O
missense	O
mutation	O
(	O
c.6799G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
)	O
that	O
predicts	O
a	O
p.D2267N	B-ProteinMutation
amino	O
acid	O
substitution	O
in	O
the	O
C-type	O
lectin	O
domain	O
within	O
the	O
G3	O
domain	O
of	O
aggrecan	O
.	O

The	O
D2267	O
residue	O
is	O
predicted	O
to	O
coordinate	O
binding	O
of	O
a	O
calcium	O
ion	O
,	O
which	O
influences	O
the	O
conformational	O
binding	O
loops	O
of	O
the	O
C-type	O
lectin	O
domain	O
that	O
mediate	O
interactions	O
with	O
tenascins	O
and	O
other	O
extracellular-matrix	O
proteins	O
.	O

Expression	O
of	O
the	O
normal	O
and	O
mutant	O
G3	O
domains	O
in	O
mammalian	O
cells	O
showed	O
that	O
the	O
mutation	O
created	O
a	O
functional	O
N-glycosylation	O
site	O
but	O
did	O
not	O
adversely	O
affect	O
protein	O
trafficking	O
and	O
secretion	O
.	O

Surface-plasmon-resonance	O
studies	O
showed	O
that	O
the	O
mutation	O
influenced	O
the	O
binding	O
and	O
kinetics	O
of	O
the	O
interactions	O
between	O
the	O
aggrecan	O
G3	O
domain	O
and	O
tenascin-C	O
.	O

These	O
findings	O
identify	O
an	O
autosomal-recessive	O
skeletal	O
dysplasia	O
and	O
a	O
significant	O
role	O
for	O
the	O
aggrecan	O
C-type	O
lectin	O
domain	O
in	O
regulating	O
endochondral	O
ossification	O
and	O
,	O
thereby	O
,	O
height	O
.	O

Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	O
muscular	O
dystrophy	O
.	O

BACKGROUND	O
:	O
Oculopharyngeal	O
muscular	O
dystrophy	O
(OPMD)	O
is	O
a	O
late	O
onset	O
autosomal	O
dominant	O
muscle	O
disorder	O
.	O

OPMD	O
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	O
tract	O
in	O
the	O
polyadenylate	O
binding-protein	O
nuclear	O
1	O
(PABPN1)	O
gene	O
.	O

We	O
identified	O
and	O
characterized	O
a	O
PABPN1	O
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	O
.	O

METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	O
family	O
.	O

Genetic	O
alterations	O
in	O
the	O
PABPN1	O
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	O
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	O
gene	O
.	O

The	O
normal	O
(GCG)6(GCA)3GCG	O
sequence	O
was	O
replaced	O
by	O
(GCG)6(GCA)(GCG)4(GCA)3GCG	O
due	O
to	O
an	O
insertion	O
of	O
(GCG)4GCA	O
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	O
subjects	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	O
patients	O
in	O
the	O
literature	O
,	O
an	O
insertion	O
of	O
(GCG)4GCA	O
in	O
the	O
PABPN1	O
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	O
subjects	O
.	O

The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross-over	O
of	O
two	O
PABPN1	O
alleles	O
.	O

Combination	O
of	O
polymorphisms	O
within	O
5'	O
and	O
3'	O
untranslated	O
regions	O
of	O
thymidylate	O
synthase	O
gene	O
modulates	O
survival	O
in	O
5	O
fluorouracil-treated	O
colorectal	O
cancer	O
patients	O
.	O

In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	O
gene	O
on	O
overall	O
and	O
progression-	O
free	O
survival	O
of	O
colorectal	O
cancer	O
(CRC)	O
patients	O
subjected	O
to	O
5FU	O
chemotherapy	O
.	O

A	O
28	O
bp	O
variable	O
number	O
of	O
tandem	O
repeats	O
(VNTR)	O
,	O
a	O
G/C	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
and	O
a	O
deletion	O
of	O
6	O
bp	O
at	O
position	O
1494	O
were	O
studied	O
.	O

The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	O
was	O
also	O
evaluated	O
.	O

A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin-embedded	O
sections	O
from	O
113	O
patients	O
diagnosed	O
of	O
advanced	O
CRC	O
.	O

TS	O
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(PCR)	O
for	O
VNTR	O
and	O
PCR	O
,	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(PCR-RFLP)	O
for	O
SNP	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
.	O

To	O
study	O
the	O
combined	O
effect	O
of	O
TS	O
polymorphisms	O
,	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
genotypes	O
:	O
C_allele	O
6-	O
,	O
C_6+/6+	O
,	O
G_allele6-	O
and	O
G_6+/6+	O
.	O

VNTR	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
genotypes	O
varied	O
with	O
tumour	O
anatomical	O
site	O
:	O
2R/2R	O
genotype	O
was	O
rare	O
in	O
left-sided	O
tumours	O
(	O
7.0%	O
vs	O
.	O

26.3%	O
of	O
right-sided	O
and	O
24.1%	O
of	O
rectal	O
cancers	O
;	O
P<0.01	O
)	O
,	O
where	O
the	O
variant	O
allele	O
6-	O
was	O
very	O
frequent	O
(69.0%)	O
.	O

Instead	O
,	O
most	O
patients	O
with	O
right-sided	O
tumours	O
were	O
wild-type	O
homozygous	O
6+/6+	O
(63.9%)	O
(P<0.01)	O
.	O

Heterozygous	O
6+/6-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	O
classified	O
as	O
C	O
(50.0%)	O
and	O
D	O
(76.5%)	O
Dukes	O
stages	O
(P=0.05)	O
.	O

None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression-free	O
survival	O
(PFS)	O
.	O

C_6+/6+	O
and	O
G_6+/6+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P=0.03	O
when	O
compared	O
with	O
each	O
other	O
)	O
,	O
while	O
combinations	O
carrying	O
the	O
allele	O
6-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O

The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	O
was	O
unexpectedly	O
high	O
(59.1%)	O
among	O
patients	O
with	O
the	O
unfavourable	O
G_6+/6+	O
combination	O
.	O

In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	O
expression	O
genotypes	O
G_6+/6+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	O
patients	O
treated	O
with	O
5FU	O
.	O

Genome-wide	O
loss	O
of	O
heterozygosity	O
and	O
uniparental	O
disomy	O
in	O
BRCA1/2-associated	O
ovarian	O
carcinomas	O
.	O

PURPOSE	O
:	O
The	O
importance	O
of	O
the	O
BRCA	O
gene	O
products	O
in	O
maintaining	O
genomic	O
stability	O
led	O
us	O
to	O
hypothesize	O
that	O
BRCA-associated	O
and	O
sporadic	O
ovarian	O
cancers	O
would	O
have	O
distinctive	O
genetic	O
profiles	O
despite	O
similarities	O
in	O
histologic	O
appearance	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
A	O
whole-genome	O
copy	O
number	O
analysis	O
of	O
fresh	O
,	O
frozen	O
,	O
papillary	O
serous	O
ovarian	O
cancer	O
DNA	O
was	O
done	O
using	O
the	O
Affymetrix	O
50K	O
Xba	O
Mapping	O
Array	O
using	O
each	O
patient's	O
normal	O
genomic	O
DNA	O
as	O
the	O
matched	O
control	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
copy	O
number	O
abnormalities	O
were	O
summarized	O
to	O
define	O
regions	O
of	O
amplification	O
,	O
deletion	O
,	O
or	O
uniparental	O
disomy	O
(UPD)	O
,	O
defined	O
as	O
loss	O
of	O
one	O
allele	O
and	O
duplication	O
of	O
the	O
remaining	O
allele	O
.	O

Genomic	O
abnormalities	O
were	O
compared	O
between	O
BRCA-associated	O
and	O
sporadic	O
tumors	O
.	O

RESULTS	O
:	O
We	O
compared	O
6	O
BRCA-associated	O
with	O
14	O
sporadic	O
papillary	O
serous	O
ovarian	O
carcinomas	O
.	O

Genetic	O
instability	O
,	O
measured	O
by	O
percentage	O
of	O
genome	O
altered	O
,	O
was	O
more	O
pronounced	O
in	O
BRCA-associated	O
tumors	O
(	O
median	O
,	O
86.6%	O
;	O
range	O
,	O
54-100%	O
)	O
than	O
sporadic	O
tumors	O
(	O
median	O
,	O
43.6%	O
;	O
range	O
,	O
2-83%	O
;	O
P	O
=	O
0.009	O
)	O
.	O

We	O
used	O
frequency	O
plots	O
to	O
show	O
the	O
proportion	O
of	O
cases	O
affected	O
by	O
each	O
type	O
abnormality	O
at	O
each	O
genomic	O
region	O
.	O

BRCA-associated	O
tumors	O
showed	O
genome-wide	O
loss	O
of	O
heterozygosity	O
primarily	O
due	O
to	O
the	O
occurrence	O
of	O
UPD	O
rather	O
than	O
deletion	O
.	O

UPD	O
was	O
found	O
in	O
100%	O
of	O
the	O
BRCA-associated	O
and	O
50%	O
of	O
the	O
sporadic	O
tumors	O
profiled	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
reports	O
on	O
a	O
previously	O
underappreciated	O
genetic	O
phenomenon	O
of	O
UPD	O
,	O
which	O
occurs	O
frequently	O
in	O
ovarian	O
cancer	O
DNA	O
.	O

We	O
observed	O
distinct	O
genetic	O
patterns	O
between	O
BRCA-associated	O
and	O
sporadic	O
ovarian	O
cancers	O
,	O
suggesting	O
that	O
these	O
papillary	O
serous	O
tumors	O
arise	O
from	O
different	O
molecular	O
pathways	O
.	O

Mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
are	O
not	O
sufficient	O
to	O
cause	O
diffuse	O
mesangial	O
sclerosis	O
.	O

Diffuse	O
mesangial	O
sclerosis	O
occurs	O
as	O
an	O
isolated	O
abnormality	O
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O

Recently	O
,	O
mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
(PLCE1)	O
were	O
found	O
to	O
cause	O
a	O
nonsyndromic	O
,	O
autosomal	O
recessive	O
form	O
of	O
this	O
disease	O
.	O

Here	O
we	O
describe	O
three	O
children	O
from	O
one	O
consanguineous	O
kindred	O
of	O
Pakistani	O
origin	O
with	O
diffuse	O
mesangial	O
sclerosis	O
who	O
presented	O
with	O
congenital	O
or	O
infantile	O
nephrotic	O
syndrome	O
.	O

Homozygous	O
mutations	O
in	O
PLCE1	O
(	O
also	O
known	O
as	O
KIAA1516	O
,	O
PLCE	O
,	O
or	O
NPHS3	O
)	O
were	O
identified	O
following	O
genome-wide	O
mapping	O
of	O
single-nucleotide	O
polymorphisms	O
.	O

All	O
affected	O
children	O
were	O
homozygous	O
for	O
a	O
four-basepair	O
deletion	O
in	O
exon	O
3	O
,	O
which	O
created	O
a	O
premature	O
translational	O
stop	O
codon	O
.	O

Analysis	O
of	O
the	O
asymptomatic	O
father	O
of	O
two	O
of	O
the	O
children	O
revealed	O
that	O
he	O
was	O
also	O
homozygous	O
for	O
the	O
same	O
mutation	O
.	O

We	O
conclude	O
this	O
nonpenetrance	O
may	O
be	O
due	O
to	O
compensatory	O
mutations	O
at	O
a	O
second	O
locus	O
and	O
that	O
mutation	O
within	O
PLCE1	O
is	O
not	O
always	O
sufficient	O
to	O
cause	O
diffuse	O
mesangial	O
sclerosis	O
.	O

Somatic	O
TP53	O
mutation	O
mosaicism	O
in	O
a	O
patient	O
with	O
Li-Fraumeni	O
syndrome	O
.	O

We	O
present	O
a	O
girl	O
who	O
developed	O
adrenocortical	O
adenoma	O
at	O
the	O
age	O
of	O
1	O
year	O
and	O
osteosarcoma	O
at	O
the	O
age	O
of	O
5	O
years	O
.	O

There	O
was	O
no	O
history	O
of	O
cancer	O
in	O
her	O
parents	O
and	O
their	O
relatives	O
.	O

However	O
,	O
both	O
tumors	O
were	O
typical	O
for	O
the	O
Li-Fraumeni	O
syndrome	O
(LFS)	O
,	O
and	O
the	O
patient	O
met	O
criteria	O
for	O
germline	O
TP53	O
mutation	O
testing	O
.	O

A	O
mutation	O
in	O
codon	O
282	O
Arg282Trp	B-ProteinMutation
was	O
identified	O
in	O
her	O
blood	O
lymphocyte	O
genomic	O
DNA	O
.	O

The	O
substitution	O
was	O
found	O
in	O
neither	O
of	O
her	O
parents	O
,	O
which	O
indicated	O
a	O
possibility	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

Unexpectedly	O
,	O
sequencing	O
of	O
the	O
DNA	O
of	O
the	O
patient	O
repeatedly	O
showed	O
allelic	O
imbalance	O
in	O
favor	O
of	O
the	O
normal	O
allele	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
investigate	O
the	O
putative	O
somatic	O
mosaicism	O
in	O
the	O
patient	O
consisting	O
of	O
normal	O
cells	O
and	O
cells	O
heterozygous	O
for	O
the	O
mutation	O
.	O

The	O
imbalance	O
was	O
also	O
examined	O
in	O
two	O
other	O
non-invasively	O
sampled	O
tissues	O
,	O
buccal	O
cells	O
,	O
and	O
cells	O
from	O
the	O
urine	O
sediment	O
,	O
and	O
sequencing	O
was	O
confirmed	O
with	O
two	O
other	O
independent	O
methods	O
.	O

While	O
the	O
findings	O
in	O
blood	O
and	O
the	O
urine	O
sediment	O
were	O
similar	O
,	O
in	O
buccal	O
cells	O
both	O
alleles	O
were	O
present	O
in	O
equal	O
amounts	O
.	O

The	O
allele	O
ratio	O
in	O
lymphocytes	O
was	O
consistent	O
with	O
a	O
mosaic	O
where	O
about	O
2/3	O
of	O
cells	O
carried	O
two	O
normal	O
alleles	O
and	O
only	O
1/3	O
was	O
heterozygous	O
for	O
the	O
mutation	O
.	O

Despite	O
the	O
mosaicism	O
the	O
girl	O
developed	O
two	O
early	O
childhood	O
tumors	O
of	O
mesodermal	O
origin	O
,	O
and	O
her	O
phenotype	O
was	O
thus	O
not	O
milder	O
than	O
that	O
of	O
other	O
germline	O
TP53	O
mutation	O
carriers	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
description	O
of	O
somatic	O
mosaicism	O
for	O
a	O
de	O
novo	O
TP53	O
mutation	O
in	O
LFS	O
.	O

A	O
comprehensive	O
analysis	O
of	O
the	O
CDKN2A	O
gene	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
reveals	O
genomic	O
deletion	O
,	O
copy	O
number	O
neutral	O
loss	O
of	O
heterozygosity	O
,	O
and	O
association	O
with	O
specific	O
cytogenetic	O
subgroups	O
.	O

Inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
CDKN2A	O
,	O
can	O
occur	O
by	O
deletion	O
,	O
methylation	O
,	O
or	O
mutation	O
.	O

We	O
assessed	O
the	O
principal	O
mode	O
of	O
inactivation	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
and	O
frequency	O
in	O
biologically	O
relevant	O
subgroups	O
.	O

Mutation	O
or	O
methylation	O
was	O
rare	O
,	O
whereas	O
genomic	O
deletion	O
occurred	O
in	O
21%	O
of	O
B-cell	O
precursor	O
ALL	O
and	O
50%	O
of	O
T-ALL	O
patients	O
.	O

Single	O
nucleotide	O
polymorphism	O
arrays	O
revealed	O
copy	O
number	O
neutral	O
(CNN)	O
loss	O
of	O
heterozygosity	O
(LOH)	O
in	O
8%	O
of	O
patients	O
.	O

Array-based	O
comparative	O
genomic	O
hybridization	O
demonstrated	O
that	O
the	O
mean	O
size	O
of	O
deletions	O
was	O
14.8	O
Mb	O
and	O
biallelic	O
deletions	O
composed	O
a	O
large	O
and	O
small	O
deletion	O
(	O
mean	O
sizes	O
,	O
23.3	O
Mb	O
and	O
1.4	O
Mb	O
)	O
.	O

Among	O
86	O
patients	O
,	O
only	O
2	O
small	O
deletions	O
were	O
below	O
the	O
resolution	O
of	O
detection	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

Patients	O
with	O
high	O
hyperdiploidy	O
,	O
ETV6-RUNX1	O
,	O
or	O
11q23/MLL	O
rearrangements	O
had	O
low	O
rates	O
of	O
deletion	O
(	O
11%	O
,	O
15%	O
,	O
13%	O
)	O
,	O
whereas	O
patients	O
with	O
t(9;22)	O
,	O
t(1;19)	O
,	O
TLX3	O
,	O
or	O
TLX1	O
rearrangements	O
had	O
higher	O
frequencies	O
(	O
61%	O
,	O
42%	O
,	O
78%	O
,	O
and	O
89%	O
)	O
.	O

In	O
conclusion	O
,	O
CDKN2A	O
deletion	O
is	O
a	O
significant	O
secondary	O
abnormality	O
in	O
childhood	O
ALL	O
strongly	O
correlated	O
with	O
phenotype	O
and	O
genotype	O
.	O

The	O
variation	O
in	O
the	O
incidence	O
of	O
CDKN2A	O
deletions	O
by	O
cytogenetic	O
subgroup	O
may	O
explain	O
its	O
inconsistent	O
association	O
with	O
outcome	O
.	O

CNN	O
LOH	O
without	O
apparent	O
CDKN2A	O
inactivation	O
suggests	O
the	O
presence	O
of	O
other	O
relevant	O
genes	O
in	O
this	O
region	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
enhancing	O
hGR-mediated	O
gene	O
expression	O
.	O

CONTEXT	O
:	O
Interindividual	O
variations	O
in	O
glucocorticoid	O
sensitivity	O
have	O
been	O
associated	O
with	O
manifestations	O
of	O
cortisol	O
excess	O
or	O
deficiency	O
and	O
may	O
be	O
partly	O
explained	O
by	O
polymorphisms	O
in	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
.	O

We	O
studied	O
a	O
43-yr-old	O
female	O
,	O
who	O
presented	O
with	O
manifestations	O
consistent	O
with	O
tissue-selective	O
glucocorticoid	O
hypersensitivity	O
.	O

We	O
detected	O
a	O
novel	O
,	O
single	O
,	O
heterozygous	O
nucleotide	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
(	O
exon	O
2	O
)	O
of	O
the	O
hGR	O
gene	O
,	O
which	O
resulted	O
in	O
aspartic	O
acid	O
to	O
histidine	O
substitution	O
at	O
amino	O
acid	O
position	O
401	O
in	O
the	O
amino-terminal	O
domain	O
of	O
the	O
hGRalpha	O
.	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
of	O
action	O
of	O
the	O
natural	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
.	O

METHODS-RESULTS	O
:	O
Compared	O
with	O
the	O
wild-type	O
hGRalpha	O
,	O
the	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
demonstrated	O
a	O
2.4-fold	O
increase	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid-inducible	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	O
in	O
response	O
to	O
dexamethasone	O
but	O
had	O
similar	O
affinity	O
for	O
the	O
ligand	O
(	O
dissociation	O
constant	O
=	O
6.2	O
+/-	O
0.6	O
vs	O
.	O

6.1	O
+/-	O
0.6	O
nm	O
)	O
and	O
time	O
to	O
nuclear	O
translocation	O
(	O
14.75	O
+/-	O
0.25	O
vs	O
.	O

14.25	O
+/-	O
1.13	O
min	O
)	O
.	O

The	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
did	O
not	O
exert	O
a	O
dominant	O
positive	O
or	O
negative	O
effect	O
upon	O
the	O
wild-type	O
receptor	O
,	O
it	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
glucocorticoid	O
response	O
elements	O
,	O
and	O
displayed	O
a	O
normal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
enhances	O
the	O
transcriptional	O
activity	O
of	O
glucocorticoid-responsive	O
genes	O
.	O

The	O
presence	O
of	O
the	O
D401H	B-ProteinMutation
mutation	O
may	O
predispose	O
subjects	O
to	O
obesity	O
,	O
hypertension	O
,	O
and	O
other	O
manifestations	O
of	O
the	O
metabolic	O
syndrome	O
.	O

Novel	O
mutations	O
in	O
the	O
IRF6	O
gene	O
in	O
Brazilian	O
families	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
Syndrome	O
(VWS)	O
is	O
an	O
autosomal	O
craniofacial	O
disorder	O
characterized	O
by	O
lower	O
lip	O
pits	O
and	O
cleft	O
lip	O
and/or	O
palate	O
.	O

Mutations	O
in	O
the	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
VWS	O
.	O

To	O
identify	O
novel	O
IRF6	O
mutations	O
in	O
patients	O
affected	O
by	O
VWS	O
,	O
we	O
screened	O
2	O
Brazilian	O
families	O
,	O
sequencing	O
the	O
entire	O
IRF6-coding	O
region	O
and	O
flanking	O
intronic	O
boundaries	O
.	O

Two	O
novel	O
heterozygous	O
mutations	O
were	O
identified	O
:	O
a	O
frame	O
shift	O
mutation	O
with	O
deletion	O
of	O
G	O
at	O
the	O
nucleotide	O
position	O
520	O
in	O
the	O
exon	O
6	O
520delG	B-DNAMutation
,	O
and	O
a	O
missense	O
single	O
nucleotide	O
substitution	O
from	O
T	O
to	O
A	O
at	O
nucleotide	O
position	O
1135	O
in	O
exon	O
8	O
T1135A	B-DNAMutation
.	O

By	O
using	O
restriction	O
enzyme	O
analysis	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
the	O
lack	O
of	O
similar	O
mutations	O
in	O
unrelated	O
healthy	O
individuals	O
and	O
non-syndromic	O
cleft	O
lip	O
and	O
palate	O
patients	O
.	O

Our	O
results	O
further	O
confirmed	O
that	O
haploinsufficiency	O
of	O
the	O
IRF6	O
gene	O
results	O
in	O
VWS	O
.	O

Genetics	O
of	O
Meesmann	O
corneal	O
dystrophy	O
:	O
a	O
novel	O
mutation	O
in	O
the	O
keratin	O
3	O
gene	O
in	O
an	O
asymptomatic	O
family	O
suggests	O
genotype-phenotype	O
correlation	O
.	O

PURPOSE	O
:	O
Juvenile	O
epithelial	O
corneal	O
dystrophy	O
of	O
Meesmann	O
(	O
MCD	O
,	O
OMIM	O
122100	O
)	O
is	O
a	O
dominantly	O
inherited	O
disorder	O
characterized	O
by	O
fragility	O
of	O
the	O
anterior	O
corneal	O
epithelium	O
and	O
intraepithelial	O
microcyst	O
formation	O
.	O

Although	O
the	O
disease	O
is	O
generally	O
mild	O
and	O
affected	O
individuals	O
are	O
often	O
asymptomatic	O
,	O
some	O
suffer	O
from	O
recurrent	O
erosions	O
leading	O
to	O
lacrimation	O
,	O
photophobia	O
,	O
and	O
deterioration	O
in	O
visual	O
acuity	O
.	O

MCD	O
is	O
caused	O
by	O
mutations	O
in	O
keratin	O
3	O
(KRT3)	O
or	O
keratin	O
12	O
(KRT12)	O
genes	O
,	O
which	O
encode	O
cornea-specific	O
cytoskeletal	O
proteins	O
.	O

Seventeen	O
mutations	O
in	O
KRT12	O
and	O
two	O
in	O
KRT3	O
have	O
been	O
described	O
so	O
far	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
genetic	O
background	O
of	O
MCD	O
in	O
a	O
Polish	O
family	O
.	O

METHODS	O
:	O
We	O
report	O
on	O
a	O
three-generation	O
family	O
with	O
MCD	O
.	O

Epithelial	O
lesions	O
characteristic	O
for	O
MCD	O
were	O
visualized	O
with	O
slit-lamp	O
examination	O
and	O
confirmed	O
by	O
in	O
vivo	O
confocal	O
microscopy	O
.	O

Using	O
genomic	O
DNA	O
as	O
a	O
template	O
,	O
all	O
coding	O
regions	O
of	O
KRT3	O
and	O
KRT12	O
were	O
amplified	O
and	O
sequenced	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
verified	O
with	O
restriction	O
endonuclease	O
digestion	O
.	O

RESULTS	O
:	O
In	O
the	O
proband	O
,	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
product	O
from	O
amplified	O
coding	O
regions	O
of	O
KRT3	O
and	O
KRT12	O
revealed	O
a	O
novel	O
1493A>T	B-DNAMutation
heterozygous	O
missense	O
mutation	O
in	O
exon	O
7	O
of	O
KRT3	O
,	O
which	O
predicts	O
the	O
substitution	O
of	O
glutamic	O
acid	O
for	O
valine	O
at	O
codon	O
498	O
E498V	B-ProteinMutation
.	O

Using	O
PCR-Restriction	O
Fragment	O
Length	O
Polymorphism	O
(RFLP)	O
analysis	O
,	O
the	O
mutation	O
was	O
demonstrated	O
to	O
segregate	O
with	O
the	O
disease	O
(	O
four	O
affected	O
members	O
,	O
three	O
non-affected	O
)	O
and	O
to	O
be	O
absent	O
in	O
100	O
controls	O
from	O
the	O
Polish	O
population	O
,	O
indicating	O
that	O
it	O
is	O
not	O
a	O
common	O
polymorphism	O
.	O

CONCLUSIONS	O
:	O
Location	O
of	O
the	O
E498V	B-ProteinMutation
mutation	O
emphasizes	O
the	O
functional	O
relevance	O
of	O
the	O
highly	O
conserved	O
boundary	O
motifs	O
at	O
the	O
COOH-terminus	O
of	O
the	O
alpha-helical	O
rod	O
domain	O
in	O
keratin	O
3	O
(K3)	O
.	O

Identification	O
of	O
a	O
gain-of-function	O
mutation	O
of	O
the	O
prolactin	O
receptor	O
in	O
women	O
with	O
benign	O
breast	O
tumors	O
.	O

There	O
is	O
currently	O
no	O
known	O
genetic	O
disease	O
linked	O
to	O
prolactin	O
(Prl)	O
or	O
its	O
receptor	O
(PrlR)	O
in	O
humans	O
.	O

Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
,	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl/PrlR	O
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	O
diseases	O
with	O
high	O
proliferative	O
potential	O
.	O

Multiple	O
fibroadenomas	O
(MFA)	O
are	O
benign	O
breast	O
tumors	O
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	O
,	O
including	O
at	O
puberty	O
,	O
when	O
Prl	O
has	O
well-recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O

In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	O
patients	O
and	O
170	O
control	O
subjects	O
,	O
we	O
identified	O
four	O
patients	O
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	O
gene	O
,	O
encoding	O
Ile(146)-->Leu	B-ProteinMutation
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O

This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
PrlR(I146L)	B-ProteinMutation
,	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba/F3	O
,	O
HEK293	O
and	O
MCF-7	O
cells	O
)	O
by	O
Prl-independent	O
(i)	O
PrlR	O
tyrosine	O
phosphorylation	O
,	O
(ii)	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(STAT5)	O
signaling	O
,	O
(iii)	O
transcriptional	O
activity	O
toward	O
a	O
Prl-responsive	O
reporter	O
gene	O
,	O
and	O
(iv)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O

Constitutive	O
activity	O
of	O
PrlR(I146L)	B-ProteinMutation
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	O
was	O
supported	O
by	O
increased	O
STAT5	O
signaling	O
.	O

This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	O
associated	O
with	O
a	O
human	O
disease	O
.	O

Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	O
antagonist	O
,	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	O
,	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O

Genetic	O
variation	O
in	O
an	O
individual	O
human	O
exome	O
.	O

There	O
is	O
much	O
interest	O
in	O
characterizing	O
the	O
variation	O
in	O
a	O
human	O
individual	O
,	O
because	O
this	O
may	O
elucidate	O
what	O
contributes	O
significantly	O
to	O
a	O
person's	O
phenotype	O
,	O
thereby	O
enabling	O
personalized	O
genomics	O
.	O

We	O
focus	O
here	O
on	O
the	O
variants	O
in	O
a	O
person's	O
'exome,'	O
which	O
is	O
the	O
set	O
of	O
exons	O
in	O
a	O
genome	O
,	O
because	O
the	O
exome	O
is	O
believed	O
to	O
harbor	O
much	O
of	O
the	O
functional	O
variation	O
.	O

We	O
provide	O
an	O
analysis	O
of	O
the	O
approximately	O
12,500	O
variants	O
that	O
affect	O
the	O
protein	O
coding	O
portion	O
of	O
an	O
individual's	O
genome	O
.	O

We	O
identified	O
approximately	O
10,400	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
(nsSNPs)	O
in	O
this	O
individual	O
,	O
of	O
which	O
approximately	O
15-20%	O
are	O
rare	O
in	O
the	O
human	O
population	O
.	O

We	O
predict	O
approximately	O
1,500	O
nsSNPs	O
affect	O
protein	O
function	O
and	O
these	O
tend	O
be	O
heterozygous	O
,	O
rare	O
,	O
or	O
novel	O
.	O

Of	O
the	O
approximately	O
700	O
coding	O
indels	O
,	O
approximately	O
half	O
tend	O
to	O
have	O
lengths	O
that	O
are	O
a	O
multiple	O
of	O
three	O
,	O
which	O
causes	O
insertions/deletions	O
of	O
amino	O
acids	O
in	O
the	O
corresponding	O
protein	O
,	O
rather	O
than	O
introducing	O
frameshifts	O
.	O

Coding	O
indels	O
also	O
occur	O
frequently	O
at	O
the	O
termini	O
of	O
genes	O
,	O
so	O
even	O
if	O
an	O
indel	O
causes	O
a	O
frameshift	O
,	O
an	O
alternative	O
start	O
or	O
stop	O
site	O
in	O
the	O
gene	O
can	O
still	O
be	O
used	O
to	O
make	O
a	O
functional	O
protein	O
.	O

In	O
summary	O
,	O
we	O
reduced	O
the	O
set	O
of	O
approximately	O
12,500	O
nonsilent	O
coding	O
variants	O
by	O
approximately	O
8-fold	O
to	O
a	O
set	O
of	O
variants	O
that	O
are	O
most	O
likely	O
to	O
have	O
major	O
effects	O
on	O
their	O
proteins'	O
functions	O
.	O

This	O
is	O
our	O
first	O
glimpse	O
of	O
an	O
individual's	O
exome	O
and	O
a	O
snapshot	O
of	O
the	O
current	O
state	O
of	O
personalized	O
genomics	O
.	O

The	O
majority	O
of	O
coding	O
variants	O
in	O
this	O
individual	O
are	O
common	O
and	O
appear	O
to	O
be	O
functionally	O
neutral	O
.	O

Our	O
results	O
also	O
indicate	O
that	O
some	O
variants	O
can	O
be	O
used	O
to	O
improve	O
the	O
current	O
NCBI	O
human	O
reference	O
genome	O
.	O

As	O
more	O
genomes	O
are	O
sequenced	O
,	O
many	O
rare	O
variants	O
and	O
non-SNP	O
variants	O
will	O
be	O
discovered	O
.	O

We	O
present	O
an	O
approach	O
to	O
analyze	O
the	O
coding	O
variation	O
in	O
humans	O
by	O
proposing	O
multiple	O
bioinformatic	O
methods	O
to	O
hone	O
in	O
on	O
possible	O
functional	O
variation	O
.	O

Genome-wide	O
analysis	O
identifies	O
16q	O
deletion	O
associated	O
with	O
survival	O
,	O
molecular	O
subtypes	O
,	O
mRNA	O
expression	O
,	O
and	O
germline	O
haplotypes	O
in	O
breast	O
cancer	O
patients	O
.	O

Breast	O
carcinomas	O
are	O
characterized	O
by	O
DNA	O
copy	O
number	O
alterations	O
(CNAs)	O
with	O
biological	O
and	O
clinical	O
significance	O
.	O

This	O
explorative	O
study	O
integrated	O
CNA	O
,	O
expression	O
,	O
and	O
germline	O
genotype	O
data	O
of	O
112	O
early-stage	O
breast	O
cancer	O
patients	O
.	O

Recurrent	O
CNAs	O
differed	O
substantially	O
between	O
tumor	O
subtypes	O
classified	O
according	O
to	O
expression	O
pattern	O
.	O

Deletion	O
of	O
16q	O
was	O
overrepresented	O
in	O
Luminal	O
A	O
,	O
and	O
a	O
predictor	O
of	O
good	O
prognosis	O
,	O
both	O
overall	O
and	O
for	O
the	O
nonluminal	O
A	O
subgroups	O
.	O

The	O
deleted	O
region	O
most	O
significantly	O
associated	O
with	O
survival	O
mapped	O
to	O
16q22.2	O
,	O
harboring	O
the	O
genes	O
TXNL4B	O
and	O
DXH38	O
,	O
whose	O
expression	O
was	O
strongly	O
correlated	O
with	O
the	O
deletion	O
.	O

The	O
area	O
most	O
frequently	O
deleted	O
resided	O
on	O
16q23.1	O
,	O
3.5	O
MB	O
downstream	O
of	O
the	O
area	O
most	O
significantly	O
associated	O
with	O
survival	O
,	O
and	O
included	O
the	O
tumor	O
suppressor	O
gene	O
ADAMTS18	O
and	O
the	O
cell	O
recognition	O
gene	O
CNTNAP4	O
.	O

Whole-genome	O
association	O
analysis	O
identified	O
germline	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
their	O
corresponding	O
haplotypes	O
,	O
residing	O
on	O
several	O
different	O
chromosomes	O
,	O
to	O
be	O
associated	O
with	O
deletion	O
of	O
16q	O
.	O

The	O
genes	O
where	O
these	O
SNPs	O
reside	O
encode	O
proteins	O
involved	O
in	O
the	O
extracellular	O
matrix	O
(	O
CHST3	O
and	O
SPOCK2	O
)	O
,	O
in	O
regulation	O
of	O
the	O
cell	O
cycle	O
(	O
JMY	O
,	O
PTPRN2	O
,	O
and	O
Cwf19L2	O
)	O
and	O
chromosome	O
stability	O
(KPNB1)	O
.	O

TNFA	O
-308G>A	B-DNAMutation
in	O
two	O
international	O
population-based	O
cohorts	O
and	O
risk	O
of	O
asthma	O
.	O

Genetic	O
association	O
studies	O
have	O
related	O
the	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
(TNFA)	O
guanine	O
to	O
adenine	O
substitution	O
of	O
nucleotide	O
-308	O
-308G>A	B-DNAMutation
polymorphism	O
to	O
increased	O
risk	O
of	O
asthma	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
whether	O
two	O
single-nucleotide	O
polymorphisms	O
,	O
of	O
TNFA	O
and	O
of	O
the	O
lymphotoxin-alpha	O
gene	O
(LTA)	O
,	O
are	O
associated	O
with	O
asthma	O
,	O
bronchial	O
hyperresponsiveness	O
and	O
atopy	O
in	O
adults	O
,	O
by	O
combining	O
the	O
results	O
of	O
two	O
large	O
population-based	O
multicentric	O
studies	O
and	O
conducting	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

The	O
European	O
Community	O
Respiratory	O
Health	O
Survey	O
(ECRHS)	O
and	O
Swiss	O
Cohort	O
Study	O
on	O
Air	O
Pollution	O
and	O
Lung	O
and	O
Heart	O
Diseases	O
in	O
Adults	O
(SAPALDIA)	O
used	O
comparable	O
protocols	O
,	O
including	O
questionnaires	O
for	O
respiratory	O
symptoms	O
and	O
measures	O
of	O
lung	O
function	O
and	O
atopy	O
.	O

DNA	O
samples	O
from	O
11,136	O
participants	O
were	O
genotyped	O
at	O
TNFA	O
-308	O
and	O
LTA	O
252	O
.	O

Logistic	O
regression	O
employing	O
fixed	O
and	O
random	O
effects	O
models	O
and	O
nonparametric	O
techniques	O
were	O
used	O
.	O

The	O
prevalence	O
of	O
asthma	O
was	O
6%	O
.	O

The	O
TNFA	O
-308G>A	B-DNAMutation
polymorphism	O
was	O
associated	O
with	O
increased	O
asthma	O
prevalence	O
and	O
with	O
bronchial	O
hyperresponsiveness	O
.	O

No	O
consistent	O
association	O
was	O
found	O
for	O
atopy	O
.	O

The	O
LTA	O
252A>G	B-DNAMutation
polymorphism	O
was	O
not	O
associated	O
with	O
any	O
of	O
the	O
outcomes	O
.	O

A	O
meta-analysis	O
of	O
17	O
studies	O
showed	O
an	O
increased	O
asthma	O
risk	O
for	O
the	O
TNFA	O
-308	O
adenine	O
allele	O
.	O

The	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
nucleotide	O
-308	O
polymorphism	O
is	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
asthma	O
and	O
bronchial	O
hyperresponsiveness	O
,	O
but	O
not	O
with	O
atopy	O
.	O

These	O
results	O
are	O
supported	O
by	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

A	O
splice	O
site	O
mutation	O
in	O
hERG	O
leads	O
to	O
cryptic	O
splicing	O
in	O
human	O
long	O
QT	O
syndrome	O
.	O

Mutations	O
in	O
the	O
human	O
ether-a-go-go-related	O
gene	O
(hERG)	O
cause	O
type	O
2	O
long	O
QT	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
pathogenic	O
mechanism	O
of	O
the	O
hERG	O
splice	O
site	O
mutation	O
2398+1G>C	B-DNAMutation
and	O
the	O
genotype-phenotype	O
relationship	O
of	O
mutation	O
carriers	O
in	O
three	O
unrelated	O
kindreds	O
with	O
long	O
QT	O
syndrome	O
.	O

The	O
effect	O
of	O
2398+1G>C	B-DNAMutation
on	O
mRNA	O
splicing	O
was	O
studied	O
by	O
analysis	O
of	O
RNA	O
isolated	O
from	O
lymphocytes	O
of	O
index	O
patients	O
and	O
using	O
minigenes	O
expressed	O
in	O
HEK293	O
cells	O
and	O
neonatal	O
rat	O
ventricular	O
myocytes	O
.	O

RT-PCR	O
analysis	O
revealed	O
that	O
the	O
2398+1G>C	B-DNAMutation
mutation	O
disrupted	O
the	O
normal	O
splicing	O
and	O
activated	O
a	O
cryptic	O
splice	O
donor	O
site	O
in	O
intron	O
9	O
,	O
leading	O
to	O
the	O
inclusion	O
of	O
54	O
nt	O
of	O
the	O
intron	O
9	O
sequence	O
in	O
hERG	O
mRNA	O
.	O

The	O
cryptic	O
splicing	O
resulted	O
in	O
an	O
in-frame	O
insertion	O
of	O
18	O
amino	O
acids	O
in	O
the	O
middle	O
of	O
the	O
cyclic	O
nucleotide	O
binding	O
domain	O
.	O

In	O
patch	O
clamp	O
experiments	O
the	O
splice	O
mutant	O
did	O
not	O
generate	O
hERG	O
current	O
.	O

Western	O
blot	O
and	O
immunostaining	O
studies	O
showed	O
that	O
the	O
mutant	O
expressed	O
an	O
immature	O
form	O
of	O
hERG	O
protein	O
that	O
failed	O
to	O
reach	O
the	O
plasma	O
membrane	O
.	O

Coexpression	O
of	O
the	O
mutant	O
and	O
wild-type	O
channels	O
led	O
to	O
a	O
dominant	O
negative	O
suppression	O
of	O
wild-type	O
channel	O
function	O
by	O
intracellular	O
retention	O
of	O
heteromeric	O
channels	O
.	O

Our	O
results	O
demonstrate	O
that	O
2398+1G>C	B-DNAMutation
activates	O
a	O
cryptic	O
site	O
and	O
generates	O
a	O
full-length	O
hERG	O
protein	O
with	O
an	O
insertion	O
of	O
18	O
amino	O
acids	O
,	O
which	O
leads	O
to	O
a	O
trafficking	O
defect	O
of	O
the	O
mutant	O
channel	O
.	O

Catechol-O-methyltransferase	O
(COMT)	O
gene	O
variants	O
:	O
possible	O
association	O
of	O
the	O
Val158Met	B-ProteinMutation
variant	O
with	O
opiate	O
addiction	O
in	O
Hispanic	O
women	O
.	O

Catechol-O-methyltransferase	O
(COMT)	O
catalyzes	O
the	O
breakdown	O
of	O
catechol	O
neurotransmitters	O
,	O
including	O
dopamine	O
,	O
which	O
plays	O
a	O
prominent	O
role	O
in	O
drug	O
reward	O
.	O

A	O
common	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
G472A	B-DNAMutation
,	O
codes	O
for	O
a	O
Val158Met	B-ProteinMutation
substitution	O
and	O
results	O
in	O
a	O
fourfold	O
down	O
regulation	O
of	O
enzyme	O
activity	O
.	O

We	O
sequenced	O
exon	O
IV	O
of	O
COMT	O
gene	O
in	O
search	O
for	O
novel	O
polymorphisms	O
and	O
then	O
genotyped	O
four	O
out	O
of	O
five	O
identified	O
by	O
direct	O
sequencing	O
,	O
using	O
TaqMan	O
assay	O
on	O
266	O
opioid-dependent	O
and	O
173	O
control	O
subjects	O
.	O

Genotype	O
frequencies	O
of	O
the	O
G472A	B-DNAMutation
SNP	O
varied	O
significantly	O
(	O
P	O
=	O
0.029	O
)	O
among	O
the	O
three	O
main	O
ethnic/cultural	O
groups	O
(	O
Caucasians	O
,	O
Hispanics	O
,	O
and	O
African	O
Americans	O
)	O
.	O

Using	O
a	O
genotype	O
test	O
,	O
we	O
found	O
a	O
trend	O
to	O
point-wise	O
association	O
(	O
P	O
=	O
0.053	O
)	O
of	O
the	O
G472A	B-DNAMutation
SNP	O
in	O
Hispanic	O
subjects	O
with	O
opiate	O
addiction	O
.	O

Further	O
analysis	O
of	O
G472A	B-DNAMutation
genotypes	O
in	O
Hispanic	O
subjects	O
with	O
data	O
stratified	O
by	O
gender	O
identified	O
a	O
point-wise	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
association	O
of	O
G/A	O
and	O
A/A	O
genotypes	O
with	O
opiate	O
addiction	O
in	O
women	O
,	O
but	O
not	O
men	O
.	O

These	O
point-wise	O
significant	O
results	O
are	O
not	O
significant	O
experiment-wise	O
(	O
at	O
P	O
<	O
0.05	O
)	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O

No	O
significant	O
association	O
was	O
found	O
with	O
haplotypes	O
of	O
the	O
three	O
most	O
common	O
SNPs	O
.	O

Linkage	O
disequilibrium	O
patterns	O
were	O
similar	O
for	O
the	O
three	O
ethnic/cultural	O
groups	O
.	O

Histamine-N-methyl	O
transferase	O
polymorphism	O
and	O
risk	O
for	O
migraine	O
.	O

BACKGROUND/OBJECTIVES	O
:	O
Histamine	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
migraine	O
.	O

In	O
the	O
CNS	O
,	O
histamine	O
is	O
almost	O
exclusively	O
metabolized	O
by	O
the	O
polymorphic	O
enzyme	O
histamine	O
N-methyltransferase	O
(HNMT)	O
.	O

The	O
HNMT	O
gene	O
(	O
chromosome	O
2q22.1	O
)	O
,	O
shows	O
diverse	O
single	O
nucleotide	O
polymorphisms	O
.	O

One	O
of	O
these	O
,	O
located	O
in	O
exon	O
4	O
C314T	B-DNAMutation
,	O
causes	O
the	O
amino	O
acid	O
substitution	O
Thr105Ile	B-ProteinMutation
,	O
related	O
to	O
decreased	O
enzyme	O
activity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
HNMT	O
polymorphism	O
and	O
the	O
risk	O
for	O
migraine	O
.	O

METHODS	O
:	O
We	O
studied	O
the	O
frequency	O
of	O
the	O
HNMT	O
genotypes	O
and	O
allelic	O
variantes	O
in	O
197	O
patients	O
with	O
migraine	O
and	O
245	O
healthy	O
controls	O
using	O
a	O
PCR-RLFP	O
method	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
HNMT	O
genotypes	O
and	O
allelic	O
variants	O
did	O
not	O
differ	O
significantly	O
between	O
migraine	O
patients	O
and	O
controls	O
,	O
and	O
were	O
unrelated	O
with	O
the	O
age	O
of	O
onset	O
of	O
migraine	O
attacks	O
,	O
gender	O
,	O
personal	O
history	O
of	O
allergic	O
diseases	O
,	O
family	O
history	O
of	O
migraine	O
,	O
or	O
presence	O
of	O
aura	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
HNMT	O
polymorphism	O
in	O
not	O
related	O
with	O
the	O
risk	O
for	O
migraine	O
.	O

Mutations	O
in	O
the	O
hairless	O
gene	O
underlie	O
APL	O
in	O
three	O
families	O
of	O
Pakistani	O
origin	O
.	O

BACKGROUND	O
:	O
Atrichia	O
with	O
papular	O
lesions	O
(APL)	O
(OMIM#209500)	O
is	O
a	O
rare	O
autosomal	O
recessively	O
inherited	O
form	O
of	O
irreversible	O
alopecia	O
characterized	O
by	O
papular	O
lesions	O
of	O
keratin-filled	O
cysts	O
on	O
various	O
regions	O
of	O
the	O
body	O
.	O

Males	O
and	O
females	O
are	O
equally	O
affected	O
and	O
present	O
with	O
a	O
distinct	O
pattern	O
of	O
total	O
hair	O
loss	O
on	O
scalp	O
,	O
axilla	O
and	O
body	O
.	O

It	O
begins	O
shortly	O
after	O
birth	O
with	O
the	O
development	O
of	O
hair	O
loss	O
,	O
and	O
patients	O
are	O
normally	O
devoid	O
of	O
eyelashes	O
and	O
eyebrows	O
.	O

Mutations	O
in	O
the	O
hairless	O
(HR)	O
gene	O
have	O
been	O
previously	O
shown	O
to	O
be	O
responsible	O
for	O
APL	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
,	O
we	O
studied	O
the	O
molecular	O
basis	O
of	O
APL	O
in	O
three	O
unrelated	O
families	O
of	O
Pakistani	O
origin	O
.	O

METHOD	O
:	O
Molecular	O
analysis	O
of	O
the	O
HR	O
genes	O
was	O
performed	O
on	O
genomic	O
DNA	O
from	O
probands	O
and	O
family	O
members	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
of	O
the	O
HR	O
gene	O
in	O
family	O
A	O
revealed	O
a	O
novel	O
homozygous	O
2bp	O
deletion	O
in	O
exon	O
6	O
leading	O
to	O
a	O
frameshift	O
and	O
a	O
downstream	O
premature	O
termination	O
codon	O
in	O
exon	O
8	O
1782-83delAG	B-DNAMutation
.	O

In	O
family	O
B	O
,	O
we	O
identified	O
a	O
novel	O
homozygous	O
deletion	O
of	O
a	O
G	O
nucleotide	O
at	O
the	O
exon	O
15-intron	O
15	O
boundary	O
,	O
termed	O
3097delG	B-DNAMutation
.	O

Family	O
C	O
carries	O
a	O
previously	O
reported	O
missense	O
mutation	O
consisting	O
of	O
an	O
A-to-G	O
transition	O
at	O
nucleotide	O
276	O
resulting	O
in	O
the	O
mutation	O
N970S	B-ProteinMutation
in	O
exon	O
14	O
.	O

CONCLUSION	O
:	O
Two	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
novel	O
mutations	O
in	O
the	O
HR	O
gene	O
and	O
extend	O
the	O
body	O
of	O
evidence	O
implicating	O
the	O
hairless	O
gene	O
family	O
in	O
the	O
pathogenesis	O
of	O
human	O
skin	O
disorders	O
.	O

The	O
one	O
previously	O
reported	O
mutation	O
suggests	O
it	O
may	O
represent	O
a	O
recurrent	O
mutation	O
,	O
or	O
alternatively	O
,	O
an	O
allele	O
that	O
is	O
widely	O
dispersed	O
around	O
the	O
world	O
.	O

Identification	O
of	O
apolipoprotein	O
E	O
Guangzhou	O
(	O
arginine	B-ProteinMutation
150	I-ProteinMutation
proline	I-ProteinMutation
)	O
,	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	O
glomerulopathy	O
.	O

BACKGROUND/AIMS	O
:	O
Lipoprotein	O
glomerulopathy	O
(LPG)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus-like	O
substances	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	O
E	O
(apoE)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	O
,	O
but	O
LPG	O
may	O
not	O
be	O
caused	O
by	O
apoE	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	O
with	O
LPG	O
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
:	O
The	O
apoE	O
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	O
patients	O
was	O
sequenced	O
.	O

The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	O
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18-T	O
vector	O
and	O
then	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	O
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	O
patients	O
and	O
1	O
asymptomatic	O
family	O
member	O
.	O

Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	O
to	O
C	O
point	O
mutation	O
in	O
exon	O
4	O
(	O
base	O
308	O
)	O
of	O
the	O
apoE	O
gene	O
in	O
all	O
patients	O
and	O
the	O
asymptomatic	O
family	O
member	O
.	O

This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	O
residue	O
for	O
arginine	O
residue	O
at	O
position	O
150	O
of	O
apoE	O
.	O

Those	O
patients	O
were	O
all	O
heterozygotes	O
with	O
apoE	O
Guangzhou	O
.	O

One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	O
Guangzhou	O
,	O
although	O
he	O
did	O
not	O
have	O
proteinuria	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	O
(	O
arginine	B-ProteinMutation
150	I-ProteinMutation
proline	I-ProteinMutation
)	O
is	O
a	O
novel	O
apoE	O
variant	O
that	O
etiologically	O
related	O
to	O
LPG	O
.	O

This	O
variant	O
(	O
apoE	O
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	O
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	O
.	O

Single	O
nucleotide	O
polymorphisms	O
in	O
bone	O
turnover-related	O
genes	O
in	O
Koreans	O
:	O
ethnic	O
differences	O
in	O
linkage	O
disequilibrium	O
and	O
haplotype	O
.	O

BACKGROUND	O
:	O
Osteoporosis	O
is	O
defined	O
as	O
the	O
loss	O
of	O
bone	O
mineral	O
density	O
that	O
leads	O
to	O
bone	O
fragility	O
with	O
aging	O
.	O

Population-based	O
case-control	O
studies	O
have	O
identified	O
polymorphisms	O
in	O
many	O
candidate	O
genes	O
that	O
have	O
been	O
associated	O
with	O
bone	O
mass	O
maintenance	O
or	O
osteoporotic	O
fracture	O
.	O

To	O
investigate	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
that	O
are	O
associated	O
with	O
osteoporosis	O
,	O
we	O
examined	O
the	O
genetic	O
variation	O
among	O
Koreans	O
by	O
analyzing	O
81	O
genes	O
according	O
to	O
their	O
function	O
in	O
bone	O
formation	O
and	O
resorption	O
during	O
bone	O
remodeling	O
.	O

METHODS	O
:	O
We	O
resequenced	O
all	O
the	O
exons	O
,	O
splice	O
junctions	O
and	O
promoter	O
regions	O
of	O
candidate	O
osteoporosis	O
genes	O
using	O
24	O
unrelated	O
Korean	O
individuals	O
.	O

Using	O
the	O
common	O
SNPs	O
from	O
our	O
study	O
and	O
the	O
HapMap	O
database	O
,	O
a	O
statistical	O
analysis	O
of	O
deviation	O
in	O
heterozygosity	O
depicted	O
.	O

RESULTS	O
:	O
We	O
identified	O
942	O
variants	O
,	O
including	O
888	O
SNPs	O
,	O
43	O
insertion/deletion	O
polymorphisms	O
,	O
and	O
11	O
microsatellite	O
markers	O
.	O

Of	O
the	O
SNPs	O
,	O
557	O
(63%)	O
had	O
been	O
previously	O
identified	O
and	O
331	O
(37%)	O
were	O
newly	O
discovered	O
in	O
the	O
Korean	O
population	O
.	O

When	O
compared	O
SNPs	O
in	O
the	O
Korean	O
population	O
with	O
those	O
in	O
HapMap	O
database	O
,	O
1%	O
(	O
or	O
less	O
)	O
of	O
SNPs	O
in	O
the	O
Japanese	O
and	O
Chinese	O
subpopulations	O
and	O
20%	O
of	O
those	O
in	O
Caucasian	O
and	O
African	O
subpopulations	O
were	O
significantly	O
differentiated	O
from	O
the	O
Hardy-Weinberg	O
expectations	O
.	O

In	O
addition	O
,	O
an	O
analysis	O
of	O
the	O
genetic	O
diversity	O
showed	O
that	O
there	O
were	O
no	O
significant	O
differences	O
among	O
Korean	O
,	O
Han	O
Chinese	O
and	O
Japanese	O
populations	O
,	O
but	O
African	O
and	O
Caucasian	O
populations	O
were	O
significantly	O
differentiated	O
in	O
selected	O
genes	O
.	O

Nevertheless	O
,	O
in	O
the	O
detailed	O
analysis	O
of	O
genetic	O
properties	O
,	O
the	O
LD	O
and	O
Haplotype	O
block	O
patterns	O
among	O
the	O
five	O
sub-populations	O
were	O
substantially	O
different	O
from	O
one	O
another	O
.	O

CONCLUSION	O
:	O
Through	O
the	O
resequencing	O
of	O
81	O
osteoporosis	O
candidate	O
genes	O
,	O
118	O
unknown	O
SNPs	O
with	O
a	O
minor	O
allele	O
frequency	O
(MAF)	O
>	O
0.05	O
were	O
discovered	O
in	O
the	O
Korean	O
population	O
.	O

In	O
addition	O
,	O
using	O
the	O
common	O
SNPs	O
between	O
our	O
study	O
and	O
HapMap	O
,	O
an	O
analysis	O
of	O
genetic	O
diversity	O
and	O
deviation	O
in	O
heterozygosity	O
was	O
performed	O
and	O
the	O
polymorphisms	O
of	O
the	O
above	O
genes	O
among	O
the	O
five	O
populations	O
were	O
substantially	O
differentiated	O
from	O
one	O
another	O
.	O

Further	O
studies	O
of	O
osteoporosis	O
could	O
utilize	O
the	O
polymorphisms	O
identified	O
in	O
our	O
data	O
since	O
they	O
may	O
have	O
important	O
implications	O
for	O
the	O
selection	O
of	O
highly	O
informative	O
SNPs	O
for	O
future	O
association	O
studies	O
.	O

Novel	O
TULP1	O
mutation	O
causing	O
leber	O
congenital	O
amaurosis	O
or	O
early	O
onset	O
retinal	O
degeneration	O
.	O

PURPOSE	O
:	O
To	O
report	O
a	O
large	O
,	O
consanguineous	O
Algerian	O
family	O
affected	O
with	O
Leber	O
congenital	O
amaurosis	O
(LCA)	O
or	O
early-onset	O
retinal	O
degeneration	O
(EORD)	O
.	O

METHODS	O
:	O
All	O
accessible	O
family	O
members	O
underwent	O
a	O
complete	O
ophthalmic	O
examination	O
,	O
and	O
blood	O
was	O
obtained	O
for	O
DNA	O
extraction	O
.	O

Homozygosity	O
mapping	O
was	O
performed	O
with	O
markers	O
flanking	O
12	O
loci	O
associated	O
with	O
LCA	O
.	O

The	O
15	O
exons	O
of	O
TULP1	O
were	O
sequenced	O
.	O

RESULTS	O
:	O
Seven	O
of	O
30	O
examined	O
family	O
members	O
were	O
affected	O
,	O
including	O
five	O
with	O
EORD	O
and	O
two	O
with	O
LCA	O
.	O

All	O
patients	O
had	O
nystagmus	O
,	O
hemeralopia	O
,	O
mild	O
myopia	O
,	O
and	O
low	O
visual	O
acuity	O
without	O
photophobia	O
.	O

Fundus	O
features	O
were	O
variable	O
among	O
EORD	O
patients	O
:	O
typical	O
spicular	O
retinitis	O
pigmentosa	O
or	O
clumped	O
pigmented	O
retinopathy	O
with	O
age-dependent	O
macular	O
involvement	O
.	O

A	O
salt-and-pepper	O
retinopathy	O
with	O
midperipheral	O
retinal	O
pigment	O
epithelium	O
(RPE)	O
atrophy	O
was	O
present	O
in	O
the	O
older	O
patients	O
with	O
LCA	O
,	O
whereas	O
the	O
retina	O
appeared	O
virtually	O
normal	O
in	O
the	O
younger	O
ones	O
.	O

Both	O
scotopic	O
and	O
photopic	O
electroretinograms	O
were	O
nondetectable	O
.	O

Fundus	O
imaging	O
revealed	O
a	O
perifoveal	O
ring	O
of	O
increased	O
fundus	O
autofluorescence	O
(FAF)	O
in	O
the	O
proband	O
,	O
and	O
optical	O
coherence	O
tomography	O
disclosed	O
a	O
thinned	O
retina	O
,	O
mainly	O
due	O
to	O
photoreceptor	O
loss	O
.	O

Linkage	O
analysis	O
identified	O
a	O
region	O
of	O
homozygosity	O
on	O
chromosome	O
6	O
,	O
region	O
p21.3	O
,	O
and	O
mutation	O
screening	O
revealed	O
a	O
novel	O
6-base	O
in-frame	O
duplication	O
,	O
in	O
the	O
TULP1	O
gene	O
.	O

CONCLUSIONS	O
:	O
Mutation	O
in	O
the	O
TULP1	O
gene	O
is	O
a	O
rare	O
cause	O
of	O
LCA/EORD	O
,	O
with	O
only	O
14	O
mutations	O
reported	O
so	O
far	O
.	O

The	O
observed	O
intrafamilial	O
phenotypic	O
variability	O
could	O
be	O
attributed	O
to	O
disease	O
progression	O
or	O
possibly	O
modifier	O
alleles	O
.	O

This	O
study	O
provides	O
the	O
first	O
description	O
of	O
FAF	O
and	O
quantitative	O
reflectivity	O
profiles	O
in	O
TULP1-related	O
retinopathy	O
.	O